
The 2x2 Matrix

A.Â J.Â Larner
The 2x2 Matrix
Contingency, Confusion, andÂ theÂ Metrics 
ofÂ Binary Classification

ISBN 978-3-030-74919-4â€ƒ â€ƒ â€ƒ â€ƒ ISBN 978-3-030-74920-0â€ƒ (eBook)
https://doi.org/10.1007/978-3-030-74920-0
Â© Springer Nature Switzerland AG 2021
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of 
the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, 
broadcasting, reproduction on microfilms or in any other physical way, and transmission or information 
storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology 
now known or hereafter developed.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication 
does not imply, even in the absence of a specific statement, that such names are exempt from the relevant 
protective laws and regulations and therefore free for general use.
The publisher, the authors, and the editors are safe to assume that the advice and information in this book 
are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the 
editors give a warranty, expressed or implied, with respect to the material contained herein or for any 
errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional 
claims in published maps and institutional affiliations.
This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
A.Â J.Â Larner
Cognitive Function Clinic
Walton Centre for Neurology and Neurosurgery
Liverpool, UK

To LF
Even in our deepest, most lasting friendships, 
we never speak as openly as when we face a 
blank page and address a reader we do not 
know [Michel Houellebecq. Submission]

vii
Preface
It is important to state at the outset what this book is not. It is not a textbook of medi-
cal statistics, as I have no training, far less any expertise, in that discipline. Rather it 
is a heuristic, based on experience of using and developing certain mathematical 
operations in the context of evaluating the outcomes of diagnostic and screening test 
accuracy studies. It therefore stands at the intersection of different disciplines, bor-
rowing from them (a dialogic discourse?) in the hope that the resulting fusion or 
intermingling will result in useful outcomes. This reflects part of a wider commit-
ment to interdisciplinary studies [6, 16].
Drawing as they do on concepts derived from decision theory, signal detection 
theory, and Bayesian methods, 2Â Ã—Â 2 contingency tables may find application in 
many areas, for example medical decision making, weather forecasting, informa-
tion retrieval, machine learning and data mining. Of necessity, this volume is writ-
ten from the perspective of the first of these areas, as the author is a practising 
clinician, but nevertheless it contains much material which will be of relevance to a 
wider audience.
Accordingly, this book is a distillate of what I have found to be helpful as a clini-
cian working in the field of test accuracy studies, specifically related to the screen-
ing and diagnosis of dementia and cognitive impairment, undertaken in the context 
of a dedicated cognitive disorders clinic. The conceptual framework described here 
is supplemented with worked examples in each section of the book, over 60Â in all, 
since, to quote Edwin Abbott, â€œAn instance will do more than a volume of generali-
ties to make my meaning clearâ€ ([1], p.Â 56). Many of these examples are based on a 
large (NÂ =Â 755) pragmatic prospective screening test accuracy study of one particu-
lar brief cognitive screening instrument, the Mini-Addenbrookeâ€™s Cognitive 
Examination (MACE) [3], the use of which in my clinical work has been exten-
sively analysed and widely presented [7â€“9, 11â€“15]. (It has also been included in a 
systematic review of MACE [2].) Further analyses of MACE are presented here, 
along with material from some of the other studies which have been undertaken in 
the clinic [4]. My previous books documenting the specifics of such pragmatic test 
accuracy studies of cognitive screening instruments [5, 10] may be categorised as 
parerga, the current work being more general in scope and hence applicable to many 

viii
branches of medical decision making as well as to disciplines beyond medicine 
wherein binary classification is required. Statistical programmes are not discussed.
James Clerk Maxwell (1831â€“1879) believed that there was â€œa department of the 
mind conducted independently of consciousnessâ€ where ideas could be â€œfermented 
and decocted so that when they run off they come clearâ€ ([17], p.Â 94â€“5, 154), views 
with which I am largely in agreement (clarity of my own ideas, however, seldom 
being apparent). This prompts me to acknowledge two periods of annual leave, both 
spent at Center Parcs, Whinfell Forest, Cumbria, which lead to the embryonic over-
all plan for this book (January 2019) and to the formulation of ideas about the epis-
temological matrix (November 2016).
References
	 1.	Abbott EA.Â  Flatland. An edition with notes and commentary by William F Lindgren and 
Thomas F Banchoff. NewÂ York: Cambridge University Press/Mathematical Association of 
America; [1884] 2010.
	 2.	Beishon LC, Batterham AP, Quinn TJ, etÂ al. Addenbrookeâ€™s Cognitive Examination III (ACE-
III) and mini-ACE for the detection of dementia and mild cognitive impairment. Cochrane 
Database Syst Rev. 2019;12:CD013282. [There are several numerical errors relating to my 
data in this publication, viz.: P7, Summary of findings: PPV for MCI vs. none incorrect for 
both 21 and 25 test threshold; P17, FigureÂ 8: Incorrect N (= 754!), TP, FP, TN.Â FigureÂ 9: 
Incorrect TP, FP, FN; P18, FigureÂ 10: Incorrect N (= 756!), FP.Â FigureÂ 11: Incorrect TP, FP, TN; 
P29, Characteristics of individual studies: â€œ22 with MCIâ€ should read â€œ222 with MCIâ€; P52, 
Appendix 6, Summary of included studies: â€œDSM-Vâ€ should read â€œDSM-IVâ€.]
	 3.	Hsieh S, McGrory S, Leslie F, Dawson K, Ahmed S, Butler CR, etÂ al. The Mini-Â­Addenbrookeâ€™s 
Cognitive Examination: a new assessment tool for dementia. Dement Geriatr Cogn Disord. 
2015;39:1â€“11.
	 4.	Larner AJ.Â Dementia in clinical practice: a neurological perspective. Pragmatic studies in the 
Cognitive Function Clinic. 3rd edition. London: Springer; 2018.
	 5.	Larner AJ.Â Diagnostic test accuracy studies in dementia: a pragmatic approach. 2nd edition. 
London: Springer; 2019.
	 6.	Larner AJ.Â Neuroliterature. Patients, doctors, diseases. Literary perspectives on disorders of 
the nervous system. Gloucester: Choir Press; 2019.
	 7.	Larner A.Â MACE: optimal cut-offs for dementia and MCI.Â J Neurol Neurosurg Psychiatry. 
2019;90:A19.
	 8.	Larner AJ.Â MACE for diagnosis of dementia and MCI: examining cut-offs and predictive val-
ues. Diagnostics (Basel). 2019;9:E51.
	 9.	Larner AJ.Â Applying Kraemerâ€™s Q (positive sign rate): some implications for diagnostic test 
accuracy study results. Dement Geriatr Cogn Dis Extra. 2019:9:389â€“96.
	10.	Larner AJ.Â  Manual of screeners for dementia. Pragmatic test accuracy studies. London: 
Springer; 2020.
	11.	Larner AJ.Â Screening for dementia: Q* index as a global measure of test accuracy revisited. 
medRxiv. 2020; https://doi.org/10.1101/2020.04.01.20050567.
	12.	Larner AJ.Â Defining â€œoptimalâ€ test cut-off using global test metrics: evidence from a cognitive 
screening instrument. Neurodegener Dis Manag. 2020;10:223â€“30.
	13.	Larner AJ.Â Mini-Addenbrookeâ€™s Cognitive Examination (MACE): a useful cognitive screening 
instrument in older people? Can Geriatr J. 2020;23:199â€“204.
Liverpool, UK
A.Â J.Â Larner  
Preface

ix
	14.	Larner AJ.Â Assessing cognitive screening instruments with the critical success index. Prog 
Neurol Psychiatry. 2021;25(3):33â€“7.
	15.	Larner AJ.Â Cognitive testing in the COVID-19 era: can existing screeners be adapted for tele-
phone use? Neurodegener Dis Manag. 2021;11:77â€“82.
	16.	Larner AJ.Â Neuroliterature 2. Biography, semiology, miscellany. Further literary perspectives 
on disorders of the nervous system. In preparation.
	17.	Mahon B.Â The man who changed everything. The life of James Clerk Maxwell. Chichester: 
Wiley; 2004.
Preface

xi
Acknowledgements
Thanks are due to Alison Zhu, a proper mathematician (1st in mathematics from 
Trinity College Cambridge) for advising on many of the equations in this book, 
although I hasten to add the any remaining errors are solely my own. Thanks also to 
Elizabeth Larner who drew Fig. 7.7.

xiii
Contents
	1	
Introductionï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ â€‚ 1
	1.1	 History and Nomenclatureï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ â€‚ 1
	1.2	 The Fourfold (2 Ã— 2) Contingency Tableï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ â€‚ 2
	1.3	 Marginal Totals and Marginal Probabilitiesï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ â€‚ 3
	1.3.1	 Marginal Totals ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ â€‚ 3
	1.3.2	 Marginal Probabilities; P, Qï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ â€‚ 6
	1.3.3	 Pre-test Oddsï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ â€‚ 9
	1.4	 Type I (Î±) and Type II (Î²) Errorsï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 10
	1.5	 Calibration: Decision Thresholds or Cut-Offsï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 11
	1.6	 Uncertain or Inconclusive Test Resultsï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 12
	1.7	 Measures Derived from a 2 Ã— 2 Contingency Table;  
Confidence Intervals ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 13
Referencesï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 13
	2	
Paired Measuresï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 15
	2.1	 Introductionï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 15
	2.2	 Error-Based Measuresï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 16
	2.2.1	 Sensitivity (Sens) and Specificity (Spec),  
or True Positive and True Negative Rates  
(TPR, TNR)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 16
	2.2.2	 Quality Measures (QSN, QSP) ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 19
	2.2.3	 False Positive Rate (FPR), False Negative Rate (FNR)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 21
	2.3	 Information-Based Measuresï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 23
	2.3.1	 Positive and Negative Predictive Values  
(PPV, NPV)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 23
	2.3.2	 Bayesâ€™ Formula; Standardized Positive and Negative  
Predictive Values (SPPV, SNPV)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 24
	2.3.3	 False Discovery Rate (FDR), False Reassurance  
Rate (FRR)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 27
	2.3.4	 Positive and Negative Likelihood Ratios  
(LR+, LRâˆ’)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 29

xiv
	2.3.5	 Post-test Odds; Net Harm to Net Benefit (H/B) Ratioï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 34
	2.3.6	 Conditional Probability Plot ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 35
	2.3.7	 Positive and Negative Predictive Ratios  
(PPR, NPR)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 36
	2.4	 Association-Based Measuresï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 39
	2.4.1	 Diagnostic Odds Ratio (DOR) and Error Odds  
Ratio (EOR)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 39
	2.4.2	 Clinical Utility Index (CUI+, CUIâˆ’) and Clinical  
Disutility Index (CDI+, CDIâˆ’)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 43
Referencesï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 45
	3	
Paired Complementary Measuresï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 49
	3.1	 Introductionï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 49
	3.2	 Error-Based Measuresï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 50
	3.2.1	 Sensitivity (Sens) and False Negative Rate (FNR)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 50
	3.2.2	 Specificity (Spec) and False Positive Rate (FPR)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 51
	3.2.3	 â€œSnNoutâ€ and â€œSpPinâ€ Rulesï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 52
	3.2.4	 Accuracy and Inaccuracyï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 53
	3.2.5	 Classification and Misclassification Rates;  
Misclassification Costs ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 57
	3.3	 Information-Based Measuresï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 60
	3.3.1	 Positive Predictive Value (PPV) and False  
Discovery Rate (FDR)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 60
	3.3.2	 Negative Predictive Value (NPV) and False  
Reassurance Rate (FRR)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 61
	3.4	 Dependence of Paired Complementary Measures  
on Prevalence (P)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 62
Referencesï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 68
	4	
Unitary Measuresï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 71
	4.1	 Introductionï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 71
	4.2	 Youden Index (Y) or Statistic (J)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 71
	4.3	 Predictive Summary Index (PSI, Î¨) ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 76
	4.4	 Harmonic Mean of Y and PSI (HMYPSI)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 78
	4.5	 Matthewsâ€™ Correlation Coefficient (MCC)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 81
	4.6	 Identification Index (II)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 83
	4.7	 Net Reclassification Improvement (NRI) ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 84
	4.8	 Critical Success Index (CSI) or Threat Score (TS)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 86
	4.9	 F Measure (F) or F1 Score (Dice Coefficient)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 89
	4.10	 Summary Utility Index (SUI) and Summary Disutility  
Index (SDI) ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 92
Referencesï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 94
Contents

xv
	5	
Reciprocal Measuresï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 97
	5.1	 Introductionï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 97
	5.2	 Number Needed to Diagnose (NND)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ â€‚ 98
	5.3	 Number Needed to Predict (NNP)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 100
	5.4	 Number Needed to Misdiagnose (NNM)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 101
	5.5	 Likelihood to Be Diagnosed or Misdiagnosed (LDM)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 102
	5.6	 Number Needed to Screen (NNS)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 106
	5.7	 Number Needed for Screening Utility (NNSU)  
and Number Needed for Screening Disutility (NNSD)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 108
Referencesï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 110
	6	
Measures Not Directly Related to the 2 Ã— 2 Contingency Tableï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 113
	6.1	 Introductionï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 113
	6.2	 Receiver Operating Characteristic (ROC) Plot or Curveï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 114
	6.2.1	 Defining Optimal Cut-Off: Youden Index (Y)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 119
	6.2.2	 Defining Optimal Cut-Off: Euclidean Index (d)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 120
	6.2.3	 Defining Optimal Cut-Off: Q* Indexï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 121
	6.2.4	 Defining Optimal Cut-Off: Other ROC-Based  
Methodsï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 122
	6.2.5	 Defining Optimal Cut-Off: Diagnostic Odds  
Ratio (DOR)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 123
	6.2.6	 Defining Optimal Cut-Off: Non-ROC-Based  
Methodsï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 123
	6.3	 Other Graphing Methodsï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 123
	6.3.1	 ROC Plot in Likelihood Ratio Coordinatesï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 123
	6.3.2	 Precision-Recall (PR) Plot or Curveï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 125
	6.3.3	 Prevalence Value Accuracy Plotsï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 125
	6.3.4	 Agreement Charts ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 125
	6.4	 Effect Sizes ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 125
	6.4.1	 Correlation Coefficientï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 126
	6.4.2	 Cohenâ€™s dï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 126
	6.4.3	 Binomial Effect Size Display (BESD)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 128
Referencesï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 129
	7	
Other Measures, Other Tablesï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 133
	7.1	 Introductionï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 133
	7.2	 Other measuresï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 133
	7.2.1	 Measure of Association: McNemarâ€™s Testï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 133
	7.2.2	 Measure of Agreement: Cohenâ€™s Kappa (Îº) Statisticï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 136
	7.2.3	 Limits of Agreement: Bland-Altman Methodï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 142
	7.3	 Other Tablesï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 142
	7.3.1	 Higher Order Tablesï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 142
	7.3.2	 Interval Likelihood Ratios (ILRs)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 142
Contents

xvi
	7.3.3	 Three-Way Classification (Trichotomisation)ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 144
	7.3.4	 Combining Test Resultsï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 145
	7.3.5	 Decision Trees; Machine Learningï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 154
	7.3.6	 Fourfold Pattern of Risk Attitudesï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 157
	7.3.7	 Epistemological Matrixï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 157
	7.4	 Conclusion: Which Measure(s) Should Be Used?ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 158
Referencesï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½â€‚ 159
Indexï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½163
Contents

1
Â© Springer Nature Switzerland AG 2021
A. J. Larner, The 2x2 Matrix, https://doi.org/10.1007/978-3-030-74920-0_1
Chapter 1
Introduction
Contents
1.1â€ƒ History andÂ Nomenclature
â€ƒ 1
1.2â€ƒ The Fourfold (2Â Ã—Â 2) Contingency Table
â€ƒ 2
1.3â€ƒ Marginal Totals andÂ Marginal Probabilities
â€ƒ 3
1.3.1â€ƒ Marginal Totals
â€ƒ 3
1.3.2â€ƒ Marginal Probabilities; P, Q
â€ƒ 6
1.3.3â€ƒ Pre-test Odds
â€ƒ 9
1.4â€ƒ Type IÂ (Î±) andÂ Type II (Î²) Errors
â€ƒ 10
1.5â€ƒ Calibration: Decision Thresholds or Cut-Offs
â€ƒ 11
1.6â€ƒ Uncertain or Inconclusive Test Results
â€ƒ 12
1.7â€ƒ Measures Derived fromÂ aÂ 2Â Ã—Â 2 Contingency Table; Confidence Intervals
â€ƒ 13
References
â€ƒ 13
1.1â€ƒ History andÂ Nomenclature
Use of a fourfold or quadripartite 2Â Ã—Â 2 table to represent counts of different classes, 
a dichotomous classification, may date back to Aristotle [23]. Examples of the 
application of such tables to medical issues may be found in the work of Gavarret in 
the 1840s and Liebermeister in the 1870s [18, 23].
The term â€œcontingency tableâ€ to describe a matrix format used to display a fre-
quency distribution of variables is generally credited to Karl Pearson (1857â€“1936) 
in his lecture to the Draperâ€™s Society in 1904 [20]. Furthermore, in his book, The 
grammar of science, Pearson stated:
â€¦ all we can do is to classify things into like within a certain degree of observation, and 
record whether what we note as following from them are like within another degree of 
observation. Whenever we do this â€¦ we really form a contingency table, â€¦ (cited from the 
3rd edition of The grammar of science [18], pp.90â€“1).
Nevertheless, â€œcontingency tableâ€ barely features in Porterâ€™s biography of 
Pearson ([21] p.266, 273).
The term â€œconfusion matrixâ€ or error matrix, or table of confusion, has also been 
applied to 2Â Ã—Â 2 tables, with the columns denoting instances of an actual class and 
the rows denoting instances of a predicted class. The term â€œconfusion matrixâ€ 
derives from the observation that this form of cross tabulation (or crosstab) makes it 
easy to see if the system is confusing two classes. The confusion matrix may be 

2
described as a special kind (2Â Ã—Â 2) of contingency table, since higher order contin-
gency tables may be constructed, cross tabulating instances into more classes, rep-
resented by more columns and/or rows (see Sect. 7.3.1). Another term sometimes 
used to describe the 2Â Ã—Â 2 table is a â€œtruth tableâ€, by analogy with those tables 
developed by Ludwig Wittgenstein (1889â€“1951) for use in logic (see Sects. 1.3.1 
and 7.3.4).
The 2Â Ã—Â 2 contingency table or confusion matrix hence reifies a binary system of 
classification. This should not, however, be confused with the binary or dyadic nota-
tion, using the base 2, the development of which is often associated (perhaps unjus-
tifiably) with Gottfried Leibniz (1646â€“1716) [3].
The 2Â Ã—Â 2 contingency table is applicable to decision making in many disciplines. 
The details of this table are now described.
1.2â€ƒ The Fourfold (2Â Ã—Â 2) Contingency Table
The simple 2Â Ã—Â 2 contingency table or confusion matrix cross-tabulates all instances 
(N) into classes, according to some form of reference standard or â€œtrue statusâ€ (e.g. 
diagnosis, or meteorological observations) in the vertical columns, against the out-
come of a test or classifier of interest (e.g. a diagnostic or screening test, or meteo-
rological forecasts) in the horizontal rows. In other words, there is a mapping of all 
instances to predicted classes, giving an indication of the performance of the classi-
fier. The columns may be characterised as explanatory variables, the rows as 
response variables.
This quadripartite classification thus categorises all individuals, observations, or 
events as:
â€¢	 true positive (TP), or â€œhitsâ€
â€¢	 false positive (FP), or â€œfalse alarmsâ€ or â€œfalse hitsâ€
â€¢	 false negative (FN), or â€œmissesâ€
â€¢	 true negative (TN), or â€œnon eventsâ€ or â€œcorrect rejectionsâ€
This cross-classification is shown in a 2Â  Ã—Â  2 contingency table in Fig.Â  1.1. 
Henceforward the terms TP, FP, FN, TN will be referred to as â€œliteral notationâ€, and 
metrics derived from the 2Â Ã—Â 2 contingency table and denoted by equations using 
this notation as â€œliteral equationsâ€. Some readers may find such literal terminology 
easier to use and comprehend than algebraic notation.
The 2Â Ã—Â 2 table is often set out using algebraic terms, where:
â€¢	 TP = a
â€¢	 FP = b
â€¢	 FN = c
â€¢	 TN = d
This is shown in Fig.Â 1.2. Henceforward the terms a, b, c, d will be referred to as 
â€œalgebraic notationâ€, and equations using this notation as â€œalgebraic equationsâ€. 
1â€ƒ Introduction

3
Some readers may find this algebraic terminology easier to use and comprehend 
than literal notation.
N is used throughout this book to denote the total number of instances observed 
or counted (e.g. patients or observations), in other words a population, such that:
	
N
TP
FP
FN
TN
a
b
c
d






 
	
It should be noted, however, that some authors have used N to denote total nega-
tives or negative instances (FN + TN, or c + d), for which the term qâ€² is used here 
(see Sect. 1.3.1).
1.3â€ƒ Marginal Totals andÂ Marginal Probabilities
1.3.1â€ƒ Marginal Totals
It is immediately obvious that the four cells of the 2Â Ã—Â 2 table will generate six mar-
ginal values or totals by simple addition in the vertical, horizontal, and diagonal 
directions (Fig.Â 1.3). These totals will be denoted here using lower case letters.
True Status
Test 
Outcome
Condition 
present
Condition 
absent
Positive
Negative
True positive
[TP]
False positive
[FP]
True negative
[TN]
False negative
[FN]
Fig. 1.1â€‚ 2Â Ã—Â 2 contingency 
table using literal notation
True Status
Test 
Outcome
Condition 
present 
Condition 
absent 
Positive
Negative
True positive 
(a)
False positive
(b)
True negative
(d)
False negative
(c)
Fig. 1.2â€‚ 2Â Ã—Â 2 contingency 
table using algebraic 
notation
1.3â€ƒ Marginal Totals andÂ Marginal Probabilities

4
Reading vertically, down the columns:
	
p
TP
FN
a
c
p
FP
TN
b
d
p
p
N












	
True Status
Test 
Outcome
Condition 
present 
(= case)
Condition 
absent 
(= non case)
Positive
Negative
True positive 
[TP] (a)
False positive
[FP] (b)
True negative 
[TN] (d)
True negative 
[TN] (d)
False negative
[FN] (c)
p
pÊ¹
qÊ¹
q
rÊ¹
r
Marginal totals:
p
=
TP + FN
=
a + c
p'
=
FP + TN
=
b + d
p + p' 
= 
N
=
a + b + c + d
q
=
TP + FP
=
a + b
q'
=
FN + TN
=
c + d
q + q' 
= 
N
=
a + b + c + d
r
=
TP + TN
=
a + d
r'
=
FP + FN
=
b + c
r + r' 
= 
N
=
a + b + c + d
Marginal probabilities:
P
=
(TP + FN)/N
=
p/N
(1 â€“ P) = P'
=
(FP + TN)/N
=
p'/N
Q
=
(TP + FP)/N
=
q/N
(1 â€“ Q) = Q'
=
(FN + TN)/N
=
q'/N
R
=
(TP + TN)/N
=
r/N
(1 â€“ R) = R'
=
(FP + FN)/N
=
r'/N
Fig. 1.3â€‚ 2Â Ã—Â 2 contingency table with marginal totals and marginal probabilities
1â€ƒ Introduction

5
In other words, p = positive instances and pâ€² = negative instances. This may also 
be illustrated in a simple truth table akin to that used in logic when using â€œpâ€ and 
â€œâ€“pâ€ or â€œnot pâ€ for propositions (Fig.Â 1.4).
A dataset is said to be balanced when p = pâ€². A difference in these columnar 
marginal totals (i.e. in the numbers of positive, p, and negative, pâ€², instances) is 
termed class imbalance. This may impact on the utility of some measures derived 
from the 2Â Ã—Â 2 contingency table.
Reading horizontally, across the rows:
	
q
TP
FP
a
b
q
FN
TN
c
d
q
q
N












	
In other words, q = positive classifications and qâ€² = negative classifications.
It is also possible to read the table diagonally:
	
r
TP
TN
a
d
r
FP
FN
b
c
r
r
N












	
In other words, r = true instances and râ€² = false instances. (It should be noted that 
the use of â€œrâ€ here has a different meaning from that used by other authors with 
respect to ratios of relevant costs, and in kappa values.)
Henceforward the terms p, pâ€², q, qâ€², r, râ€² will be referred to as marginal totals and 
will be substituted in some algebraic equations.
Criterion diagnosis
Classifier
diagnosis
D+
D-
D+
D-
True
False
True
False
p
pÊ¹
Fig. 1.4â€‚ 2Â Ã—Â 2 truth table 
for â€œpâ€ and â€œnot pâ€ (or 
â€œâ€“pâ€)
1.3â€ƒ Marginal Totals andÂ Marginal Probabilities

6
1.3.2â€ƒ Marginal Probabilities; P, Q
The six absolute marginal totals may be converted to six probabilities, or rates, by 
dividing each by N.Â These probabilities or rates will be denoted using upper case 
letters.
Reading vertically in Fig.Â 1.3:
	
P
TP
FN
N
a
c
N
p N
P
P
FP
TN
N
b
d
N
p
N









 












/
/
/
/
/
/
1
	
As probabilities, these values necessarily sum to unity:
	
P
P



1	
P is the prevalence, or prevalence rate, or base rate. When P = 0.5 there is a bal-
anced class distribution (i.e. no class imbalance) because by definition Pâ€² = 0.5.
P is used throughout this book to denote prevalence. It should be noted, however, 
that some authors use P to denote total positives or positive instances (TP + FP, or a 
+ b), for which the term q is used here (Sect. 1.3.1).
Prevalence may also be expressed in probability notation, as the probability that 
disease is either present, the pre-test probability, p(D+), or absent, p(Dâˆ’).
Worked Example: Prevalence Rates (P, Pâ€²)
The Mini-Addenbrookeâ€™s Cognitive Examination (MACE) [8], a brief cogni-
tive screening instrument, was subjected to a screening test accuracy study in 
a large patient cohort, N = 755 [11]. A reference (criterion) diagnosis of 
dementia, based on the application of widely accepted diagnostic criteria for 
dementia, was made in 114 patients. At the MACE cut-off of â‰¤20/30, the test 
outcomes were as follows: TP = 104, FN =10, FP = 188, and TN = 453.
Hence the prevalence (P) or pre-test probability of dementia patients in this 
cohort was:
P
=
TP
FN
N
D












/
/
.
104 10
755
0 151
p
1â€ƒ Introduction

7
Prevalence may be a useful estimate of pre-test probability (see also Sect. 4.7) 
from which pre-test odds may be calculated (Sect. 1.3.3). However, sample preva-
lence may differ from population prevalence, and hence this base rate may be no 
more than an anchor from which to make adjustments. Many of the measures 
derived from the 2Â Ã—Â 2 contingency table may be dependent on prevalence. This 
variation may be examined empirically, for example by using patient cohorts with 
different base rates of disease prevalence (e.g. [14, 15, 24], and [16], p.160,165) or 
by calculation at fixed values of prevalence (Sect. 2.3.2) (e.g. [11, 16]).
Reading horizontally in Fig.Â 1.3:
	
Q
TP
FP
N
a
b
N
q N









/
/
/
	
Hence Q may be described as the positive sign rate [9] or the probability of a 
positive test in the study population.
	


 
 








Q
Q
FN
TN
N
c
d
N
q
N
1
/
/
/
	
Hence Qâ€² may be described as the negative sign rate [12] or the probability of a 
negative test in the study population.
	
Q
Q



1	
Q may also be expressed in probability notation, as the probability that the test is 
either positive, p(T+), or negative, p(Tâˆ’).
The prevalence (Pâ€²) of patients without dementia, or pre-test probability 
against dementia, in the cohort was:













P
=
FP
TN
N
P
D
/
/
.
188
453
755
0 849
1

p
1.3â€ƒ Marginal Totals andÂ Marginal Probabilities

8
Many of the measures derived from the 2Â Ã—Â 2 contingency table may be depen-
dent on level of the test, Q, evident as variation with test cut-off. Looking at Q is one 
of the recommended steps in designing, conducting, reporting, and interpreting 
receiver operating characteristic (ROC) analyses to support clinical decision mak-
ing ([25], p.205) (see Sect. 6.2).
Reading the main diagonal (upper left to lower right) in Fig.Â 1.3:
	
R
TP
TN
N
a
d
N
r N









/
/
/
	
Reading the off diagonal (lower left to upper right) in Fig.Â 1.3:
	



 
 










R
R
FP
FN
N
b
c
N
r
N
R
R
1
1

/
/
/
	
R is sometimes known as â€œproportion correctâ€ or â€œtrue rateâ€ or accuracy (Sect. 
3.2.4), and Râ€² as â€œproportion incorrectâ€ or â€œfalse rateâ€ or misclassifications or inac-
curacy or error rate (Sect. 3.2.4).
Worked Example: Positive and Negative Sign Rates (Q, Qâ€²)
In the screening test accuracy study of (MACE) [11], from the patient cohort 
(N = 755) at the MACE cut-off of â‰¤20/30, the test outcomes were as follows: 
TP = 104, FN =10, FP = 188, and TN = 453.
Hence the positive sign rate (Q) at MACE cut-off â‰¤20/30 was:
Q
TP
FP
N
T













/
/
.
104 188
755
0 387
p
The negative sign rate (Qâ€²) at this cut-off was:














Q
FN
TN
N
Q
T
/
/
.
10
453
755
0 613
1

p
1â€ƒ Introduction

9
1.3.3â€ƒ Pre-test Odds
Pre-test odds are given by the ratio of prevalence (or pre-test probability; Sect. 
1.3.2) of instances with and without the item of interest (e.g. diagnosis, observation):
	
Pre-test odds
P
P
P P





/
/
1
	
In probability notation:
	
Pre-test odds
D
D







p
p
/
	
These are the odds favouring an event. Odds against the event are given by:
	
Pre-test odds against
P
P
P
P





1
/
/
	
In probability notation:
	
Pre-test odds against
D
D







p
p
/
	
The pre-test odds can be simply converted to pre-test probability:
Worked Example: Proportions Correct and Incorrect (R, Râ€²)
In the screening test accuracy study of (MACE) [11], from the patient cohort 
(N = 755), at the MACE cut-off of â‰¤20/30, the test outcomes were as follows: 
TP = 104, FN =10, FP = 188, and TN = 453.
Hence the proportion correct (R) at MACE cut-off â‰¤20/30 was:
R
TP
TN
N









/
/
.
104
453
755
0 737
The proportion incorrect (Râ€²) at this cut-off was:












R
FP
FN
N
R
/
/
.
188 10
755
0 263
1
1.3â€ƒ Marginal Totals andÂ Marginal Probabilities

10
	
Pre-test probability
Pre-test odds
Pre-test odds




/ 1
	
	
Pre-test probability
Pre-test odds against




1
1
/
	
Comparison of pre-test odds and post-test odds may be used in the Bayesian 
evaluation of tests (see Sect. 2.3.5). These odds also have a role in combining test 
results (Sect. 7.3.4).
1.4â€ƒ Type IÂ (Î±) andÂ Type II (Î²) Errors
A variant of the simple 2Â Ã—Â 2 contingency table may be constructed which cross-Â­
classifies all instances (N) according to the outcome of the null hypothesis (Fig.Â 1.5), 
since this leads to a binary outcome (reject or do not reject). Here, the â€œtrue statusâ€ 
(vertical columns) refers to whether the null hypothesis is true or false, whilst the 
â€œtest outcomeâ€ (horizontal rows) refers to whether or not the null hypothesis is 
rejected.
Type I (or Î±) error rate is the probability of rejecting the null hypothesis when in 
reality the null hypothesis is true; in other words detecting an effect that does not 
exist (false positive), an error of commission.
Type II (or Î²) error rate, sometimes denoted power, is the probability of not 
rejecting the null hypothesis when it is in reality false (false negative); in other 
words failing to detect an effect that does exist, an error of omission.
Worked Example: Pre-test Odds for and against
In the screening test accuracy study of (MACE) [11], in the total patient 
cohort (N = 755) the prevalence of dementia (P) was 0.151 and the prevalence 
of the absence of dementia (1Â â€“ P) was therefore 0.849.
Hence the pre-test odds of dementia were:
Pre-test odds
P
P






/
.
/ .
.
1
0 151 0 849
0 178
The pre-test odds against dementia were:
Pre-test odds against
P
P






1
0 849 0 151
5 62
/
.
/ .
.
1â€ƒ Introduction

11
These terms may be rearranged, such that 1Â â€“ Î² is the probability of rejecting the 
null hypothesis when it is false, or Î² = (1Â â€“ power).
â€¢	 Null hypothesis false, rejected (i.e. correct) = 1Â â€“ Î² (â€œpowerâ€)
â€¢	 Null hypothesis true, rejected = Î± (false positive, type I error)
â€¢	 Null hypothesis false, fail to reject = Î² (false negative, type II error)
â€¢	 Null hypothesis true, fail to reject (i.e. correct) = 1Â â€“ Î±
It should be noted that the four cells here are not equivalent to the four cells in 
the simple 2Â Ã—Â 2 table (Figs.Â 1.1 and 1.2).
Testing the null hypothesis by calculating p values is fraught with the possibility 
of drawing incorrect conclusions. The conventional tendency to â€œdichotomiseâ€ p 
values as significant or non-significant at the 0.05 level risks both type I (p < 0.05 
may be a false positive) and type II (p > 0.05 may be a false negative) errors [2].
Henceforward the terms 1Â â€“ Î², Î±, Î², 1Â â€“ Î± will be referred to as â€œerror notationâ€, 
and equations using this notation as â€œerror equationsâ€.
1.5â€ƒ Calibration: Decision Thresholds or Cut-Offs
When constructing a 2Â Ã—Â 2 contingency table, test outcome may be obvious (e.g. a 
clinical sign is either present or absent, a forecast was either made or not made). 
Sometimes, however, the classification is not binary or categorical, for example 
when using tests with a quantitative range of scores or continuous values. 
Measurement scales may be classified in various ways, with one system distinguish-
ing between those scales with variables in ordered categories the distances between 
which either have the same meaning (linear; interval data) or have different or 
unknown meaning (non-linear; ordinal data) [22]. Many scales used in clinical prac-
tice are ordinal in nature [16].
True Status
Test 
Outcome
Null 
hypothesis 
false
Null 
hypothesis
true
Reject 
null
Fail to 
reject 
null
Correct: 
1 â€“ Î², power
Type I error: 
Î±, false 
positive
Correct:
1 â€“ Î±
Type II error: 
Î², false 
negative
Fig. 1.5â€‚ 2Â Ã—Â 2 table using error notation
1.5â€ƒ Calibration: Decision Thresholds or Cut-Offs

12
For the purposes of constructing a 2Â Ã—Â 2 contingency table using quantitative 
scales, there is a need to dichotomise results according to a chosen threshold, also 
variously known as a cut-off, cut-point, decision threshold, dichotomisation point, 
or positivity criterion. For some tests, cut-off point(s) may be specified, for example 
in the test manual or in the index publication. However, these may not be readily 
transferable to other study populations. Defining the optimal cut-off(s) may be 
achieved by various methods ([13], p.36â€“41, [17]) (see Sect. 6.2), although it has 
been argued that cut-offs should not be determined post hoc as this risks introducing 
bias into study results [6]. This calibration process, the setting of the decision 
threshold(s) or cut-off(s), so that tests which produce continuous scale data may be 
used as if they were binary classifiers, will affect many of the outcome measures of 
a 2Â Ã—Â 2 contingency table. The setting of a cut-off will determine the level of the test, 
Q (Sect. 1.3.2).
The shortcomings of such dichotomisation are recognised: greater statistical 
power is afforded by the continuous approach [1, 5]. However, in clinical practice 
such dichotomisation is often pragmatic. Clinicians (and indeed patients) may gen-
erally be said to prefer binary classifiers (e.g. screen positive vs screen negative; 
target diagnosis present vs absent) since their categorical nature gives an impression 
of certainty and clarifies whether or not a medical intervention is applied.
1.6â€ƒ Uncertain or Inconclusive Test Results
There are potential problems with the use of dichotomous thresholds. Things which 
once appeared or were conceptualised as binary or dimorphic may prove to be part 
of a spectrum or continuum (e.g. consciousness, sexuality). Disease entities once 
codified as binary may subsequently be recognised as spectrum disorders (e.g. 
Alzheimerâ€™s disease, compare diagnostic criteria of 1984 [19] and 2014 [7]). 
Providing a single cut-off score may therefore risk misclassifications. Indeed some 
authors advocate the abandonment of binary disease categories in favour of a prob-
ability dysfunction model based on risk of harm according to risk banding [4].
Three-way classification, or trichotomisation, has been suggested as a method to 
allow better classification accuracy but at the cost of not classifying a proportion of 
cases. Specifically, uncertain test scores, the most error-prone, are excluded or dese-
lected from classification. This may be a substantial proportion of the test cohort, 
particularly if the test has limited strength, with unclassified individuals requiring 
further assessment for correct classification, achieved either by watchful waiting/
active surveillance or by the application of further (more sophisticated, more expen-
sive, more risky) tests [10].
Higher order contingency tables (2Â Ã—Â 3, 2Â Ã—Â 4, 3Â Ã—Â 3) may also be a method to 
handle problems of this kind (Sect. 7.3.1).
1â€ƒ Introduction

13
1.7â€ƒ Measures Derived fromÂ aÂ 2Â Ã—Â 2 Contingency Table; 
Confidence Intervals
Aside from the marginal totals and probabilities (Sect. 1.3), a large number of other 
measures may be derived from a 2Â Ã—Â 2 contingency table. Many of these measures 
will be described in the subsequent chapters of this book, including but not limited 
to sensitivity and specificity, predictive values, and likelihood ratios. None is per-
fect, all have potential shortcomings, as well as utilities, in describing the outcomes 
of a contingency table. Indeed, it might be intuited that the very multiplicity of these 
measures suggests their inadequacy: all summary statistics reduce the information 
to a single characteristic of the data. (Perhaps a vector in the unit 4-dimensional 
space of a hypercube or tesseract might be a unique outcome descriptor for each 
2Â Ã—Â 2 table, and be a potential comparator measure, but whether this would prove 
readily applicable, particularly in clinical practice, is highly questionable.)
To account for sampling variability, calculation of confidence intervals (or com-
patibility intervals) for each point estimate is recommended as a measure of preci-
sion. This quantification of statistical uncertainty is typically expressed using the 
95% confidence interval (95% CI), in other words one can be 95% certain that the 
true value lies between these limits. Narrow confidence intervals (greater precision) 
result from large sample sizes, whereas small sample sizes may be associated with 
broad confidence intervals (lesser precision, hence more often give extreme results). 
Failure to quote confidence intervals may influence the generalizability of diagnos-
tic studies ([13], p.53â€“4).
References
	 1.	Altman DG, Royston P.Â  The cost of dichotomising continuous variables. Br Med 
J. 2006;332:1080.
	 2.	Amrhein V, Greenland S, McShane B.Â Scientists rise up against statistical significance. Nature. 
2019;567:305â€“7.
	 3.	Ares J, Lara J, Lizcano D, Martinez MA.Â Who discovered the binary system and arithmetic? 
Did Leibniz plagiarize Caramuel? Sci Eng Ethics. 2018;24:173â€“88.
	 4.	Baum ML.Â The neuroethics of biomarkers. What the development of bioprediction means for 
moral responsibility, justice, and the nature of mental disorder. Oxford, Oxford University 
Press; 2016.
	 5.	Cohen J.Â The cost of dichotomization. Appl Psychol Meas. 1983;7:249â€“53.
	 6.	Davis DH, Creavin ST, Noel-Storr A, etÂ  al. Neuropsychological tests for the diagnosis of 
Alzheimerâ€™s disease dementia and other dementias: a generic protocol for cross-sectional and 
delayed-verification studies. Cochrane Database Syst Rev. 2013;3:CD010460.
	 7.	Dubois B, Feldman HH, Jacova C, etÂ al. Advancing research diagnostic criteria for Alzheimerâ€™s 
disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614â€“29. [Erratum Lancet Neurol. 
2014;13:757]
	 8.	Hsieh S, McGrory S, Leslie F, Dawson K, Ahmed S, Butler CR, etÂ al. The Mini-Addenbrookeâ€™s 
Cognitive Examination: a new assessment tool for dementia. Dement Geriatr Cogn Disord. 
2015;39:1â€“11.
References

14
	 9.	Kraemer HC.Â Evaluating medical tests. Objective and quantitative guidelines. Newbery Park: 
Sage; 1992.
	10.	Landsheer JA.Â The clinical relevance of methods for handling inconclusive medical test results: 
quantification of uncertainty in medical decision-making and screening. Diagnostics (Basel). 
2018;8:32.
	11.	Larner AJ.Â MACE for diagnosis of dementia and MCI: examining cut-offs and predictive val-
ues. Diagnostics (Basel). 2019;9:E51.
	12.	Larner AJ.Â Applying Kraemerâ€™s Q (positive sign rate): some implications for diagnostic test 
accuracy study results. Dement Geriatr Cogn Dis Extra. 2019;9:389â€“96.
	13.	Larner AJ.Â  Diagnostic test accuracy studies in dementia. A pragmatic approach. 2nd ed. 
London: Springer; 2019.
	14.	Larner AJ.Â The â€œattended aloneâ€ and â€œattended withâ€ signs in the assessment of cognitive 
impairment: a revalidation. Postgrad Med. 2020;132:595â€“600.
	15.	Larner AJ.Â Mini-Addenbrookeâ€™s Cognitive Examination (MACE): a useful cognitive screening 
instrument in older people? Can Geriatr J. 2020;23:199â€“204.
	16.	Larner AJ.Â  Manual of screeners for dementia. Pragmatic test accuracy studies. London: 
Springer; 2020.
	17.	Larner AJ.Â Defining â€œoptimalâ€ test cut-off using global test metrics: evidence from a cognitive 
screening instrument. Neurodegener Dis Manag. 2020;10:223â€“30.
	18.	Matthews JR.Â Quantification and the quest for medical certainty. Princeton University Press: 
Princeton; 1995.
	19.	McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM.Â Clinical diagnosis 
of Alzheimerâ€™s disease. Report of the NINCDS-ADRDA work group under the auspices of 
the Department of Health and Human Service Task forces on Alzheimerâ€™s disease. Neurology. 
1984;34:939â€“44.
	20.	Pearson K.Â Draperâ€™s company research memoirs. Biometric series I.Â Mathematical contribu-
tions to the theory of evolution XIII.Â On the theory of contingency and its relation to associa-
tion and normal correlation. London: Dulau & Co.; 1904.
	21.	Porter TM.Â Karl Pearson: the scientific life in a statistical age. Princeton/Oxford: Princeton 
University Press; 2004.
	22.	Stevens SS.Â On the theory of scales of measurement. Science. 1946;103:677â€“80.
	23.	Stigler S.Â  The missing early history of contingency tables. Ann Fac Sci Toulouse. 
2002;11:563â€“73.
	24.	Wojtowicz A, Larner AJ.Â Diagnostic test accuracy of cognitive screeners in older people. Prog 
Neurol Psychiatry. 2017;21(1):17â€“21.
	25.	Youngstrom EA.Â  A primer on receiver operating characteristic analysis and diagnos-
tic efficiency statistics for pediatric psychology: we are ready to ROC.Â J Pediatr Psychol. 
2014;39:204â€“21.
1â€ƒ Introduction

15
Â© Springer Nature Switzerland AG 2021
A. J. Larner, The 2x2 Matrix, https://doi.org/10.1007/978-3-030-74920-0_2
Chapter 2
Paired Measures
Contents
2.1â€ƒ Introduction
â€ƒ 15
2.2â€ƒ Error-Based Measures
â€ƒ 16
2.2.1â€ƒ Sensitivity (Sens) andÂ Specificity (Spec), or True Positive andÂ True Negative 
Rates (TPR, TNR)
â€ƒ 16
2.2.2â€ƒ Quality Measures (QSN, QSP)
â€ƒ 19
2.2.3â€ƒ False Positive Rate (FPR), False Negative Rate (FNR)
â€ƒ 21
2.3â€ƒ Information-Based Measures
â€ƒ 23
2.3.1â€ƒ Positive andÂ Negative Predictive Values (PPV, NPV)
â€ƒ 23
2.3.2â€ƒ Bayesâ€™ Formula; Standardized Positive andÂ Negative Predictive Values 
(SPPV, SNPV)
â€ƒ 24
2.3.3â€ƒ False Discovery Rate (FDR), False Reassurance Rate (FRR)
â€ƒ 27
2.3.4â€ƒ Positive andÂ Negative Likelihood Ratios (LR+, LRâˆ’)
â€ƒ 29
2.3.5â€ƒ Post-test Odds; Net Harm toÂ Net Benefit (H/B) Ratio
â€ƒ 34
2.3.6â€ƒ Conditional Probability Plot
â€ƒ 35
2.3.7â€ƒ Positive andÂ Negative Predictive Ratios (PPR, NPR)
â€ƒ 36
2.4â€ƒ Association-Based Measures
â€ƒ 39
2.4.1â€ƒ Diagnostic Odds Ratio (DOR) andÂ Error Odds Ratio (EOR)
â€ƒ 39
2.4.2â€ƒ Clinical Utility Index (CUI+, CUIâˆ’) andÂ Clinical Disutility Index  
(CDI+, CDIâˆ’)
â€ƒ 43
References
â€ƒ 45
2.1â€ƒ Introduction
Several paired measures may be derived from the basic 2Â Ã—Â 2 contingency table. The 
classification of these measures as error-based, information-based, and association-Â­
based, following Bossuyt [2], is used in this chapter. Other classifications might 
have been used, such as test-oriented measures (e.g. sensitivity and specificity, false 
positive and false negative rates, likelihood ratios) versus patient-oriented measures 
(predictive values, predictive ratios).

16
2.2â€ƒ Error-Based Measures
2.2.1â€ƒ Sensitivity (Sens) andÂ Specificity (Spec), or True Positive 
andÂ True Negative Rates (TPR, TNR)
Yerushalmy [36] and Neyman [30] are usually credited as the first authors to discuss 
the statistical aspects of screening and diagnostic tests, and Yerushalmy introduced 
the terms sensitivity (Sens) and specificity (Spec) to denote respectively the inher-
ent ability of a test to detect correctly a condition when it is present and to rule it out 
correctly when it is absent. Sens and Spec are conditional probabilities with range 
from 0 to 1, with higher values better. They are â€œuncalibrated measures of test qual-
ity ... with a variable zero-point and scaleâ€ ([14], p.65). There is a trade-off between 
Sens and Spec, since as the value of one rises the other falls.
Sensitivity (Sens) is sometimes known as true positive rate or ratio (TPR), hit 
rate, recall, or success ratio. In medical practice it is the probability of a positive test 
given the presence of disease, or the proportion of test positivity in the presence of 
a target condition, hence more generally a positive classification by the test in the 
presence of a given class.
In literal notation (Fig.Â 2.1):
	
Sens
TP
TP
FN
=
+
(
)
/
	
or, with marginal total notation:
	
Sens
TP p
=
/
	
In algebraic notation:
	
Sens
a
a
c
a p
=
+
(
)
=
/
/
	
In error notation (see Fig. 1.5):
	
Sens
=
(
)
1âˆ’Î² 	
Sens may also be expressed in probability notation. If a test may be either posi-
tive, T+, or negative, Tâˆ’ , when used to distinguish between the presence, D+, or 
absence, Dâˆ’, of a target disease, then:
	
Sens
T
D
=
+
+
(
)
p
|
	
Specificity (Spec) is sometimes known as true negative rate or ratio (TNR). In 
medical practice it is the probability of a negative test given the absence of disease, 
or the proportion of test negativity among the healthy, hence more generally a nega-
tive classification by the test in the absence of a given class. Hence both Sens and 
Spec are test-oriented measures.
2â€ƒ Paired Measures

17
Paired measures (algebraic notation only):
Sens (TPR)
=
a/(a + c)
Spec (TNR)
=
d/(b + d)
FPR
=
(1 â€“ Spec) 
=
b/(b + d)
FNR
=
(1 â€“ Sens) 
=
c/(a + c)
PPV
=
a/(a + b)
NPV
=
d/(c + d)
FDR
=
(1 â€“ PPV) 
=
b/(a + b)
FRR
=
(1 â€“ NPV) 
=
c/(c + d)
LR+
=
TPR/(1 â€“ TNR)   =
[a/(a + c)]/[b/(b + d)]
LRâˆ’
=
(1 â€“ TPR)/TNR   = 
[c/(a + c)]/[d/(b + d)]
DOR
=
LR+/LRâˆ’      =          ad/bc
EOR
=
ab/cd
True Status
Test 
Outcome
Condition 
present 
(= case)
Condition 
absent 
(= non case)
Positive
Negative
True positive 
[TP] (a)
False positive
[FP] (b)
True negative 
[TN] (d)
True negative 
[TN] (d)
False negative
[FN] (c)
p
p
q
q
r
r
CUI+
=
Sens x PPV
=
a/(a + c) x a/(a + b)
CUIâˆ’
=
Spec x NPV
=
d/(b + d) x d/(c + d)
Fig. 2.1â€‚ 2Â Ã—Â 2 contingency table with literal and algebraic notation, marginal totals, and derived 
paired measures
Worked Example: Sens, Spec
The Mini-Addenbrookeâ€™s Cognitive Examination (MACE) [11] was sub-
jected to a screening test accuracy study in a large patient cohort, N = 755 
[15]. At the MACE cut-off of â‰¤20/30, the test outcomes for the diagnosis of 
dementia were as shown in the 2Â Ã—Â 2 contingency table (Fig.Â 2.2): TP = 104, 
FN =10, FP = 188, and TN = 453.
2.2â€ƒ Error-Based Measures

18
In literal notation:
	
Spec
TN
FP
TN
TN p
=
+
(
)
=
â€²
/
/
	
In algebraic notation:
	
Spec
d
b
d
d p
=
+
(
)
=
â€²
/
/
	
In error notation (see Fig. 1.5):
	
Spec
=
(
)
1â€“ Î± 	
In probability notation:
	
Spec
T
D
=
âˆ’
âˆ’
(
)
p
|
	
Diagnosis
MACE
Outcome
Dementia
present
Dementia
absent
â‰¤20/30
>20/30
True positive
[TP] = 104
False positive
[FP] = 188
True negative
[TN] = 453
False negative
[FN] = 10
Fig. 2.2â€‚ 2Â Ã—Â 2 contingency table for Mini-Addenbrookeâ€™s Cognitive Examination (MACE) out-
comes (N = 755) for the diagnosis of dementia at MACE cut-off of â‰¤20/30. (Data from [15])
Hence the values for Sens and Spec at this cut-off are:
Sens
TP
TP
FN
=
+
(
)
=
+
(
)
=
/
/
.
104
104
10
0 912
Spec
TN
FP
TN
=
+
(
)
=
+
(
)
=
/
/
.
453
188
453
0 707
2â€ƒ Paired Measures

19
Sens and Spec were once thought to be invariant, intrinsic test properties, inde-
pendent of study sample and location. Certainly they are algebraically unrelated to 
the base rate, P (Sect. 1.3.2), and hence insensitive to changes in class distribution, 
being strict columnar ratios. However, in medical practice it is now recognised that 
heterogeneity of clinical populations (spectrum bias) imposes potentially serious 
limitations on the utility of Sens and Spec measures, since very different values may 
be found, for example in different patient subgroups within the sampled population, 
i.e. Sens and Spec are not independent of disease prevalence [3, 10, 23, 24] (Sect. 3.4).
Sens and Spec also vary with test cut-off [15] or Q [16], prompting the develop-
ment of â€œquality measuresâ€ (Sect. 2.2.2).
2.2.2â€ƒ Quality Measures (QSN, QSP)
As previously discussed (Sect. 1.3.2), Kraemer [14] developed a metric, Q, the level 
of a test, also known as the â€œpositive sign rateâ€, which is the probability of a positive 
test in the population examined.
In literal notation (Fig.Â 2.1):
	
Q
TP
FP
N
=
+
(
) /
	
Worked Example: Effect of Prevalence on Sens, Spec
In the aforementioned study of MACE [15], test performance was analysed in 
patient cohorts aged â‰¥65 years (n = 287) and â‰¥75 years (n = 119), in whom 
the prevalence of cognitive impairment (dementia and mild cognitive impair-
ment) was anticipated to be higher than in the whole cohort, since the preva-
lence of dementia increases with age. The table shows Sens and Spec for 
cognitive impairment at the MACE cut-off of â‰¤25/30 (with 95% confidence 
intervals) in the different cohorts.
Cohort
Whole
â‰¥65 years
â‰¥75 years
N
755
287
119
Prevalence of cognitive impairment
0.445
0.749
0.933
Sens
0.967
(0.948â€“0.986)
0.963
(0.937â€“0.988)
0.991
(0.973â€“1.00)
Spec
0.458
(0.411â€“0.506)
0.528
(0.412â€“0.643)
0.375
(0.040â€“0.710)
Hence this analysis clearly illustrates the different values for Sens and 
Spec in subgroups with different disease prevalence (or pre-test probabil-
ity) [18].
2.2â€ƒ Error-Based Measures

20
In algebraic notation:
	
Q
a
b
N
q N
=
+
(
)
=
/
/
	
The probability of a negative test (â€œnegative sign rateâ€) in the population is 1Â â€“ 
Q or Qâ€².
In literal notation:
	
â€²
=
+
(
)
Q
FN
TN
N
/
	
In algebraic notation:
	
â€²
â€²
=
+
(
)
=
Q
c
d
N
q
N
/
/
	
From these values, quality sensitivity and specificity values, denoted as QSN and 
QSP [14], or TPRQ and TNRQ, may be calculated which give the increment in each 
parameter beyond the level, such that:
	
QSNorTPR
Sens
Q
Q
Q
=
(
)
â€²
â€“
/
	
	
QSPorTNR
Spec
Q
Q
Q
=
(
)â€²
â€“
/
	
QSN and QSP range from 0 to 1, with higher values better, as for Sens and Spec.
Worked Example: QSN, QSP
In a screening test accuracy study of MACE [15], at the cut-off of â‰¤20/30 
(Fig.Â 2.2), Sens = 0.912 and Spec = 0.707 (see Sect. 2.2.1), and Q = 0.387 and 
Q' = 0.613 (Sect. 1.3.2) [16].
Hence the value for QSN or TPRQ is:
QSN
Sens
Q
Q
=
(
)
= (
)
=
â€²
â€“
/
.
â€“ .
/ .
.
0 912
0 387
0 613
0 857
The values for QSP or TNRQ is:
QSP
Spec
Q
Q
=
(
)
= (
)
=
â€²
â€“
/
.
â€“ .
/ .
.
0 707
0 613
0 387
0 242
Note how these quality measures differ from Sens (lower) and Spec (very 
much lower).
2â€ƒ Paired Measures

21
Like Sens and Spec, QSN and QSP will vary with the chosen test cut-off. These 
calibrated, rescaled, or standardized indices of test parameters have been suggested 
to be more comparable across different samples [22]. Values of QSN and QSP are 
generally inferior to the corresponding values of Sens and Spec [16]. The use of 
these quality measures has not been widely adopted
2.2.3â€ƒ False Positive Rate (FPR), False Negative Rate (FNR)
False positive and false negative rates denote respectively the inherent capacity or 
propensity of a test to detect incorrectly a condition when it is absent and not to 
detect it correctly when it is present. Like Sens and Spec, false positive and false 
negative rates are conditional probabilities with range from 0 to 1,
False positive rate or ratio (FPR) is a measure of incorrect classification. In medi-
cal practice this is the probability of the test classifying non-cases as cases, and 
more generally of classifying non-events as events (â€œovercallsâ€). FPR ranges from 
0 to 1, with lower values better.
FPR is sometimes known as the â€œfalse alarm rateâ€ but this latter terminology is 
not used here because of possible confusion with another parameter for which this 
term may also be used which is also known as the false discovery rate (see Sect. 
2.3.3). The term â€œfall outâ€ is also sometimes used to denote FPR.
In literal notation (Fig.Â 2.1):
	
FPR
FP
FP
TN
FP p
=
+
(
)
=
â€²
/
/
	
In algebraic notation:
	
FPR
b
b
d
b p
=
+
(
)
=
â€²
/
/
	
In error notation (see Fig. 1.5):
	
FPR
=
Î± 	
In probability notation:
	
FPR
T
D
=
+
âˆ’
(
)
p
|
	
FPR is analogous to Type I or Î± error (Sect. 1.5). FPR is the complement, or 
negation, of specificity (see Sect. 3.2.2).
False negative rate or ratio (FNR), or miss rate, is another measure of incorrect 
classification. In medical practice it is the probability of the test classifying cases as 
2.2â€ƒ Error-Based Measures

22
non-cases, and more generally of classifying events or instances as non-events or 
non-instances (â€œundercallsâ€). FNR ranges from 0 to 1, with lower values better.
In literal notation (Fig.Â 2.1):
	
FNR
FN
FN
TP
FN p
=
+
(
)
=
/
/
	
In algebraic notation:
	
FNR
c
a
c
c p
=
+
(
)
=
/
/
	
In error notation (see Fig. 1.5):
	
FNR
=
Î² 	
In probability notation:
	
FNR
T
D
=
âˆ’
+
(
)
p
|
	
FNR is analogous to Type II or Î² error (Sect. 1.5). FNR is the complement, or 
negation, of sensitivity (see Sect. 3.2.1).
Like Sens and Spec, FPR and FNR are strict columnar ratios and hence algebra-
ically are unrelated to the base rate, P, and hence are (at least notionally) insensitive 
to changes in class distribution. However, as with Sens and Spec, values may vary 
with the heterogeneity of clinical populations (spectrum bias). FPR and FNR vary 
with test cut-off [15].
Worked Example: FPR, FNR
In a screening test accuracy study of MACE [15], at the MACE cut-off of 
â‰¤20/30, the test outcomes were as follows (Fig.Â 2.2): TP = 104, FN =10, FP = 
188, and TN = 453.
Hence the values for FPR and FNR at this cut-off are:
FPR
FP
FP
TN
=
+
(
)
=
+
(
)
=
/
/
.
188
188
453
0 293
FNR
FN
FN
TP
=
+
(
)
=
+
(
)
=
/
/
.
10
10
104
0 088
2â€ƒ Paired Measures

23
The appropriate balance between FP and FN in any test, or their relative costs, 
may need to be factored into clinical judgments (see Sect. 3.2.5 for further discus-
sion). Of note, many measures assume these costs to be equal (e.g. diagnostic odds 
ratio, Sect. 2.4.1; accuracy, Sect. 3.2.4; Youden index, Sect. 4.2) but this is often not 
the case in clinical practice.
2.3â€ƒ Information-Based Measures
2.3.1â€ƒ Positive andÂ Negative Predictive Values (PPV, NPV)
Predictive values give the probability that a disease is present or absent given the 
test is positive or negative, or more generally that the test will forecast the correct 
outcome or classification [1]. Predictive values range from 0 to 1, with higher values 
better. Predictive values are calculated using values from both columns of the 2Â Ã—Â 2 
contingency table (cf. Sens and Spec; Sect. 2.2.1), hence are sensitive to class 
imbalance or skews, or in other words are dependent on disease prevalence,
Positive predictive value (PPV) is the probability of disease in a patient given a 
positive test, also known as the post-positive test probability of disease, or post-test 
probability, or precision. In the weather forecasting literature, the term probability 
of detection (POD) or prefigurance is sometimes used [34].
In literal notation (Fig.Â 2.1):
	
PPV
TP
TP
FP
TP q
=
+
(
)
=
/
/
	
In algebraic notation:
	
PPV
a
a
b
a q
=
+
(
)
=
/
/
	
In probability notation:
	
PPV
D
T
=
+
+
(
)
p
|
	
Negative predictive value (NPV) is the probability of the absence of disease in a 
patient given a negative test, hence also known as the post-negative test probability 
of absence of disease. Hence both PPV and NPV may be described as patient-Â­
oriented measures (cf. Sens and Spec as test-oriented measures).
In literal notation (Fig.Â 2.1):
	
NPV
TN
FN
TN
TN q
=
+
(
)
=
â€²
/
/
	
2.3â€ƒ Information-Based Measures

24
In algebraic notation:
	
NPV
d
c
d
d q
=
+
(
)
=
â€²
/
/
	
In probability notation:
	
NPV
D
T
=
âˆ’
âˆ’
(
)
p
|
	
Predictive values are scalar values based on information from both columns of 
the 2Â Ã—Â 2 table (cf. Sens and Spec), hence vary with prevalence, P (Sects. 2.3.2 and 
2.3.5), for which reason their values may be described as â€œunstableâ€ and do not 
necessarily travel well from one situation to another. Predictive values also vary 
with the level of the test, Q, and are sensitive to class imbalance.
2.3.2â€ƒ Bayesâ€™ Formula; Standardized Positive andÂ Negative 
Predictive Values (SPPV, SNPV)
It is possible to calculate PPV and NPV at any disease prevalence based on values 
for Sens and Spec since the latter are (relatively) resistant to changes in prevalence, 
although not immutably fixed (Sect. 2.2.1). This approach to probability revision is 
given by Bayesâ€™ formula, after Thomas Bayes (1702-61), hence [1]:
	
PPV
Sens P
Sens P
Spec
P
Sens P
Sens P
FPR
=
Ã—
Ã—
(
) +
âˆ’
(
)Ã—
âˆ’
(
)
ï£®ï£°
ï£¹ï£»
=
Ã—
Ã—
(
) +
/
/
1
1
Ã—
âˆ’
(
)
ï£®ï£°
ï£¹ï£»
1
P
	
Worked Example: PPV, NPV
In a screening test accuracy study of MACE [15], at the MACE cut-off of 
â‰¤20/30, the test outcomes were as follows (Fig.Â 2.2): TP = 104, FN =10, FP = 
188, and TN = 453.
Hence the raw, unadjusted, predictive values at this cut-off are:
PPV
TP
TP
FP
=
+
(
)
=
+
(
)
=
/
/
.
104
104
188
0 356
NPV
TN
FN
TN
=
+
(
)
=
+
(
)
=
/
/
.
453
10
453
0 978
2â€ƒ Paired Measures

25
	
NPV
Spec
P
Spec
P
Sens
P
Spec
P
Sp
=
Ã—(
)
Ã—(
)
ï£®ï£°
ï£¹ï£»+ (
)Ã—
ï£®ï£°
ï£¹ï£»
=
Ã—(
)
1
1
1
1
â€“
/
â€“
â€“
â€“
/
ec
P
FNR
P
Ã—(
)
ï£®ï£°
ï£¹ï£»+
Ã—
[
]
1â€“
	
This may be expressed in probability notation as:
	 PPV
T
D
D
T
D
D
T
D
D
=
+
+
(
)
+
(
)
+
+
(
)
+
(
) +
+
âˆ’
(
)
âˆ’
(
)
p
p
p
p
p
p
|
.
/
|
.
|
.
	
	 NPV
T
D
D
T
D
D
T
D
D
=
âˆ’
âˆ’
(
)
âˆ’
(
)
âˆ’
âˆ’
(
)
âˆ’
(
) +
âˆ’
+
(
)
+
(
)
p
p
p
p
p
p
|
.
/
|
.
|
.
	
Heston [8, 9] defined â€œstandardized predictive valuesâ€ as the predictive values 
calculated at 50% disease prevalence, hence:
	
SPPV
Sens
Sens
Spec
Sens
Sen
=
Ã—
Ã—
(
) +
Ã—
âˆ’
(
)
ï£®ï£°
ï£¹ï£»
=
Ã—
Ã—
0 5
0 5
0 5
1
0 5
0 5
.
/
.
.
.
/
.
s
FPR
(
) +
Ã—
(
)
0 5.
	
	
SNPV
Spec
Spec
Sens
Spec
Spe
=
Ã—
Ã—
(
) +
Ã—
âˆ’
(
)
ï£®ï£°
ï£¹ï£»
=
Ã—
Ã—
0 5
0 5
0 5
1
0 5
0 5
.
/
.
.
.
/
.
c
FNR
(
) +
Ã—
(
)
0 5.
	
Heston also suggested the potential clinical value of performing predictive value 
calculations for prevalence rates of 25% and 75%. Estimates of standardized predic-
tive values, SPPV and SNPV, may differ from PPV and NPV, the differences being 
larger when prevalence deviates more strongly from 0.5.
Worked Example: SPPV, SNPV
In a screening test accuracy study of the MACE [15], at the MACE cut-off 
â‰¤20/30 (Fig.Â 2.2), Sens = 0.912 and Spec = 0.707 (see Sect. 2.2.1). Dementia 
prevalence in the patient cohort (N = 755) was 0.151 (Sect. 1.3.2).
For a dementia prevalence of 0.5, the standardized predictive values are:
SPPV
Sens
Sens
Spec
=
Ã—
Ã—
(
) +
Ã—
âˆ’
(
)
ï£®ï£°
ï£¹ï£»
=
Ã—
Ã—
0 5
0 5
0 5
1
0 5 0 912
0 5 0
.
/
.
.
.
.
/
.
.912
0 5
1
0 707
0 757
(
) +
Ã—
âˆ’
(
)
ï£®ï£°
ï£¹ï£»
=
.
.
.
SNPV
Spec
Spec
Sens
=
Ã—
Ã—
[
]+
Ã—
âˆ’
(
)
ï£®ï£°
ï£¹ï£»
=
Ã—
Ã—
0 5
0 5
0 5
1
0 5 0 707
0 5 0
.
/
.
.
.
.
/
.
.707
0 5
1
0 912
0 889
[
]+
Ã—
âˆ’
(
)
ï£®ï£°
ï£¹ï£»
=
.
.
.
Comparing the SPPV and SNPV values with PPV and NPV (Sect. 2.3.1), 
SPPV is much better than PPV (0.757 vs 0.356), whilst SNPV is a little worse 
than NPV (0.889 vs 0.978).
2.3â€ƒ Information-Based Measures

26
This possibility for rescaling PPV and NPV for different values of P is some-
times exploited by researchers to give an indication of test performance in settings 
other than that of their own study. Examples amongst cognitive screening tests 
include the Addenbrookeâ€™s Cognitive Examination [26], the Addenbrookeâ€™s 
Cognitive Examination Revised [28], and the Mini-Addenbrookeâ€™s Cognitive 
Examination [15], with PPV and NPV calculated at prevalence rates of 0.05, 0.1, 
0.2, and 0.4. PPV may be calculated across the complete range of prevalence or pre-Â­
test probabilities to produce a conditional probability plot (Sect. 2.3.5).
The rescaling of Sens and Spec according to the level of the test, Q (see Sect. 
2.2.2) may also be applied to other parameters. Since, from Kraemerâ€™s [14] 
equations:
	
QSN
Sens
Q
Q
NPV
P
P
=
(
)
= (
)
â€²
â€²
â€“
/
â€“
/
	
and
	
QSP
Spec
Q
Q
PPV
P
P
=
(
)
= (
)
â€²
â€²
â€“
/
â€“
/
	
rearranging it follows that:
	
NPV
QSN
P
P
Q
=
Ã—
(
) + â€² 	
and
	
PPV
QSP
P
P
Q
=
Ã—
(
) +
â€²
	
This allows rescaled predictive values to be calculated at different levels of Q, as 
for Sens and Spec being recalculated as QSN or TPRQ and QSP or TNRQ [16] (e.g. 
Sect. 2.2.2).
Worked Examples: PPVQ, NPVQ
In a screening test accuracy study of MACE [15], at the cut-off â‰¤20/30, QSN 
= 0.857 and QSP = 0.242 (see Sect. 2.2.2), and dementia prevalence in the 
patient cohort (N = 755) was P = 0.151 (Sect. 1.3.2).
Hence the values for PPVQ and NPVQ are:
PPV
QSP
P
P
Q
=
Ã—
(
) +
=
Ã—
(
) +
=
â€²
0 242 0 849
0 151
0 356
.
.
.
.
NPV
QSN
P
P
Q
=
Ã—
(
) +
=
Ã—
(
) +
=
â€²
0 857 0 151
0 849
0 978
.
.
.
.
2â€ƒ Paired Measures

27
2.3.3â€ƒ False Discovery Rate (FDR), False Reassurance 
Rate (FRR)
The false discovery rate (FDR) is a measure of the probability of the absence of 
disease given an abnormal test (i.e. identifying a non-case as a case), hence also 
known as the post-positive test probability of absence of disease. FDR ranges from 
0 to 1, with lower values better.
FDR has sometimes been known as the false alarm rate. â€œFalse alarm rateâ€ is 
potentially an ambiguous term: it has also been used on occasion to mean both the 
false positive rate (FPR) (e.g. [14], p.64] and the false negative rate (FNR) [32] 
(Sect. 2.2.3). Hence the FDR terminology is preferred here in order to avoid any 
possible confusion.
These values are identical to the unscaled values of PPV and NPV (Sect. 
2.3.1) because the same MACE cut-off was used, hence the positive sign rate 
Q = 0.387 (Sect. 1.3.2) was the same. If we select a different value of Q, say 
0.5, then:
QSN
Sens
Q
Q
= (
)
= (
)
=
â€²
â€“
/
.
â€“ .
/ .
.
0 912
0 5
0 5
0 824
QSP
Spec
Q
Q
= (
)
= (
)
=
â€²
â€“
/
.
â€“ .
/ .
.
0 707
0 5
0 5
0 414
Hence the values for PPVQ and NPVQ are now:
PPV
QSP
P
P
Q
=
Ã—
(
) +
=
Ã—
(
) +
=
â€²
0 414 0 849
0 151
0 502
.
.
.
.
NPV
QSN
P
P
Q
=
Ã—
(
) +
=
Ã—
(
) +
=
â€²
0 824 0 151
0 849
0 973
.
.
.
.
With the change in Q, QSN and particularly NPVQ have changed little, 
reflecting the high sensitivity of MACE, whereas QSP and PPVQ have shown 
greater change.
2.3â€ƒ Information-Based Measures

28
In literal notation (Fig.Â 2.1):
	
FDR
FP
TP
FP
FP q
=
+
(
)
=
/
/
	
In algebraic notation:
	
FDR
b
a
b
b q
=
+
(
)
=
/
/
	
FDR is the complement of PPV (see Sect. 3.3.1):
	
FDR
PPV
=
1â€“
	
In probability notation:
	
FDR
D
T
=
âˆ’
+
(
)
p
|
	
By Bayesâ€™ equation:
	 FDR
T
D
D
T
D
D
T
D
D
=
+
âˆ’
(
)
âˆ’
(
)
+
âˆ’
(
)
âˆ’
(
) +
+
+
(
)
+
(
)
p
p
p
p
p
p
|
.
/
|
.
|
.
	
False reassurance rate (FRR), sometimes known as false omission rate (FOR), is 
a measure of the probability of the presence of disease given a normal test (i.e. iden-
tifying a case as a non-case), hence also known as the post-negative test probability 
of disease. FRR ranges from 0 to 1, with lower values better.
In literal notation (Fig.Â 2.1):
	
FRR
FN
FN
TN
FN q
=
+
(
)
=
â€²
/
/
	
In algebraic notation:
	
FRR
c
c
d
c q
=
+
(
)
=
â€²
/
/
	
FRR is the complement of NPV (see Sect. 3.3.2):
	
FRR
NPV
=
1â€“
	
In probability notation:
	
FRR
D
T
=
+
âˆ’
(
)
p
|
	
By Bayesâ€™ equation:
	
FRR
T
D
D
T
D
D
T
D
D
=
âˆ’
+
(
)
+
(
)
âˆ’
+
(
)
+
(
) +
âˆ’
âˆ’
(
)
âˆ’
(
)
p
p
p
p
p
p
|
.
/
|
.
|
.
	
2â€ƒ Paired Measures

29
2.3.4â€ƒ Positive andÂ Negative Likelihood Ratios (LR+, LRâˆ’)
Likelihood ratios (LRs), also sometimes known as diagnostic likelihood ratios 
(DLRs), measure the change in pre-test odds (Sect. 1.3.3) to post-test odds (Sect. 
2.3.5), and hence may be characterised as measures of probability revision based on 
Bayesâ€™ formula, or measures of diagnostic gain. They combine information about 
sensitivity and specificity [32] and hence are closely related to these terms.
The positive likelihood ratio (LR+, also sometimes denoted PLR) gives the odds 
of a positive test result in an affected individual relative to an unaffected:
	
LR
Sens
Spec
Sens FPR
TPR FPR
+
=
âˆ’
(
)
=
=
/
/
/
1
	
In literal notation:
	
LR
TP
TP
FN
FP
FP
TN
TP p
FP p
TP p
F
+
=
+
(
)
ï£®ï£°
ï£¹ï£»
+
(
)
ï£®ï£°
ï£¹ï£»
=
[
] [
]
=
] [
â€²
â€²
/
/
/
/
/
/
.
/
P p.
ï£®ï£°
ï£¹ï£»
	
In algebraic notation:
	
LR
a
a
c
b
b
d
a b
d
b a
c
a p
+
=
+
(
)
ï£®ï£°
ï£¹ï£»
+
(
)
ï£®ï£°
ï£¹ï£»
=
+
(
)
ï£®ï£°
ï£¹ï£»
+
(
)
ï£®ï£°
ï£¹ï£»
=
]â€²
/
/
/
.
/
.
.
/[
ï£®ï£°
ï£¹ï£»
b p.
	
Worked Example: FDR, FRR
In a screening test accuracy study of MACE [15], at the MACE cut-off of 
â‰¤20/30 (Fig.Â 2.2), TP = 104, FN =10, FP = 188, and TN = 453.
Hence the values for FDR and FRR are:
FDR
FP
TP
FP
=
+
(
)
=
+
(
)
=
/
/
.
188
104
188
0 644
FRR
FN
FN
TN
=
+
(
)
=
+
(
)
=
/
/
.
10
10
453
0 0215
2.3â€ƒ Information-Based Measures

30
In error notation:
	
LR+
=
(
)
1âˆ’Î²
Î±
/
	
LR+ can also be expressed in probability notation:
	
LR
TPR FPR
T
D
T
D
+
=
=
+
+
(
)
+
âˆ’
(
)
/
|
/
|
p
p
	
If the outcome of a test is Ri, then more generally:
	
LR
D
D
=
+
(
)
âˆ’
(
)
p R
p R
i
i
|
/
|
	
The negative likelihood ratio (LRâˆ’, also sometimes denoted NLR) gives the 
odds of a negative test result in an affected individual relative to an unaffected.
	
LR
Sens
Spec
FNR Spec
FNR TNR
âˆ’
=
(
)
=
=
1âˆ’
/
/
/
	
In literal notation:
	
LR
FN
TP
FN
TN
FP
TN
FN p
TN p
FN p
T
âˆ’
=
+
(
)
ï£®ï£°
ï£¹ï£»
+
(
)
ï£®ï£°
ï£¹ï£»
=
[
] [
]
=
] [
â€²
â€²
/
/
/
/
/
/
.
/
N p.
ï£®ï£°
ï£¹ï£»
	
In algebraic notation:
	
LR
c
a
c
d
b
d
c b
d
d a
c
c p
âˆ’
=
+
(
)
ï£®ï£°
ï£¹ï£»
+
(
)
ï£®ï£°
ï£¹ï£»
=
+
(
)
ï£®ï£°
ï£¹ï£»
+
(
)
ï£®ï£°
ï£¹ï£»
=
]â€²
/
/
/
.
/
.
.
/[
ï£®ï£°
ï£¹ï£»
d p.
	
In error notation:
	
LRâˆ’
=
âˆ’
(
)
Î²
Î±
/ 1
	
LRâˆ’ can also be expressed in probability notation:
	
LR
FNR TNR
T
D
T
D
âˆ’
=
=
âˆ’
+
(
)
âˆ’
âˆ’
(
)
/
|
/
|
p
p
	
Likelihood ratios may be qualitatively classified according to their distance from 
1, a useless test, to indicate the change in probability of disease (TableÂ 2.1, left hand 
column) [13]; for LR+ end points are 1 to âˆ; for LRâˆ’ they are 0 to 1.
2â€ƒ Paired Measures

31
A distinction may be drawn between result-specific and category-specific LRs 
([12], p.175). A result-specific LR refers to the ratio of the probability of observing 
that result conditional on the presence of the target (disease, diagnosis) to the prob-
ability of observing that result conditional on the absence of the target. More often 
in clinical practice dichotomised test results are cumulated to produce a category-Â­
specific LR.
Table 2.1â€‚ Classification of LRs
LR value
Qualitative classification:
Change in probability of disease 
[12]
Approximate change in probability (%) 
[27]
â‰¤ 0.1
Very large decrease
â€“
0.1
Large decrease
â€“45
â‰¤ 0.2
Large decrease
â€“30
0.3
Moderate decrease
â€“25
0.4
Moderate decrease
â€“20
â‰¤ 0.5
Moderate decrease
â€“15
0.5 < LRâˆ’ â‰¤ 
1.0
Slight decrease
â€“
1.0
0
1.0 < LR+ < 
2.0
Slight increase
â€“
2.0
Moderate increase
+15
3.0
Moderate increase
+20
4.0
Moderate increase
+25
â‰¤ 5.0
Moderate increase
+30
6.0
Large increase
+35
8.0
Large increase
+40
â‰¤ 10.0
Large increase
+45
â‰¥ 10.0
Very large increase
â€“
Worked Example: Result-Specific LR
The â€œattended withâ€ (AW) sign has been proposed as a useful screening test 
for the diagnosis of cognitive impairment. In a screening test accuracy study 
in a large consecutive patient cohort (N = 1209), AW sign was observed in 473 
of 507 patients with major and minor neurocognitive disorder and in 306 of 
702 patients with no cognitive impairment [19].
Hence, the probability of AW given cognitive impairment is 473/507 = 
0.933, and the probability of AW given no cognitive impairment is 306/702 = 
0.436. Note that these values are equivalent to the true positive rate (TPR) or 
2.3â€ƒ Information-Based Measures

32
sensitivity of the test and the false positive rate (FPR). Hence the result-Â­
specific likelihood ratio is given by:
LR
D
D
TPR FPR
=
+
(
)
âˆ’
(
)
=
=
=
p R
p R
i
i
|
/
|
/
.
/ .
.
0 933 0 436
2 14
Following the qualitative classification of likelihood ratios described by 
Jaeschke etÂ al. [13], LR = 2.14 represents a moderate increase in the probabil-
ity of disease.
Worked Example: Category-Specific LR+, LRâˆ’
In a screening test accuracy study of the MACE [15], at the MACE cut-off 
â‰¤20/30, Sens = 0.912 and Spec = 0.707 for dementia diagnosis (Sect. 2.2.1).
Hence, the positive likelihood ratio (LR+) at this cut-off is:
LR
Sens
Spec
+
=
âˆ’
(
)
=
âˆ’
(
)
=
/
.
/
.
.
1
0 912
1 0 707
3 11
Following the qualitative classification of likelihood ratios described by 
Jaeschke etÂ al. [13], LR+ = 3.11 represents a moderate increase in the proba-
bility of disease.
The negative likelihood ratio (LRâˆ’) at this cut-off is:
LR
Sens
Spec
âˆ’
=
(
)
=
(
)
=
1
1 0 912
0 707
0 124
âˆ’
âˆ’
/
.
/ .
.
Following the qualitative classification of likelihood ratios described by 
Jaeschke etÂ al. [13], LRâˆ’ = 0.124 represents a large decrease in the probabil-
ity of disease.
Note that these results could also be obtained from the raw study data (see 
Fig.Â  2.2). For LR+, the probability of MACE â‰¤20/30 given dementia is 
104/114 = 0.912 (equivalent to sensitivity or true positive rate) and the 
probability of MACE â‰¤20/30 given no dementia is 188/641 = 0.293 
2â€ƒ Paired Measures

33
As LRs are derived from sensitivity and specificity, like these metrics they are 
algebraically unrelated to the base rate, P.Â However, as is the case for Sens and Spec, 
in practice LRs are not independent of prevalence [3].
LRs vary with test cut-off [15] (see also Fig. 7.2). Rather than dichotomising 
outcomes with a single cut-off, dividing continuous data into intervals and calculat-
ing interval likelihood ratios (ILRs) is possible [4] (Sect. 7.3.2).
LRs may be rescaled according to the level of the test, Q (see Sect. 2.2.2) [16], 
such that:
	
LR
QSN
QSP
Q+
=
âˆ’
(
)
/ 1
	
	
LR
QSN
QSP
Qâˆ’
=
(
)
1âˆ’
/
	
Calculation of LRs also provides a method for combining the results of multiple 
tests, assuming conditional independence of the tests in the presence and absence of 
the target diagnosis:
	
Post-test odds
Pre-test odds LR
LR
LRn
=
+â€¦
Ã—
Ã—
1
2
	
Combination of test results is further considered in Section 7.3.4.
(equivalent to false positive rate; Sect. 2.2.3). Hence the category-specific 
positive likelihood ratio is given by:
LR
T
D
T
D
TPR FPR
+
=
+
+
(
)
+
âˆ’
(
)
=
=
=
p
p
|
/
|
/
.
/ .
.
0 912 0 293
3 11
For LRâˆ’, the probability of MACE >20/30 given dementia is 10/114 = 
0.088 (equivalent to false negative rate; Sect. 2.2.3) and the probability of 
MACE >20/30 given no dementia is 453/641 = 0.707 (equivalent to specific-
ity or true negative rate). Hence the category-specific negative likelihood ratio 
is given by:
LR
T
D
T
D
FNR TNR
âˆ’
=
âˆ’
+
(
)
âˆ’
âˆ’
(
)
=
=
=
p
p
|
/
|
/
.
/ .
.
0 088 0 707
0 124
2.3â€ƒ Information-Based Measures

34
2.3.5â€ƒ Post-test Odds; Net Harm toÂ Net Benefit (H/B) Ratio
Post-test odds may be calculated as the product of LR+ and the pre-test odds (Sect. 
1.3.2), a form of Bayesian updating:
	
Post-test odds
Pre-testodds
LR
P P
LR
=
Ã—
+
=
(
)Ã—
+
â€²
/
	
In probability notation:
	
Post-test odds
D
D
LR
=
+
(
)
âˆ’
(
)Ã—
+
p
p
/
	
McGee [27] advocated some simple rules to obviate these calculations between 
pre- and post-test odds and probabilities, such that LR+ values of 2, 5, and 10 
increased the probability by 15%, 30%, and 45% respectively, whereas LRâˆ’ values 
of 0.5, 0.2, and 0.1 decreased the probability by 15%, 30% and 45% respectively 
(TableÂ 2.1, right hand column). These approximate figures derive from the almost 
linear relationship of probability and the natural logarithm of odds over the range 
10% to 90%, such that the change in probability may be calculated independent of 
pre-test probability:
	
Change in probability
LR
e
=
Ã—
(
)
0 19
.
log
	
Worked Example: Post-test Odds
In the screening test accuracy study of MACE [15], the pre-test odds of 
dementia were 0.178 (Sect. 1.3.2). The positive likelihood ratio, LR+, of 
MACE using the cut-off â‰¤20/30 was 3.11 (Sect. 2.3.4).
Hence the post-test odds of dementia using MACE cut-off â‰¤20/30 are:
Post-test odds
Pre-testodds
LR
=
Ã—
+
=
Ã—
=
0 178 3 11
0 553
.
.
.
If desired, post-test odds may be converted back to a post-test probability, 
for comparison with the pre-test probability:
Post-test probability
Post-test odds
post-testodds
=
+
(
)
=
/
.
1
0 553 / .
.
1 553
0 356
=
This may be compared with the pre-test probability in this cohort of 0.151 
(Sect. 1.3.2), indicating the added value of the test.
2â€ƒ Paired Measures

35
The post-test odds may also be characterised as the ratio of net harm to net ben-
efit (H/B), that is the harm (H) of treating a person without disease (i.e. a false posi-
tive) to the net benefit (B) of treating a person with disease (i.e. a true positive), the 
latter term equating to the harm of a false negative result [7]. H/B ratio may also be 
calculated using Bayesâ€™ equation:
	
NetHarm H
NetBenefit B
Pre-test odds
LR
P P
LR
P P
( )
( )
=
Ã—
+
=
(
)Ã—
+
=
(
â€²
â€²
/
/
/
)Ã—(
)
TPR FPR
/
	
For the net harm to net benefit (H/B) ratio, higher values are desirable if the harm 
of a false negative (missing a case) is deemed more significant than the harm of 
diagnosing a false positive (identifying a non-case as a case), a view most clinicians 
would hold to (Sect. 3.2.5). A higher H/B ratio means the test is less likely to miss 
cases, and hence less likely to incur the harms of false negatives. (This scoring of 
H/B ratio may seem counterintuitive if one thinks solely of â€œharmsâ€ and â€œbenefitsâ€, 
hence the important qualification of â€œnetâ€). Tests with high sensitivity may never-
theless have an undesirably low H/B ratio if they also have poor specificity [20].
This equation is also pertinent to considerations of misclassification cost (Sect. 
3.2.5) as harms are sometimes characterised as â€œcostsâ€ and hence the term 
cost:benefit ratio is sometimes used. Also, since TPR/FPR is equivalent to the slope 
of the receiver operating characteristic (ROC) curve ([12], p.68, 157, 171), this is 
also relevant to the setting of test cut-offs using the ROC curve (Section 6.2).
2.3.6â€ƒ Conditional Probability Plot
A conditional probability plot may be used to illustrate graphically the variation in 
post-test probability across the complete range of pre-test probabilities (Fig.Â 2.3). 
Two curves are generated: one for p(D+ Ç€ T+), or PPV; and one for p(D+ Ç€ Tâ€“), or 
FRR (TableÂ 2.2, left hand columns). The point at P = 0.5 on the test-positive plot 
corresponds to the standardized positive predictive value (SPPV; Sect. 2.3.2) and at 
P = 0.5 on the test-negative plot corresponds to (1Â â€“ SNPV). The diagonal line cor-
responds to the situation where a test has LR+ = 1, such that pre-test and post-test 
probabilities are equal and the test result contributes no information.
Clearly, the shape of the conditional probability plot is dependent on the chosen 
test cut-off (i.e. Q). For example, contrast the plots for MACE cut-off â‰¤20/30 
(Fig.Â 2.3) with cut-off â‰¤25/30 (from the index study [10]; Fig.Â 2.4 and TableÂ 2.2, 
right hand columns). With the higher cut-off, the test-negative plot is further from 
the LR = 1 diagonal than with the lower cut-off, indicating that p(D+ Ç€ Tâ€“) is 
extremely low at this test threshold, suggesting this it is very good for ruling out 
disease (few false negatives, high NPV). The test-positive line is closer to LR = 1, 
indicating that p(D+ Ç€ T+) at this threshold is not as effective as the lower threshold 
2.3â€ƒ Information-Based Measures

36
for ruling disease in (lower LR+). Dependence of test parameters on Q is considered 
further in the next chapter.
2.3.7â€ƒ Positive andÂ Negative Predictive Ratios (PPR, NPR)
Linn described two measures which are analogous to likelihood ratios (Sect. 2.3.4) 
but based on predictive values (Sect. 2.3.1) rather than Sens and Spec (Sect. 2.2.1), 
and named predictive ratios [25].
Table 2.2â€‚ Values of PPV and FRR for dementia diagnosis at fixed MACE cut-offs of â‰¤20/30 (left) 
and â‰¤25/30 (right) at various prevalence levels, correspondingly to Figs.Â 2.3 and 2.4 respectively
MACE
cut-off â‰¤20/30
MACE
cut-off â‰¤25/30
P, Pâ€²
PPV
FRR
PPV
FRR
0.1, 0.9
0.257
0.014
0.138
0.003
0.2, 0.8
0.437
0.030
0.266
0.007
0.3, 0.7
0.571
0.051
0.383
0.012
0.4, 0.6
0.675
0.076
0.491
0.019
0.5, 0.5
0.757
0.110
0.591
0.028
0.6, 0.4
0.824
0.157
0.685
0.041
0.7, 0.3
0.879
0.225
0.771
0.063
0.8, 0.2
0.926
0.332
0.853
0.103
0.9, 0.1
0.966
0.528
0.929
0.205
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.2
0.4
0.6
0.8
1
Post-test probability
Pre-test probability
Conditional probability plot
Fig. 2.3â€‚ Conditional probability plot of post-test probability (dependent variable; y axis) vs pre-Â­
test probability (independent variable; x axis) of MACE for dementia diagnosis at cut-off â‰¤20/30 
(data from [21], p.157). Upper curve (test positive) corresponds to PPV (see Fig. 3.10); lower 
curve (test negative) corresponds to FRR (see Fig. 3.11).
2â€ƒ Paired Measures

37
The positive predictive ratio (PPR) is given by:
	
PPR
PPV
NPV
PPV FRR
=
âˆ’
(
)
=
/
/
1
	
In literal notation:
	
PPR
TP
TP
FP
FN
FN
TN
TP q
FN q
TP q
F
=
+
(
)
ï£®ï£°
ï£¹ï£»
+
(
)
ï£®ï£°
ï£¹ï£»
=
[
] [
]
=
] [
â€²
â€²
/
/
/
/
/
/
.
/
N q.
ï£®ï£°
ï£¹ï£»
	
In algebraic notation:
	
PPR
a
a
b
c
c
d
a c
d
c a
b
a q
=
+
(
)
ï£®ï£°
ï£¹ï£»
+
(
)
ï£®ï£°
ï£¹ï£»
=
+
(
)
ï£®ï£°
ï£¹ï£»
+
(
)
ï£®ï£°
ï£¹ï£»
=
]â€²
/
/
/
.
/
.
.
/[
ï£®ï£°
ï£¹ï£»
c q.
	
In probability notation:
	
PPR
D
T
D
T
=
+
+
(
)
+
âˆ’
(
)
p
p
|
/
|
	
By Bayesâ€™ equation:
	
PPR
T |D
D
T |D
D
T |D
D
T |D
=
+
+
(
)
+
(
)
+
+
(
)
+
(
) +
+
âˆ’
(
)
âˆ’
(
)
ï£®ï£°
ï£¹ï£»Ã·
âˆ’
p
p
p
p
p
p
p
.
/
.
.
+
(
)
+
(
)
âˆ’
+
(
)
+
(
) +
âˆ’
âˆ’
(
)
âˆ’
(
)
ï£®ï£°
ï£¹ï£»
.
/
.
.
p
p
p
p
p
D
T |D
D
T |D
D
	
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.2
0.4
0.6
0.8
1
Post-test probability
Pre-test probability
Conditional probability plot
Fig. 2.4â€‚ Conditional probability plot of post-test probability vs pre-test probability of MACE for 
dementia diagnosis at cut-off â‰¤25/30. Compare with Fig.Â 2.3
2.3â€ƒ Information-Based Measures

38
The negative predictive ratio (NPR) is given by:
	
NPR
PPV
NPV
FDR NPV
= (
)
=
1â€“
/
/
	
In literal notation:
	
NPR
FP
TP
FP
TN
FN
TN
FP q
TN q
FP q
T
=
+
(
)
ï£®ï£°
ï£¹ï£»
+
(
)
ï£®ï£°
ï£¹ï£»
= [
] [
]
= [
]
â€²
â€²
/
/
/
/
/
/
.
/
N q.
[
]
	
In algebraic notation:
	
NPR
b
a
b
d
c
d
b c
d
d a
b
b q
=
+
(
)
ï£®ï£°
ï£¹ï£»
+
(
)
ï£®ï£°
ï£¹ï£»
=
+
(
)
ï£®ï£°
ï£¹ï£»
+
(
)
ï£®ï£°
ï£¹ï£»
= [
]â€²
/
/
/
.
/
.
.
/
.d q
[
]
	
In probability notation:
	
NPR
D
T
D
T
=
âˆ’
+
(
)
âˆ’
âˆ’
(
)
p
p
|
/
|
	
By Bayesâ€™ equation:
NPRâ€ƒ â€‚ =â€ƒ â€‚ [p(TÂ +Â Â âƒ’Dâˆ’)Â p(Dâˆ’)/p(TÂ +Â Â âƒ’Dâˆ’)Â p(Dâˆ’)Â +Â p(TÂ +Â Â âƒ’D+)Â p(D+)]Â Ã·Â  
â€ƒ â€ƒ â€ƒ â€ƒ â€ƒ â€‚ p(TÂ âˆ’Â Â âƒ’Dâˆ’)Â p(Dâˆ’)/p(TÂ âˆ’Â Â âƒ’Dâˆ’)Â p(Dâˆ’)Â +Â p(TÂ âˆ’Â Â âƒ’D+)Â p(D+)
Worked Example: PPR, NPR
In a screening test accuracy study of the MACE [15], at the MACE cut-off 
â‰¤20/30, PPV = 0.356 and NPV = 0.978 (Sect. 2.3.1).
Hence, the positive predictive ratio (PPR) at this cut-off is:
PPR
PPV
NPV
=
âˆ’
(
)
=
âˆ’
(
)
=
=
/
.
/
.
.
/ .
.
1
0 356
1
0 978
0 356 0 02159
16 49
The negative predictive ratio (NPR) is:
NPR
PPV
NPV
= (
)
= (
)
=
1
1
0 356
0 978
0 658
â€“
/
â€“ .
/ .
.
2â€ƒ Paired Measures

39
PPR and NPR values are seldom examined in practice [2].
2.4â€ƒ Association-Based Measures
2.4.1â€ƒ Diagnostic Odds Ratio (DOR) andÂ Error Odds 
Ratio (EOR)
The diagnostic odds ratio (DOR) or the cross product ratio [5, 6] is the ratio of the 
product of true positives and true negatives and of false negatives and false positives.
In literal notation:
	
DOR
TP
TN
FP
FN
=
Ã—
(
)
Ã—
(
)
/
	
In algebraic notation:
	
DOR
ad
bc
=
(
) (
)
/
	
As for LRs, these results can also be obtained from the raw study data (see 
Fig.Â  2.2). For PPR, the probability of dementia given MACE â‰¤20/30 is 
104/292 = 0.356 (equivalent to positive predictive value) and the probability 
of dementia given MACE >20/30 is 10/463 = 0.022 (equivalent to false reas-
surance rate; Sect. 2.3.3). Hence PPR is given by:
PPR
D
T
D
T
PPV FRR
=
+
+
(
)
+
âˆ’
(
)
=
=
=
p
p
|
/
|
/
.
/ .
.
0 356 0 02159
16 49
For NPR, the probability of no dementia given MACE â‰¤20/30 is 188/292 
= 0.644 (equivalent to false discovery rate; Sect. 2.3.3) and the probability of 
no dementia given MACE >20/30 is 453/463 = 0.978 (equivalent to negative 
predictive value). Hence NPR is given by:
NPR
D
T
D
T
FDR NPV
=
âˆ’
+
(
)
âˆ’
âˆ’
(
)
=
=
=
p
p
|
/
|
/
.
/ .
.
0 644 0 978
0 658
2.4â€ƒ Association-Based Measures

40
DOR may also be expressed in terms of other previously encountered parameters 
(Sens, Spec, likelihood ratios, predictive values, and predictive ratios):
	
DOR
Sens Spec /
1 Sens
1 Spec
Sens Spec / FNR
FPR
=
(
)
(
) (
)
ï£®ï£°
ï£¹ï£»
=
(
) (
Ã—
âˆ’
Ã—
âˆ’
Ã—
Ã—
)
=
(
) (
)
=
(
)
ï£®ï£°
ï£¹ï£»
(
)
ï£®ï£°
ï£¹ï£»
=
TPR
TNR / FNR
FPR
TPR/ 1 TPR
1
FPR /FPR
LR+
Ã—
Ã—
âˆ’
Ã—
âˆ’
/LR
PPVÃ—NPV/ 1
PPV
1
NPV
PPV
NPV/FDR
FRR
=
PPR/NPR
âˆ’
=
âˆ’
Ã—
âˆ’
Ã—
Ã—
(
) (
)
=
	
Hence, from LRs, in error notation:
	
DOR
=
(
)
] [
(
)
ï£®ï£°
ï£¹ï£»
=
(
)(
) (
)
1
1
1
1
â€“
/
/
/
â€“
â€“
â€“
/
Î²
Î±
Î²
Î±
Î²
Î±
Î±Î²
	
DOR may range from 1, a random classifier (useless test), to +/- âˆ if any of the 
cells of the 2Â Ã—Â 2 table is zero, hence there are no fixed end points. A rescaling to a 
weighted kappa statistic with endpoints of 0 (random classifier) and 1 (perfect clas-
sifier) has been described [35]. A qualitative classification of DOR values was sug-
gested by Rosenthal, as: small ~1.5, medium ~2.5, large ~4, and very large ~10 or 
greater [33].
DOR has known shortcomings [14, 17]. It treats FN and FP as equally undesir-
able, which is often not the case in clinical practice (see Sect. 3.2.5). By choosing 
Worked Examples: DOR
In a screening test accuracy study of MACE [15], at the MACE cut-off of 
â‰¤20/30 (Fig.Â 2.2), TP = 104, FN =10, FP = 188, and TN = 453.
Hence the value for DOR at this cut-off is:
DOR
TP
TN
FP
FN
=
Ã—
(
)
Ã—
(
)
=
Ã—
Ã—
=
/
/
.
104
453 188 10
25 06
Knowing Sens (0.912) and Spec (0.707) at this cut-off (Sect. 2.2.1), DOR 
could also be calculated thus:
DOR
Sens Spec
Sens
Spec
=
Ã—
(
)
(
)Ã—(
)
ï£®ï£°
ï£¹ï£»
=
Ã—
(
/
.
.
/
.
1
1
0 912 0 707
1 0 912
âˆ’
âˆ’
âˆ’
)Ã—(
)
=
Ã—
=
1 0 707
0 645 0 088 0 293
25 01
âˆ’.
.
/ .
.
.
2â€ƒ Paired Measures

41
the best quality of a test and ignoring its weaknesses, it gives the most optimistic 
results, particularly in populations with very high or very low risk. Ratios become 
unstable and inflated as the denominator approaches zero, and may be zero or infi-
nite if one of the classes is nil.
As small differences in one cell value can drastically alter DOR, use of the loga-
rithm of the DOR is sometimes used to compensate. As DOR is a combination of 
products and quotients this is easily done (either common or natural logs may 
be used):
	
log
log
log
log
log
log
log
log
DOR
TP
TN
FP
FN
a
d
(
)
=
(
) +
(
) âˆ’
(
) âˆ’
(
)
=
( ) +
( ) âˆ’
b
c
( ) âˆ’
( )
log
	
log(DOR) may also be calculated from Sens and Spec, specifically from their 
logits (logarithms of odds):
	
DOR
Sens Spec
Sens
Spec
DOR
Sens
Se
=
Ã—
(
)
(
)Ã—(
)
ï£®ï£°
ï£¹ï£»
(
)
=
/
log
log
/
1
1
1
âˆ’
âˆ’
âˆ’
ns
Spec
Spec
logit Sens
logit Spec
(
) +]
[
(
)
ï£®ï£°
ï£¹ï£»
=
(
) +
(
)
log
/ 1âˆ’
	
Knowing LR+ (3.11) and LRâˆ’ (0.124) at this cut-off (Sect. 2.3.4), DOR 
could also be calculated thus:
DOR
LR
LR
=
+
âˆ’
=
=
/
.
/ .
.
3 11 0 124
25 08
Knowing PPR (16.49) and NPR (0.658) at this cut-off (Sect. 2.3.7), DOR 
could also be calculated thus:
DOR
PPR NPR
=
=
=
/
.
/ .
.
16 49 0 658
25 06
[The slight differences in results relate to rounding errors.]
Following the qualitative classification of DORs described by Rosenthal 
[33], DOR >25 represents a very large value.
2.4â€ƒ Association-Based Measures

42
Loge(DOR) is used as an accuracy parameter in meta-analysis when model fitting 
summary ROC curves.
The relation of DOR to Sens and Spec may also be seen graphically in the 
receiver operating characteristic (ROC) plot (Sect. 6.2), and of log(DOR) to log 
likelihood ratios in the ROC plot in likelihood ratio coordinates (Sect. 6.3.1).
As DOR is related to cut-off and hence Q, a rescaled DOR may also be calcu-
lated [16]:
	
DOR
LR
LR
Q
Q
Q
=
+
âˆ’
/
	
An error odds ratio (EOR) may also be defined, as the ratio of the product of true 
positives and false positives and of true negatives and false negatives.
In literal notation:
	
EOR
TP
FP
FN
TN
=
Ã—
(
)
Ã—
(
)
/
	
In algebraic notation:
	
EOR
ab
cd
=
(
) (
)
/
	
EOR is seldom examined and not recommended [2].
Worked Example: Log(DOR)
In a screening test accuracy study of MACE [15], at the MACE cut-off of 
â‰¤20/30, Sens = 0.912 and Spec = 0.707 (Sect. 2.2.1).
Hence the value for log(DOR) at this cut-off, using common logs, is:
log
log
/
log
/
log
.
/
DOR
Sens
Sens
Spec
Spec
(
)
=
(
) +]
[
(
)
ï£®ï£°
ï£¹ï£»
=
1
1
0 912
âˆ’
âˆ’
0 088
0 707 0 293
1 0155
0 38255
1 3981
.
log
.
/ .
.
.
.
[
]+
[
]
=
+
=
=
Antilog
DOR
=
25 01
.
Worked Example: EOR
In a screening test accuracy study of MACE [15], at the MACE cut-off of 
â‰¤20/30 (Fig.Â 2.2), TP = 104, FN =10, FP = 188, and TN = 453.
Hence the values for EOR at this cut-off is:
EOR
TP
FP
FN
TN
=
Ã—
(
)
Ã—
(
)
=
Ã—
Ã—
=
/
/
.
104 188 10
453
4 32
2â€ƒ Paired Measures

43
2.4.2â€ƒ Clinical Utility Index (CUI+, CUIâˆ’) andÂ Clinical 
Disutility Index (CDI+, CDIâˆ’)
The clinical utility indexes developed by Mitchell [29] calculate the value of a diag-
nostic method for ruling in or ruling out a diagnosis.
Positive clinical utility index (CUI+) is given by:
	
CUI
Sens
PPV
TPR
PPV
+
=
Ã—
=
Ã—
	
In literal notation:
	
CUI
TP
TP
FN
TP
TP
FP
TP
TP
FN
TP
FP
TP
p q
+
=
+
(
)Ã—
+
(
)
=
+
(
)
+
(
)
ï£®ï£°
ï£¹ï£»
=
/
/
/
.
/
.
2
2 [
]
	
In algebraic notation:
	
CUI
a
a
c
a
a
b
a
a
c
a
b
a
p q
+
=
+
(
)Ã—
+
(
)
=
+
(
)
+
(
)
ï£®ï£°
ï£¹ï£»
=
[
]
/
/
/
.
/
.
2
2
	
This parameter has also been termed the Screening Marker Index [31].
Negative clinical utility index (CUIâˆ’) is given by:
	
CUI
Spec
NPV
TNR
NPV
âˆ’
=
Ã—
=
Ã—
	
In literal notation:
	
CUI
TN
FP
TN
TN
FN
TN
TN
FP
TN
FN
TN
TN
p
âˆ’
=
+
(
)Ã—
+
(
)
=
+
(
)
+
(
)
ï£®ï£°
ï£¹ï£»
=
â€²
/
/
/
.
/
.
2
2
â€²
[
]
q
	
In algebraic notation:
	
CUI
d
b
d
d
c
d
d
b
d
c
d
d
p q
âˆ’
=
+
(
)Ã—
+
(
)
=
+
(
)
+
(
)
ï£®ï£°
ï£¹ï£»
=
[
]
â€² â€²
/
/
/
.
/
.
2
2
	
Clinical utility index values range from 0 to 1, with higher values better. In addi-
tion to the absolute score, the qualitative performance of CUI values may be classi-
fied as: excellent â‰¥0.81, good â‰¥0.64, adequate â‰¥0.49, poor â‰¥0.36, or very poor 
<0.36 [29].
2.4â€ƒ Association-Based Measures

44
Rescaled CUIs may also be calculated [16]:
	
CUI
QSN
PPV
Q+ =
Ã—
	
	
CUI
QSP
NPV
Qâˆ’=
Ã—
	
Clinical disutility indexes (CDI) may also be developed, to calculate the limita-
tion of a diagnostic method for ruling in or ruling out a diagnosis, such that:
	
CDI
Sens
PPV
FNR
FDR
+
=
(
)Ã—(
)
=
Ã—
1
1
âˆ’
âˆ’
	
This is a measure of incorrectly ruling out.
	
CDI
Spec
NPV
FPR
FRR
âˆ’
=
(
)Ã—(
)
=
Ã—
1
1
âˆ’
âˆ’
	
This is a measure of incorrectly ruling in.
As for CUI, clinical disutility index values range from 0 to 1, but with lower 
values better. In addition to the absolute score, the qualitative performance of CDI 
Worked Example: CUI+, CUIâˆ’
In a screening test accuracy study of the MACE [15], at the MACE cut-off of 
â‰¤20/30, Sens = 0.912 and Spec = 0.707 (Sect. 2.2.1), and PPV = 0.356 and 
NPV = 0.978 (Sect. 2.3.1).
Hence, the positive clinical utility index (CUI+) at this cut-off is:
CUI
Sens
PPV
+
=
Ã—
=
Ã—
=
0 912 0 356
0 325
.
.
.
Following the qualitative classification of clinical utility indexes described 
by Mitchell [29], CUI+ = 0.325 is very poor.
The negative clinical utility index (CUIâˆ’) is:
CUI
Spec
NPV
âˆ’
=
Ã—
=
Ã—
=
0 707 0 978
0 691
.
.
.
Following the qualitative classification of clinical utility indexes described 
by Mitchell [29], CUIâˆ’ = 0.691 is good.
2â€ƒ Paired Measures

45
might be classified, after CUI, as: very poor â‰¥0.81, poor â‰¥0.64, adequate â‰¥0.49, 
good â‰¥0.36, or excellent <0.36.
References
	 1.	Altman DG, Bland JM.Â Diagnostic tests 2: predictive values. BMJ. 1994;309:102.
	 2.	Bossuyt PMM.Â Clinical validity: defining biomarker performance. Scand J Clin Lab Invest. 
2010;70(Suppl242):46â€“52.
	 3.	Brenner H, Gefeller O.Â Variation of sensitivity, specificity, likelihood ratios and predictive 
values with disease prevalence. Stat Med. 1997;16:981â€“91.
	 4.	Brown MD, Reeves MJ.Â Interval likelihood ratios: another advantage for the evidence-based 
diagnostician. Ann Emerg Med. 2003;42:292â€“7.
	 5.	Edwards AWF.Â  The measure of association in a 2Â  Ã—Â  2 table. J R Stat Soc Ser 
A. 1963;126:109â€“14.
	 6.	Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM.Â The diagnostic odds ratio: a single 
indicator of test performance. J Clin Epidemiol. 2003;56:1129â€“35.
	 7.	Habibzadeh F, Habibzadeh P, Yadollahie M.Â On determining the most appropriate test cut-off 
value: the case of tests with continuous results. Biochem Med (Zagreb). 2016;26:297â€“307.
	 8.	Heston TF.Â Standardizing predictive values in diagnostic imaging research. J Magn Reson 
Imaging. 2011;33:505.
Worked Example: CDI+, CDIâˆ’
In a screening test accuracy study of the MACE [15], at the MACE cut-off of 
â‰¤20/30, Sens = 0.912 and Spec = 0.707 (Sect. 2.2.1), and PPV = 0.356 and 
NPV = 0.978 (Sect. 2.3.1). Hence FNR = 0.088 and FPR = 0.293 (Sect. 2.2.3) 
and FDR = 0.644 and FRR = 0.022 (Sect. 2.3.3).
Hence, the positive clinical disutility index (CDI+) at this cut-off is:
CDI
FNR
FDR
+
=
Ã—
=
Ã—
=
0 088 0 644
0 057
.
.
.
Following the suggested qualitative classification of clinical disutility 
indexes, CDI+ = 0.057 is excellent, suggesting the test is unlikely to rule out 
the diagnosis incorrectly.
The negative clinical disutility index (CDIâˆ’) is:
CDI
FPR
FRR
âˆ’
=
Ã—
=
Ã—
=
0 293 0 022
0 006
.
.
.
Following the suggested qualitative classification of clinical disutility 
indexes, CDIâˆ’ = 0.006 is excellent, suggesting the test is unlikely to rule in 
the diagnosis incorrectly.
References

46
	 9.	Heston TF.Â Standardized predictive values. J Magn Reson Imaging. 2014;39:1338.
	10.	Hlatky MA, Mark DB, Harrell FE Jr, Lee KL, Califf RM, Pryor DB.Â Rethinking sensitivity and 
specificity. Am J Cardiol. 1987;59:1195â€“8.
	11.	Hsieh S, McGrory S, Leslie F, Dawson K, Ahmed S, Butler CR, etÂ al. The Mini-Addenbrookeâ€™s 
Cognitive Examination: a new assessment tool for dementia. Dement Geriatr Cogn Disord. 
2015;39:1â€“11.
	12.	Hunink MGM, Weinstein MC, Wittenberg E, Drummond MF, Pliskin JS, Wong JB, etÂ al. 
Decision making in health and medicine. Integrating evidence and values. 2nd ed. Cambridge: 
Cambridge University Press; 2014.
	13.	Jaeschke R, Guyatt G, Sackett DL.Â Usersâ€™ guide to the medical literature. III.Â How to use an 
article about a diagnostic test. B.Â What are the results and will they help me in caring for my 
patients? JAMA. 1994;271:703â€“7.
	14.	Kraemer HC.Â Evaluating medical tests. Objective and quantitative guidelines. Newbery Park: 
Sage; 1992.
	15.	Larner AJ.Â MACE for diagnosis of dementia and MCI: examining cut-offs and predictive val-
ues. Diagnostics (Basel). 2019;9:E51.
	16.	Larner AJ.Â Applying Kraemerâ€™s Q (positive sign rate): some implications for diagnostic test 
accuracy study results. Dement Geriatr Cogn Dis Extra. 2019;9:389â€“96.
	17.	Larner AJ.Â New unitary metrics for dementia test accuracy studies. Prog Neurol Psychiatry. 
2019;23(3):21â€“5.
	18.	Larner AJ.Â Mini-Addenbrookeâ€™s Cognitive Examination (MACE): a useful cognitive screening 
instrument in older people? Can Geriatr J. 2020;23:199â€“204.
	19.	Larner AJ.Â The â€œattended aloneâ€ and â€œattended withâ€ signs in the assessment of cognitive 
impairment: a revalidation. Postgrad Med. 2020;132:595â€“600.
	20.	Larner AJ.Â Cognitive screening instruments for dementia: comparing metrics of test limitation. 
medRxiv. 2020; https://doi.org/10.1101/2020.10.29.20222109v1.
	21.	Larner AJ.Â  Manual of screeners for dementia. Pragmatic test accuracy studies. London: 
Springer; 2020.
	22.	Larrabee GJ, Barry DTR.Â Diagnostic classification statistics and diagnostic validity of malin-
gering assessment. In: Larrabee GJ, editor. Assessment of malingered neuropsychological 
deficits. Oxford: Oxford University Press; 2007. p.Â 14â€“26.
	23.	Leeflang MM, Bossuyt PM, Irwig L.Â  Diagnostic test accuracy may vary with prevalence: 
implications for evidence-based diagnosis. J Clin Epidemiol. 2009;62:5â€“12.
	24.	Leeflang MM, Rutjes AW, Reitsma JB, Hooft L, Bossuyt PM.Â Variation of a testâ€™s sensitivity 
and specificity with disease prevalence. CMAJ. 2013;185:E537â€“44.
	25.	Linn S.Â New patient-oriented diagnostic test characteristics analogous to the likelihood ratios 
conveyed information on trustworthiness. J Clin Epidemiol. 2005;58:450â€“7.
	26.	Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR.Â  A brief cognitive test 
battery to differentiate Alzheimerâ€™s disease and frontotemporal dementia. Neurology. 
2000;55:1613â€“20.
	27.	McGee S.Â Simplifying likelihood ratios. J Gen Intern Med. 2002;17:647â€“50.
	28.	Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR.Â  The Addenbrookeâ€™s Cognitive 
Examination Revised: a brief cognitive test battery for dementia screening. Int J Geriatr 
Psychiatry. 2006;21:1078â€“85.
	29.	Mitchell AJ.Â Sensitivity x PPV is a recognized test called the clinical utility index (CUI+). Eur 
J Epidemiol. 2011;26:251â€“2.
	30.	Neyman J.Â Outline of statistical treatment of the problem of diagnosis. Public Health Rep. 
1947;62:1449â€“56.
	31.	Ostergaard SD, Dinesen PT, Foldager L.Â Quantifying the value of markers in screening pro-
grammes. Eur J Epidemiol. 2010;25:151â€“4.
	32.	Perera R, Heneghan C.Â Making sense of diagnostic tests likelihood ratios. Evid Based Med. 
2006;11:130â€“1.
2â€ƒ Paired Measures

47
	33.	Rosenthal JA.Â Qualitative descriptors of strength of association and effect size. J Soc Serv Res. 
1996;21:37â€“59.
	34.	Schaefer JT.Â The critical success index as an indicator of warning skill. Weather Forecast. 
1990;5:570â€“5.
	35.	Warrens MJ.Â A Kraemer-type rescaling that transforms the odds ratio into the weighted kappa 
coefficient. Psychometrika. 2010;75:328â€“30.
	36.	Yerushalmy J.Â Statistical problems in assessing methods of medical diagnosis, with special 
reference to x-ray techniques. Public Health Rep. 1947;62:1432â€“49.
References

49
Â© Springer Nature Switzerland AG 2021
A. J. Larner, The 2x2 Matrix, https://doi.org/10.1007/978-3-030-74920-0_3
Chapter 3
Paired Complementary Measures
Contents
3.1â€ƒ Introduction
â€ƒ 49
3.2â€ƒ Error-Based Measures
â€ƒ 50
3.2.1â€ƒ Sensitivity (Sens) andÂ False Negative Rate (FNR)
â€ƒ 50
3.2.2â€ƒ Specificity (Spec) andÂ False Positive Rate (FPR)
â€ƒ 51
3.2.3â€ƒ â€œSnNoutâ€ andÂ â€œSpPinâ€ Rules
â€ƒ 52
3.2.4â€ƒ Accuracy andÂ Inaccuracy
â€ƒ 53
3.2.5â€ƒ Classification andÂ Misclassification Rates; Misclassification Costs
â€ƒ 57
3.3â€ƒ Information-Based Measures
â€ƒ 60
3.3.1â€ƒ Positive Predictive Value (PPV) andÂ False Discovery Rate (FDR)
â€ƒ 60
3.3.2â€ƒ Negative Predictive Value (NPV) andÂ False Reassurance Rate (FRR)
â€ƒ 61
3.4â€ƒ Dependence ofÂ Paired Complementary Measures onÂ Prevalence (P)
â€ƒ 62
References
â€ƒ 68
3.1â€ƒ Introduction
This chapter considers complementary paired measures of discrimination. 
Conditional probability measures may be described as complementary (or negations) 
when they necessarily sum to unity. The summation principle that probabilities add 
to 1 holds for a mutually exclusive and exhaustive set of possibilities. This chapter 
reiterates some of the metrics previously examined in Chap. 2, as well as looking at 
other measures, namely accuracy and inaccuracy (Fig.Â  3.1). As in the previous 
chapter, the classification of measures as error-based and information-based, 
following Bossuyt [1], is used. Consideration is also given to correct classification 
and misclassification rates. The variation of paired measures with either the chosen 
cut-off or level of test (Q) or with the pre-test probability or prevalence (P) is also 
illustrated.

50
3.2â€ƒ Error-Based Measures
3.2.1â€ƒ Sensitivity (Sens) andÂ False Negative Rate (FNR)
As previously mentioned (Sect. 2.2.3), false negative rate (FNR) is the complement 
of sensitivity (Sens):
	
FNR
Sens
TPR



 

1
1
â€“
â€“
	
	
FNR
Sens


1	
	
FNR
TPR


1	
In error notation, FNR = Î², Sens = 1Â â€“ Î².
This is illustrated in the worked examples of Sens (Sect. 2.2.1) and FNR (Sect. 
2.2.3) from a study of the Mini-Addenbrookeâ€™s Cognitive Examination (MACE) 
[11] showing that the calculated values (Sens = 0.912, FNR = 0.088) sum to 1. 
Hence knowing either Sens or FNR will always disclose the other across the range 
of test cut-offs (i.e. variation with Q; Fig.Â 3.2).
Paired complementary measures (literal notation only):
Sens (TPR)
=
TP/(TP + FN)
=
TP/p
FNR (1 â€“ Sens)
=
FN/(TP + FN)
=
FN/p
Spec (TNR)
=
TN/(FP + TN)
=
TN/p'
FPR (1 â€“ Spec)
=
FP/(FP + TN)
=
FP/p'
Acc
=
(TP + TN)/(TP + FP + FN + TN)
=
TP +TN/N
Inacc (1 â€“ Acc)
=
FP + FN/(TP + FP + FN + TN)
=
FP + FN/N
PPV
=
TP/(TP + FP)
=
TP/q
FDR (1 â€“ PPV)
=
FP/(TP + FP)
=
FP/q
NPV
=
TN/(FN + TN)
=
TN/q'
FRR (1 â€“ NPV)
=
FN/(FN + TN)
=
FN/q'
q
r
rÂ¹
qÂ¹
pÂ¹
p
False negative
[FN] (c)
Fig. 3.1â€‚ 2Â Ã—Â 2 contingency table with literal and algebraic notation, marginal totals, and derived 
paired complementary measures
3â€ƒ Paired Complementary Measures

51
This also holds for rescaled values [9, 12]:
	
FNR
QSN
TPR
Q
Q






1
1
â€“
â€“
	
In the same study of MACE (Sect. 2.2.2), QSN = 0.857 and so FNRQ = (1Â â€“ 
QSN) = 0.143.
3.2.2â€ƒ Specificity (Spec) andÂ False Positive Rate (FPR)
As previously mentioned (Sect. 2.2.3), false positive rate (FPR) is the complement 
of specificity (Spec):
	
FPR
Spec
TNR



 

1
1
â€“
â€“
	
	
FPR
Spec


1	
	
FPR
TNR


1	
In error notation, FPR = Î±, Spec = 1Â â€“ Î±.
This is illustrated in the worked examples of Spec (Sect. 2.2.1) and FPR (Sect. 
2.2.3) from the MACE study [11] showing that the calculated values (Spec = 0.707, 
FPR = 0.293) sum to 1. Hence knowing either Spec or FPR will always disclose the 
other across the range of test cut-offs (i.e. variation with Q; Fig.Â 3.3).
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
10
12
14
16
18
20
22
24
26
28
30
Sens and FNR 
Fig. 3.2â€‚ Plot of Sensitivity (diamonds) and FNR (triangles) for dementia diagnosis at fixed P (= 
0.151) on y axis versus MACE cut-off (x axis). (Data from [11])
3.2â€ƒ Error-Based Measures

52
This also holds for rescaled values [9, 12]:
	
FPR
QSP
TNR
Q
Q






1
1
â€“
â€“
	
In the same study of MACE (Sect. 2.2.2), QSP = 0.242 and so FPRQ = (1Â â€“ QSP) 
= 0.758.
3.2.3â€ƒ â€œSnNoutâ€ andÂ â€œSpPinâ€ Rules
Gallagher [3] has suggested that the measures of sensitivity and specificity of diagnos-
tic tests ask the wrong question from a clinicianâ€™s point of view, since they presuppose 
that a patient either does or does not have a particular disease, in which case the 
administration of a diagnostic test would not be needed. The clinical utility of sensitiv-
ity and specificity is deemed to lie in the mathematical properties of these metrics [3].
A very sensitive test will have very few false negatives (but possibly many false 
positives). Because of the low FNR of a very sensitive test, a negative test result is 
therefore likely to be a true negative and hence rules out the diagnosis, as made 
explicit in the heuristic â€œSnNoutâ€ rule ([23], p.165â€“6):
	
Sensitive test Negativeresult
diagnosisruled out
,
,=
	
Conversely, a test with low sensitivity has many false negatives, and hence 
misses cases.
A very specific test will have very few false positives (but possibly many false 
negatives). Because of the low FPR of a very specific test, a positive test result is 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
10
12
14
16
18
20
22
24
26
28
30
Spec and FPR
Fig. 3.3â€‚ Plot of Specificity (diamonds) and FPR (triangles) for dementia diagnosis at fixed P (= 
0.151) on y axis versus MACE cut-off (x axis). (Data from [11])
3â€ƒ Paired Complementary Measures

53
therefore likely to be a true positive and hence rules in the diagnosis, as made 
explicit in the heuristic â€œSpPinâ€ rule ([23], p.165â€“6):
	
Specific test Positiveresult
diagnosisruledin.
,
, =
	
Conversely, a test with low specificity has many false positives, and hence mis-
identifies non cases as cases.
3.2.4â€ƒ Accuracy andÂ Inaccuracy
Accuracy (Acc) is the sum of true positives and true negatives divided by the total 
number of patients tested. Acc ranges from 0 to 1, with higher values better.
In literal notation (Fig.Â 3.1):
	
Acc
TP
TN
TP
FP
FN
TN
TP
TN
N













/
/
	
In algebraic notation:
	
Acc
a
d
a
b
c
d
a
d N









/
/
	
and in terms of marginal totals:
	
Acc
r N
=
/
	
This is identical to the value R, defined as one of the marginal probabilities of the 
basic 2Â Ã—Â 2 contingency table (Sect. 1.3.2). Accuracy may also be known as correct 
classification accuracy, effectiveness rate, fraction correct (FC), test efficiency, or 
posterior probability, or may be stated as the number of individuals correctly classi-
fied by the test. Accuracy, like diagnostic odds ratio (DOR; Sect. 2.4.1), treats FN 
and FP as equally undesirable, an assumption which is often not the case in clinical 
practice, and hence a shortcoming of this measure (see Sect. 3.2.5).
â€œAccuracyâ€ is potentially an ambiguous term, as other measures of â€œaccuracyâ€ 
are also described [13], including the F measure (Sect. 4.9) and Matthewsâ€™ 
correlation coefficient (Sect. 4.5), as well as the area under the receiver operating 
characteristic curve (Sect. 6.2).
Accuracy is calculated using values from both columns of the 2Â Ã—Â 2 contingency 
table and hence is sensitive to class imbalance or skews, or in other words it is 
dependent on disease prevalence, as a weighted average of sensitivity and specificity 
with weights related to sample prevalence (P and 1Â â€“ P or Pâ€²). Acc may therefore be 
expressed in terms of P, Pâ€², Sens and Spec, such that:
	
Acc
Sens P
Spec P


 

.
.
	
3.2â€ƒ Error-Based Measures

54
Hence in error notation:
	
Acc
P
P






1
1
â€“
.
â€“
.


	
Inaccuracy (Inacc), also sometimes known as error rate, or fraction incorrect, or 
misclassification rate (although this term has alternate usage; see Sect. 3.2.5), is the 
complement of Accuracy:
	
Inaccuracy
Acc



1â€“
	
Hence, Inacc ranges from 0 to 1 with lower values better. Inacc is given by the 
sum of false positives and false negatives divided by the total number of 
patients tested.
In literal notation (Fig.Â 3.1):
	
Inacc
FP
FN
TP
FP
FN
TN
FP
FN
N













/
/
	
In algebraic notation:
	
Inacc
b
c
a
b
c
d
b
c N









/
/
	
Worked Example: Acc
The Mini-Addenbrookeâ€™s Cognitive Examination (MACE) [7] was examined 
in a screening test accuracy study [11]. At the MACE cut-off of â‰¤20/30, TP = 
104, FN =10, FP = 188, and TN = 453 (see Fig. 2.2).
Hence the value for Acc at this cut-off is:
Acc
TP
TN
TP
FP
FN
TN



















/
/
.
104
453
104
188
10
453
0 738
Acc may also be expressed in terms of P, Pâ€², Sens and Spec. In the MACE 
study [11], dementia prevalence (P) in the patient cohort (N = 755) was 0.151 
(Sect. 1.3.2). Values for Sens and Spec at this MACE cut-off are 0.912 and 
0.707 respectively (Sect. 2.2.1).
Hence the value for Acc is:
Acc
Sens P
Spec P
 
 




 





.
.
.
.
.
.
.
0 912 0 151
0 707 0 849
0 738
3â€ƒ Paired Complementary Measures

55
and in terms of marginal totals:
	
Inacc
r
N

 /
	
This is identical to the value Râ€², defined as one of the marginal probabilities of 
the basic 2Â Ã—Â 2 contingency table (Sect. 1.3.2).
In terms of disease prevalence:
	
Inacc
FNR P
FPR P
Sens P
Spec P
 
 






 







.
.
.
.
1
1
	
Hence in error notation:
	
Inacc
P
P


 



.
.
	
The reciprocal of inaccuracy has been defined as the â€œnumber needed to misdi-
agnoseâ€ (Sect. 5.4).
Acc and Inacc are scalar values based on information from both columns of the 
2Â Ã—Â 2 table (cf. Sens and Spec), hence vary with prevalence, P (Sect. 2.3.2), as well 
as with the level of the test, Q, and hence with test cut-off [11, 14] (Fig.Â 3.4), and are 
also sensitive to class imbalance.
As discussed previously (Sect. 2.2.1), Sens and Spec are unscaled measures, and 
hence so is Acc. As an unscaled measure, it gives no direct measure of the degree to 
which diagnostic uncertainty is reduced. This can be addressed by taking into 
Worked Example: Inacc
In the screening test accuracy study of MACE [11], at the MACE cut-off of 
â‰¤20/30, TP = 104, FN =10, FP = 188, and TN = 453.
Hence the value for Inacc at this cut-off is:
Inacc
FP
FN
TP
FP
FN
TN



















/
/
.
188
10
104
188
10
453
0 262
Inacc may also be expressed in terms of P, Pâ€², FNR and FPR. Values for the 
latter two terms at this MACE cut-off are 0.088 and 0.293 respectively 
(Sect. 2.2.3).
Hence the value for Inacc is:
Inacc
FNR P
FPR P
 
 




 





.
.
.
.
.
.
.
0 088 0 151
0 293 0 849
0 262
3.2â€ƒ Error-Based Measures

56
account values of both P and Q, as for QSN and QSP (Sect. 2.2.2), to remove the 
biasing effects of random associations between test result and disease prevalence 
([4], p.470), such that:
	
Acc
Sens P
Spec P
P Q
P Q
P Q
P Q



 












.
.
.
.
/
.
.
1
	
The latter, equivalent to the kappa statistic (Sect. 7.2.2), has a range 0 to 1, where 
0 = ineffective test and 1 = perfect test.
Worked Example: Unbiased Acc
In the screening test accuracy study of MACE [11], dementia prevalence (P) 
was 0.151. The positive sign rate, Q = TP+FP/N, was 0.387 (Sect. 1.3.2).
At the MACE cut-off of â‰¤20/30, Sens = 0.912 and Spec = 0.707 
(Sect. 2.2.1).
Hence the value for unbiased Acc at this MACE cut-off is:
Acc
Sens P
Spec P
P Q
P Q
P Q
P Q

















.
.
.
.
/
.
.
.
.


1
0 138
0 600














0 058
0 520
1
0 058
0 520
0 738
0 579 1 0 579
0 15
.
.
/
.
.
.
.
/
.
.
9 0 421
0 378
/ .
.

Note how this differs from the standard calculation of Acc at this cut-off 
(= 0.738).
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
10
12
14
16
18
20
22
24
26
28
30
Acc and Inacc
Fig. 3.4â€‚ Plot of Accuracy (diamonds) and Inaccuracy (triangles) for dementia diagnosis at fixed P 
(= 0.151) on y axis versus MACE cut-off (x axis). (Data from [11])
3â€ƒ Paired Complementary Measures

57
3.2.5â€ƒ Classification andÂ Misclassification Rates; 
Misclassification Costs
The consideration of the complementary paired measures of Sens and FNR (Sect. 
3.2.1) and Spec and FPR (Sect. 3.2.2) prompts the inclusion here of a brief discussion 
of classification and misclassification.
Sens and Spec provide different pieces of information about a test. Is there some 
way to combine this information into a meaningful outcome parameter? One method 
has already been encountered, namely likelihood ratios (Sect. 2.3.4), and there are 
others including Youden index (Sect. 4.2) and receiver operating characteristic 
(ROC) curves (Sect. 6.2).
However, the simplest way to combine information about Sens and Spec is to 
sum them, a measure which has been termed â€œgain in certaintyâ€ [2] or overall 
correct classification rate [21].
	
Correct classification rate
Sens
Spec
TPR
TNR




	
Of note, unlike most of the parameters considered so far, correct classification 
rate has a range of 0 to 2, with higher scores better (technically this is not, therefore, 
a â€œrateâ€). It has been argued that when Sens + Spec = 1 the test provides no 
information, whilst when the sum is greatest (i.e. = 2) the expected gain is 
maximised [2].
In literal notation (Fig.Â 3.1):
	
Correct classification rate
TP
TP
FN
TN
FP
TN
TP





 






/
/
/
/
p
TN p



	
In algebraic notation:
	
Correct classification rate
a
a
c
d
b
d
a p
d p



  









/
/
/
/


	
In error notation (see Fig. 1.5):
	
Correct classification rate


 

1
1
â€“
â€“

 	
This summation of Sens and Spec is little used in clinical practice (e.g. [6], 
p.190; [17], p.100). The Youden index [24] is more frequently used (Sect. 4.2).
The term â€œmisclassification rateâ€ is potentially ambiguous, being sometimes used 
for the parameter called â€œproportion incorrectâ€ (Sect. 1.3.2) or â€œinaccuracyâ€ or â€œerror 
rateâ€ (Sect. 3.2.4). Here, the usage of Perkins and Schisterman [21] is followed:
	
Misclassification rate
Sens
Spec
FNR
FPR
Sens
Spe
 
 





1
1
2
â€“
â€“
â€“
cc


	
3.2â€ƒ Error-Based Measures

58
Misclassification rate has a range of 0 to 2, with lower scores better.
In literal notation (Fig.Â 3.1):
	
Misclassification rate
FN/ FN+TP
+ FP/ FP+TN
FN p +












FP p'


	
In algebraic notation:
	
Misclassification rate
c
a
c
b
b
d
c p
b p



  









/
/
/
/
	
In error notation (see Fig. 1.5):
Misclassification rate




Hence correct classification rate and misclassification rate are negations which 
sum to 2:
	
Correctclassificationrate
Misclassificationrate
Sens
Spec



 11
1
2
â€“
â€“
Sens
Spec

  


	
Their complement (sum to unity) is the Youden index (see Sect. 4.2).
Distinction should be drawn between this misclassification rate and another 
parameter, called misclassification cost. Evidently, both FP and FN classifications 
have costs (see also the discussion of net harm to net benefit (H/B) ratio in Sect. 
2.3.5). In the context of diagnostic or screening test accuracy studies, it may be 
argued that high test sensitivity in order to identify all true positives, hence with 
very few false negatives, is more acceptable than tests with low sensitivity but high 
specificity which risk false negatives (i.e. miss true positives), since the cost of a FN 
error may be high. Indeed, Youden ([24], p.32) spoke of an â€œinstinctive reaction 
against a test that is subject to false negativesâ€ since a missed diagnosis may mean 
missed treatment with resulting disability and even death. This argument also 
supposes that the cost of a FP error is not so serious: a healthy patient may be 
subjected to extra screening and possibly inappropriate treatment unnecessarily. 
However, the potential ramifications of FP error should not be underestimated, as 
these may be â€œprofoundly transformational on a personal levelâ€ ([18], 
p.38â€“9,362,363).
Expected benefits (B) and costs (C) at each cut-off may be expressed as â€œexpected 
costsâ€ (EC) [9, 22]:
	
EC
C
FP
C
FN
B
TN
B
TP
FP
FN
TN
TP






â€“
â€“
	
The test threshold, c*, with the lowest EC is optimal.
3â€ƒ Paired Complementary Measures

59
This may also be expressed as a cost ratio (Cr):
	
Cr
B
C
B
B
C
C
TP
FN
TP
TN
FN
FP


â€“
/
â€“
â€“
	
The term (BTPÂ â€“ CFN) represents the difference in costs if patients with disease 
(D+) are classified correctly or not, whilst the term (BTNÂ â€“ CFP) represents the differ-
ence in costs if healthy individuals (Dâˆ’) are classified correctly or not. Hence Cr is 
the costs for diseased relative to total costs, or the ratio of relative costs. Cr ranges 
from 0 to 1. When Cr = 0.5, the difference in costs between correct (T+) and incor-
rect (Tâˆ’) test classification is equal for healthy (Dâˆ’) and diseased (D+) persons. 
When Cr = 1, difference in costs is much higher for persons with disease (i.e. FN); 
when Cr = 0 the difference in costs is much higher for healthy persons (i.e. FP). In 
most disease screening situations, one anticipates Cr to tend toward 1, since FN 
errors have higher cost [22].
This notation may also be used in the expression of the net harm to net benefit 
(H/B) ratio (Sect. 2.3.5). As benefits may be expressed as negative costs if desired 
[19], and indeed all may be understood as cost expressions [8], then BTP = CTP and 
BTN = CTN. Hence the term CFPÂ â€“ CTN is equal to the net costs of treating a non-Â­
diseased patient (harm of FP), and the term CFNÂ â€“ CTP is equal to the net benefits of 
treating a diseased patient [8] or net costs of not treating a diseased patient 
(harm of FN):
	
NetHarm H
NetBenefit B
C
C
C
C
FP
TN
FN
TP
 
 



/
/
	
As the misclassification of non-diseased (FN) carries the highest cost, CFN >> 
CTP, then ideally H/B ratio values should be as high as possible (Sect. 2.3.5).
Worked Example: Correct Classification Rate and 
Misclassification Rate
In a screening test accuracy study of MACE [11], at the MACE cut-off of 
â‰¤20/30, values for Sens and Spec were 0.912 and 0.707 (Sect. 2.2.1) and 
hence for FPR and FNR were 0.293 and 0.088 respectively (Sect. 2.2.3).
Hence the value for the correct classification rate at this cut-off was:
Correct classification rate
TPR
TNR





0 912
0 707
1 619
.
.
.
The value for the misclassification rate was:
Misclassification rate
FNR
FPR





0 088
0 293
0 381
.
.
.
3.2â€ƒ Error-Based Measures

60
The ratio of harms of FP to FN (treating a FP unnecessarily to not treating a TP) 
is also used in methods for determining optimal test cut-off from the receiver 
operating characteristic (ROC) curve (Sect. 6.2) [5].
Another term sometimes used is a relative misclassification cost, defined as FP/
TP (literal notation) or b/a (algebraic notation). This is used, for example [20], in a 
method which gives weighting to the difference in Sens and Spec (Î”Sens, Î”Spec) 
of two tests, hence a weighted comparison (WC), taking into account the relative 
misclassification cost of false positive diagnosis and also disease prevalence (P), as 
expressed in the equation:
	
WC
Sens
P P
FP TP
Spec

 






1â€“
/
/
	
The relative misclassification cost, FP/TP, seeks to define how many false posi-
tives a true positive is worth, a potentially difficult estimate. An arbitrary value of 
FP/TP = 0.1 may be set [10, 16]. The WC equation does not ostensibly take false 
negatives into account, but the [(1Â â€“ P/P) x (FP/TP)] term resembles the net harm to 
net benefit (H/B) ratio definition (derived in Sect. 2.3.5), where the benefit of TP 
may be equated to the harm of a FN result.
The question of the relative cost of FP and FN also arises with respect to those 
metrics which assume FN and FP to be equally undesirable, e.g. DOR (Sect. 2.4.1), 
Acc (Sect. 3.2.4), and Youden index (Sect. 4.2). In all these situations, a trade-off 
between benefits and costs (sometimes painful) needs to be made.
3.3â€ƒ Information-Based Measures
3.3.1â€ƒ Positive Predictive Value (PPV) andÂ False Discovery 
Rate (FDR)
As previously mentioned (Sect. 2.3.3), false discovery rate (FDR) is the comple-
ment of positive predictive value (PPV):
	
FDR
PPV



1â€“
	
This is illustrated in the worked examples of PPV (Sect. 2.3.1) and FDR (Sect. 
2.3.3) from the MACE study [11] showing that the calculated values (PPV = 0.356, 
FDR = 0.644) sum to 1. Hence knowing either PPV or FDR will always disclose the 
other across the range of test cut-offs (i.e. variation with Q; Fig.Â 3.5).
This also holds for rescaled values [9, 12]:
	
FDR
PPV
Q
Q



1â€“
	
In the same study of MACE (Sect. 2.3.2), PPVQ = 0.356 and so FDRQ = (1Â â€“ 
PPVQ) = 0.644.
3â€ƒ Paired Complementary Measures

61
3.3.2â€ƒ Negative Predictive Value (NPV) andÂ False Reassurance 
Rate (FRR)
As previously mentioned (Sect. 2.3.3), false reassurance rate (FRR) is the comple-
ment of negative predictive value (NPV):
	
FRR
NPV



1â€“
	
This is illustrated in the worked examples of NPV (Sect. 2.3.1) and FRR (Sect. 
2.3.3) from the MACE study [11] showing that the calculated values (NPV = 0.978, 
FRR = 0.022) sum to 1. Hence knowing either NPV or FRR will always disclose the 
other across the range of test cut-offs (i.e. variation with Q; Fig.Â 3.6).
This also holds for rescaled values [9, 12]:
	
FRR
NPV
Q
Q



1â€“
	
In the same study (Sect. 2.3.2), NPVQ = 0.978 and so FRRQ = (1Â â€“ NPVQ) = 0.022.
Note from Fig.Â 3.6 that this is the only example in this chapter in which there is 
no cross-over between the complementary metrics, i.e. the ideal of separation is 
achieved. Clearly this is a consequence of the skewed nature of this particular data-
set, with a very large number of true negatives and a very small number of false 
negatives.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
10
12
14
16
18
20
22
24
26
28
30
PPV and FDR
Fig. 3.5â€‚ Plot of PPV (diamonds) and FDR (triangles) for dementia diagnosis at fixed P (= 0.151) 
on y axis versus MACE cut-off (x axis). (Data from [11])
3.3â€ƒ Information-Based Measures

62
3.4â€ƒ Dependence ofÂ Paired Complementary Measures 
onÂ Prevalence (P)
Having illustrated the dependence of the various paired metrics on cut-off or Q at a 
fixed prevalence (Figs.Â 3.2, 3.3, 3.4, 3.5 and 3.6), here their dependence on preva-
lence (P) at a fixed Q is shown.
Whilst choosing the fixed value of P may be straightforward (the base rate of the 
study population), choosing a fixed value of Q may not be so evident. Options 
include maximal test accuracy, or maximal Youden index ([15], p.156â€“9 and 163â€“5). 
For the purposes of this illustration, maximal Youden index has been used (Sect. 
4.2), which occurs at MACE cut-off â‰¤20/30.
Values for PPV and NPV may be calculated using Bayesâ€™ formula (Sect. 2.3.2):
	
PPV
Sens P
Sens P
Spec
P
Sens P
Sens P
FPR




 












 
/
/
1
1






1
P
	
	
NPV
Spec
P
Spec
P
Sens
P
Spec
P
Sp






  






1
1
1
1
â€“
/
â€“
â€“
â€“
/
ec
P
FNR
P



 



1â€“
	
FDR and FRR values are then the complements of PPV and NPV respectively.
Values for Acc may be calculated using the equation (Sect. 3.2.4):
	
Acc
Sens P
Spec P


 

.
.
	
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
10
12
14
16
18
20
22
24
26
28
30
NPV and FRR
Fig. 3.6â€‚ Plot of NPV (diamonds) and FRR (triangles) for dementia diagnosis at fixed P (= 0.151) 
on y axis versus MACE cut-off (x axis). (Data from [11])
3â€ƒ Paired Complementary Measures

63
At MACE cut-off â‰¤20/30, this simplifies to:
	
Acc
P
P



0 912
0 707
.
.
.
. 	
Inacc values are then the complements of Acc values.
Values for Sens and Spec at a fixed Q may be calculated using the equivalences 
(Sect. 2.3.2):
	
Sens
Q
Q
NPV
P
P
â€“
/
â€“
/


 



	
and
	
Spec
Q
Q
PPV
P
P
â€“
/
â€“
/




 

	
Hence:
	
Sens
Q
NPV
P
P
Q





 


.
/
	
and
	
Spec
Q PPV
P
P
Q





 


.
/
	
FNR and FPR values are then the complements of Sens and Spec respectively.
Calculated values for Sens, FNR, Spec and FPR at 0.1 increments of P are shown 
in TableÂ 3.1, and illustrated in Figs.Â 3.7 and 3.8. Similarly for values of Acc and 
Inacc in TableÂ 3.2 and Fig.Â 3.9; and for PPV, FDR, NPV and FRR in TableÂ 3.3 and 
Figs.Â 3.10 and 3.11.
These plots suggest that for this test accuracy study of MACE, test Spec, Acc and 
PPV are better at high prevalence whereas Sens and NPV are better at low prevalence. 
This pattern is the converse of that seen with Q, with Spec, Acc and PPV better at 
lower cut-offs (compare Figs.Â  3.3, 3.4 and 3.5 with Figs.Â  3.8, 3.9, and 3.10 
Table 3.1â€‚ Values of Sens, FNR, Spec, and FPR for dementia diagnosis at fixed MACE cut-off of 
â‰¤20/30 (= maximal Youden index; fixed Q = 0.387) at various prevalence levels
P, Pâ€²
Sens
FNR
Spec
FPR
0.1, 0.9
0.914
0.086
0.681
0.319
0.2, 0.8
0.908
0.092
0.728
0.272
0.3, 0.7
0.896
0.104
0.763
0.237
0.4, 0.6
0.884
0.116
0.790
0.210
0.5, 0.5
0.865
0.135
0.812
0.188
0.6, 0.4
0.840
0.160
0.830
0.170
0.7, 0.3
0.803
0.197
0.844
0.156
0.8, 0.2
0.746
0.254
0.857
0.143
0.9, 0.1
0.640
0.360
0.868
0.132
3.4â€ƒ Dependence ofÂ Paired Complementary Measures onÂ Prevalence (P)

64
respectively) and Sens and NPV better at higher cut-offs (compare Figs.Â 3.2 and 3.6 
with Figs.Â 3.7 and 3.11 respectively)
The interrelationship of P and Q may be illustrated by plotting a series of curves 
for different Q values against P.Â This is shown for Sens and Spec using the MACE 
dataset (TableÂ 3.4, Figs.Â 3.12 and 3.13). At different selected MACE cut-offs (fixed 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Spec and FPR
Fig. 3.8â€‚ Plot of Specificity (diamonds) and FPR (triangles) for dementia diagnosis at fixed Q (= 
0.387; MACE cut-off â‰¤20/30) on y axis versus prevalence P (x axis)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Sens and FNR
Fig. 3.7â€‚ Plot of Sensitivity (diamonds) and FNR (triangles) for dementia diagnosis at fixed Q (= 
0.387; MACE cut-off â‰¤20/30) on y axis versus prevalence P (x axis)
3â€ƒ Paired Complementary Measures

65
Table 3.2â€‚ Values of Acc and 
Inacc for dementia diagnosis 
at fixed MACE cut-off of 
â‰¤20/30 (= maximal Youden 
index; fixed Q = 0.387) at 
various prevalence levels
P, Pâ€²
Acc
Inacc
0.1, 0.9
0.728
0.272
0.2, 0.8
0.748
0.252
0.3, 0.7
0.769
0.231
0.4, 0.6
0.789
0.211
0.5, 0.5
0.810
0.190
0.6, 0.4
0.830
0.170
0.7, 0.3
0.851
0.149
0.8, 0.2
0.871
0.129
0.9, 0.1
0.892
0.108
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Acc and Inacc
Fig. 3.9â€‚ Plot of Accuracy (diamonds) and Inaccuracy (triangles) for dementia diagnosis at fixed 
Q (= 0.387; MACE cut-off â‰¤20/30) on y axis versus prevalence P (x axis)
Table 3.3â€‚ Values of PPV, FDR, NPV, and FRR for dementia diagnosis at fixed MACE cut-off of 
â‰¤20/30 (= maximal Youden index; fixed Q = 0.387) at various prevalence levels
P, Pâ€²
PPV
FDR
NPV
FRR
0.1, 0.9
0.257
0.743
0.986
0.014
0.2, 0.8
0.437
0.563
0.970
0.030
0.3, 0.7
0.571
0.429
0.949
0.051
0.4, 0.6
0.675
0.325
0.924
0.076
0.5, 0.5
0.757
0.243
0.890
0.110
0.6, 0.4
0.824
0.176
0.843
0.157
0.7, 0.3
0.879
0.121
0.775
0.225
0.8, 0.2
0.926
0.074
0.668
0.332
0.9, 0.1
0.966
0.034
0.472
0.528
3.4â€ƒ Dependence ofÂ Paired Complementary Measures onÂ Prevalence (P)

66
values of Q and Qâ€²) Sens and Spec were calculated (using the above equations) 
against variable P.Â Note that in this instance, PPV and NPV were also fixed for cut-Â­
off, and not recalculated for P (as in TableÂ 3.1, Figs.Â 3.7 and 3.8). Again the finding 
is that, for this test accuracy study of MACE, Sens improves with increasing Q as P 
increases, and conversely Spec decreases with increasing Q as P increases. These 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
PPV and FDR
Fig. 3.10â€‚ Plot of PPV (diamonds) and FDR (triangles) for dementia diagnosis at fixed Q (= 0.387; 
MACE cut-off â‰¤20/30) on y axis versus prevalence P (x axis). Note equivalence of PPV curve to 
the conditional probability plot shown in Fig. 2.3.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
NPV and FRR
Fig. 3.11â€‚ Plot of NPV (diamonds) and FRR (triangles) for dementia diagnosis at fixed Q (= 0.387; 
MACE cut-off â‰¤20/30) on y axis versus prevalence P (x axis). Note equivalence of FRR curve to 
the conditional probability plot shown in Fig. 2.3.
3â€ƒ Paired Complementary Measures

67
findings reflect the high sensitivity low specificity nature of MACE for dementia 
diagnosis [11]. Different findings may be anticipated with tests showing different 
performance characteristics (e.g. high sensitivity and high specificity, low sensitiv-
ity and high specificity).
Table 3.4â€‚ Interrelationship of P and Q illustrated using data from MACE study [11]
Cut-off
â‰¤14/30
â‰¤17/30
â‰¤20/30
â‰¤23/30
â‰¤26/30
Q
0.159
0.264
0.387
0.585
0.812
Qâ€²
0.841
0.736
0.613
0.415
0.188
PPV
0.558
0.422
0.356
0.253
0.184
NPV
0.926
0.946
0.978
0.994
0.993
Sens, Spec
P, Pâ€²
0.1, 0.9
0.378,0.922
0.603,0.830
0.865,0.723
0.975,0.514
0.986,0.264
0.2, 0.8
0.689,0.912
0.801,0.809
0.933,0.688
0.988,0.454
0.993,0.172
0.3, 0.7
0.793,0.900
0.868,0.782
0.955,0.644
0.992,0.376
0.996,0.053
0.4, 0.6
0.844,0.883
0.901,0.746
0.966,0.585
0.994,0.272
0.997, âˆ’0.104
0.5, 0.5
0.876,0.859
0.921,0.695
0.973,0.502
0.995,0.126
0.997, âˆ’0.325
0.6, 0.4
0.896,0.824
0.934,0.619
0.978,0.377
0.996, âˆ’0.09
0.998, âˆ’0.656
0.7, 0.3
0.911,0.766
0.943,0.491
0.981,0.169
0.996, âˆ’0.457
0.998, âˆ’1.21
0.8, 0.2
0.922,0.649
0.950,0.237
0.983, âˆ’0.246
0.997, âˆ’1.18
0.998, âˆ’2.31
0.9, 0.1
0.931,0.297
0.956, âˆ’0.526
0.985, âˆ’1.49
0.997, âˆ’3.37
0.999, âˆ’5.63
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Sens
Fig. 3.12â€‚ Plot of Sens for five different MACE cut-offs (hence different values of Q) on y axis 
versus prevalence P (x axis); from data in TableÂ 3.4
3.4â€ƒ Dependence ofÂ Paired Complementary Measures onÂ Prevalence (P)

68
References
	 1.	Bossuyt PMM.Â Clinical validity: defining biomarker performance. Scand J Clin Lab Invest. 
2010;70(Suppl242):46â€“52.
	 2.	Connell FA, Koepsell TD.Â Measures of gain in certainty from a diagnostic test. Am J Epidemiol. 
1985;121:744â€“53.
	 3.	Gallagher EJ.Â  The problem with sensitivity and specificityâ€¦. Ann Emerg Med. 
2003;42:298â€“303.
	 4.	Garrett CT, Sell S.Â Summary and perspective: assessing test effectivenessÂ â€“ the identifica-
tion of good tumour markers. In: Garrett CT, Sell S (eds.). Cellular cancer markers. Springer; 
1995:455-477.
	 5.	Habibzadeh F, Habibzadeh P, Yadollahie M.Â On determining the most appropriate test cut-off 
value: the case of tests with continuous results. Biochem Med (Zagreb). 2016;26:297â€“307.
	 6.	Hancock P, Larner AJ.Â Clinical utility of Patient Health Questionnaire-9 (PHQ-9) in memory 
clinics. Int J Psychiatry Clin Pract. 2009;13:188â€“91.
	 7.	Hsieh S, McGrory S, Leslie F, Dawson K, Ahmed S, Butler CR, etÂ al. The Mini-Addenbrookeâ€™s 
Cognitive Examination: a new assessment tool for dementia. Dement Geriatr Cogn Disord. 
2015;39:1â€“11.
	 8.	Kaivanto K.Â Maximization of the sum of sensitivity and specificity as a diagnostic cutpoint 
criterion. J Cin Epidemiol. 2008;61:517â€“8.
	 9.	Kraemer HC.Â Evaluating medical tests. Objective and quantitative guidelines. Newbery Park: 
Sage; 1992.
	10.	Larner AJ.Â Comparing diagnostic accuracy of cognitive screening instruments: a weighted 
comparison approach. Dement Geriatr Cogn Disord Extra. 2013;3:60â€“5.
	11.	Larner AJ.Â MACE for diagnosis of dementia and MCI: examining cut-offs and predictive val-
ues. Diagnostics (Basel). 2019;9:E51.
	12.	Larner AJ.Â Applying Kraemerâ€™s Q (positive sign rate): some implications for diagnostic test 
accuracy study results. Dement Geriatr Cogn Dis Extra. 2019;9:389â€“96.
	13.	Larner AJ.Â What is test accuracy? Comparing unitary accuracy metrics for cognitive screening 
instruments. Neurodegener Dis Manag. 2019;9:277â€“81.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Spec
Fig. 3.13â€‚ Plot of Spec for five different MACE cut-offs (hence different values of Q) on y axis 
versus prevalence P (x axis); from data in TableÂ 3.4
3â€ƒ Paired Complementary Measures

69
	14.	Larner AJ.Â Defining â€œoptimalâ€ test cut-off using global test metrics: evidence from a cognitive 
screening instrument. Neurodegener Dis Manag. 2020;10:223â€“30.
	15.	Larner AJ.Â  Manual of screeners for dementia. Pragmatic test accuracy studies. London: 
Springer; 2020.
	16.	Mallett S, Halligan S, Thompson M, Collins GS, Altman DG.Â Interpreting diagnostic accuracy 
studies for patient care. BMJ. 2012;345:e3999.
	17.	McCrea MA.Â Mild traumatic brain injury and postconcussion syndrome. The new evidence 
base for diagnosis and treatment. Oxford: Oxford University Press; 2008.
	18.	McKay RA.Â Patient Zero and the making of the AIDS epidemic. Chicago/London: University 
of Chicago Press; 2017.
	19.	Metz CE.Â Basic principles of ROC analysis. Semin Nucl Med. 1978;8:283â€“98.
	20.	Moons KGM, Stijnen T, Michel BC, BÃ¼ller HR, Van Es GA, Grobbee DE, Habbema 
DF.Â Application of treatment thresholds to diagnostic-test evaluation: an alternative to the 
comparison of areas under receiver operating characteristic curves. Med Decis Making. 
1997;17:447â€“54.
	21.	Perkins NJ, Schisterman EF.Â The inconsistency of â€œoptimalâ€ cutpoints obtained using two 
criteria based on the receiver operating characteristic curve. Am J Epidemiol. 2006;163:670â€“5.
	22.	Smits N.Â A note on Youdenâ€™s J and its cost ratio. BMC Med Res Methodol. 2010;10:89.
	23.	Strauss SE, Glasziou P, Richardson WS, Haynes RB.Â Evidence-based medicine. How to prac-
tice and teach EBM. 5th ed. Edinburgh: Elsevier; 2019.
	24.	Youden WJ.Â Index for rating diagnostic tests. Cancer. 1950;3:32â€“5.
References

71
Â© Springer Nature Switzerland AG 2021
A. J. Larner, The 2x2 Matrix, https://doi.org/10.1007/978-3-030-74920-0_4
Chapter 4
Unitary Measures
Contents
4.1â€ƒ Introduction
â€ƒ 71
4.2â€ƒ Youden Index (Y) or Statistic (J)
â€ƒ 71
4.3â€ƒ Predictive Summary Index (PSI, Î¨)
â€ƒ 76
4.4â€ƒ Harmonic Mean ofÂ Y andÂ PSI (HMYPSI)
â€ƒ 78
4.5â€ƒ Matthewsâ€™ Correlation Coefficient (MCC)
â€ƒ 81
4.6â€ƒ Identification Index (II)
â€ƒ 83
4.7â€ƒ Net Reclassification Improvement (NRI)
â€ƒ 84
4.8â€ƒ Critical Success Index (CSI) or Threat Score (TS)
â€ƒ 86
4.9â€ƒ F Measure (F) or F1 Score (Dice Coefficient)
â€ƒ 89
4.10â€ƒ Summary Utility Index (SUI) andÂ Summary Disutility Index (SDI)
â€ƒ 92
References
â€ƒ 94
4.1â€ƒ Introduction
In addition to the paired test metrics examined in chapters 2 and 3, there are also a 
number of global, single, or unitary metrics which may be used to summarise the 
outcomes of a 2Â Ã—Â 2 contingency table. Accuracy (Sect. 3.2.4) and diagnostic odds 
ratio (Sect. 2.4.1) are sometimes used as global outcome measures, but these are in 
fact paired (with inaccuracy and error odds ratio, respectively, although both the 
latter metrics are seldom used).
4.2â€ƒ Youden Index (Y) or Statistic (J)
Youden [41] defined the Youden index (Y), or Youden J statistic, as:
	
Y
Sens
Spec


â€“1 	
Hence, like likelihood ratios (Sect. 2.3.4) and correct classification rate (Sect. 
3.2.5), this is a metric which attempts to combine information from sensitivity 
(Sens) and specificity (Spec).
Values of Y may range from âˆ’1 to +1. However, most values of Y would be 
expected to fall within the range 0 (worthless, no diagnostic value) to 1 (perfect 
diagnostic value, no false positives or false negatives), with negative values 

72
occurring only if the test were misleading, i.e. the test result was negatively associ-
ated with the true diagnosis. Y may be termed â€œinformednessâ€ in the informatics 
literature [34]. It has also been characterised as the maximum proportional reduc-
tion in expected â€œregretâ€ achieved by a test, i.e. the difference in outcome between 
the action taken and the best action that could, in retrospect, have been taken [11].
Y may also be expressed in terms of false positive rate (FPR) and false negative 
rate (FNR) (Sect. 2.2.3) as:
	
Y
Sens
Spec
Sens
FPR
TPR
FPR





â€“
â€“
â€“
â€“
1
	
or
	
Y
Spec
Sens
Spec
FNR
TNR
FNR
FPR
FNR














1
1
	
Hence Y is the difference between the two positive rates (TPRÂ â€“ FPR) or between 
the two negative rates (TNRÂ â€“ FNR). The outcomes of the addition of the two true 
rates (TPR + TNR) and of the two false rates (FNR + FPR), as the correct classifica-
tion rate and the misclassification rate respectively, have previously been described 
(Sect. 3.2.5). Hence:
	
Y
Sens
Spec
TPR
TNR
Correct classification rate








1
1
1 	
or
	
Y
FPR
FNR
Misclassification rate





1
1


	
Y is therefore the complement or negation of the correct classification and mis-
classification rates (or the sum of the two false rates), with the end points of 
+1 and âˆ’1.
In literal notation (Fig. 1.1):
	
Y
TP
TP
FN
TN
FP
TN
TP p
TN p





 




 
 



/
/
/
/
1
1
	
Y may also be computed from the raw cell values from the 2Â Ã—Â 2 contingency 
table without first calculating Sens and Spec:
	
Y
TP
TN
FP
FN
TP
FN
FP
TN

















â€“
/
	
In algebraic notation (Fig. 1.2):
4â€ƒ Unitary Measures

73
	
Y
a
a
c
d
b
d





 




 
/
/
1 	
or, without first calculating Sens and Spec:
	
Y
ad
bc
a
c
b
d
 









â€“
/
.
	
or, in terms of marginal totals (Sect. 1.3.1):
	
Y
ad
bc
p p
 
 

â€“
/
.
	
In error notation:
	
Y


 





1
1
1
1








	
Y can also be expressed in terms of likelihood ratios (Sect. 2.3.4):
	
Y
Sens
Spec
LR
Specificity
LR
FPR
LR




















1
1
1
1
1
Specificity
LR
LR
LR
LR













1
1
/
	
For the particular case of a single-threshold binary classifier, there is also a 
method to calculate Y from the area under the receiver operating characteristic 
(ROC) plot (see Sect. 6.2).
Y varies with test cut-off (Fig.Â 4.1) [16, 20].
Worked Examples: Youden Index (Y)
The Mini-Addenbrookeâ€™s Cognitive Examination (MACE) [12] was sub-
jected to a screening test accuracy study [16]. At the MACE cut-off of â‰¤20/30, 
TP = 104, FN =10, FP = 188, and TN = 453 (Fig. 2.2).
Hence the values for Sens and Spec are (Sect. 2.2.1):
Sens
TP
TP
FN









/
/
.
104
104 10
0 912
Spec
TN
TN
FP









/
/
.
453
453 188
0 707
4.2â€ƒ Youden Index (Y) or Statistic (J)

74
Y has some shortcomings as a global measure [17]. Being derived from Sens and 
Spec, strict columnar ratios, it would be anticipated that Y, like Sens and Spec, is 
independent of prevalence. Certainly Youden ([41], p.33) stated that Y was indepen-
dent of the size, relative or absolute, of the control and disease groups. In practice, 
Sens and Spec, and hence Y, are not independent of disease prevalence [2], as is 
shown for the MACE study in TableÂ 4.1 and Fig.Â 4.2 which indicate that in this 
dataset Y is optimal at P = 0.5. Moreover, Y implicitly employs a ratio of misclas-
sification costs for FN and FP which varies with prevalence and so Y is not truly 
optimal [39]. Its maximal value arbitrarily assumes disease prevalence to be 50%, 
and treats FN and FP as equally undesirable, which is often not the case in clinical 
practice. In terms of cost ratio (Sect. 3.2.5), Y assumes Cr = 0.5, i.e. that the 
Therefore the value for Y is:
Y
Sens
Spec







1
0 912
0 707 1
0 619
.
.
.
Examining all test cut-offs, this was the cut-off giving the maximal value 
for Youden index for dementia diagnosis [16] (hence use of this cut-off in 
previous worked examples).
Y may also be calculated without first knowing Sens and Spec:
Y
TP
TN
FP
FN
TP
FN
FP
TN

























/
104 453
188 10












/
/
.
104 10 188
453
45232 73074
0 619
It was previously shown (Sect. 2.3.4) that LR+ = 3.11 and LR- = 0.124 at 
MACE cut-off â‰¤20/30. Expressing Y in terms of LRs:
Y
LR
LR
LR
LR











 








1
1
3 11 1
1 0 124
3 11 0 124
/
.
.
/
.
.




2 11 0 876 2 986
0 619
.
.
/ .
.
It was also previously shown (Sect. 3.2.5) that Correct classification rate 
was 1.619, hence Y = Correct classification rateÂ â€“ 1
It was also shown (Sect. 3.2.5) that Misclassification rate was 0.381, hence 
Y = 1Â â€“ Misclassification rate.
4â€ƒ Unitary Measures

75
difference in costs between correct and incorrect test classification is equal for both 
the healthy and diseased [39].
Y has an application in defining optimal test cut-off from the receiver operating 
characteristic (ROC) curve (Sect. 6.2.1) [38].
Y may be rescaled according to the level of the test, Q (see Sect. 2.2.2), such 
that [18]:
	
Y
QSN
QSP
Q


â€“1	
The reciprocal (multiplicative inverse) of Y has been termed the number needed 
to diagnose (NND) [27] (see Sect. 5.2).
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
10
12
14
16
18
20
22
24
26
28
30
Y
Fig. 4.1â€‚ Plot of Youden index (y axis) for dementia diagnosis at fixed P (= 0.151) versus MACE 
cut-off (x axis) [19]
Table 4.1â€‚ Values of Sens, Spec (from Table 3.1), and Y for dementia diagnosis at fixed MACE 
cut-off of â‰¤20/30 at various prevalence levels
P, Pâ€²
Sens
Spec
Y
0.1, 0.9
0.914
0.681
0.595
0.2, 0.8
0.908
0.728
0.636
0.3, 0.7
0.896
0.763
0.659
0.4, 0.6
0.884
0.790
0.674
0.5, 0.5
0.865
0.812
0.677
0.6, 0.4
0.840
0.830
0.670
0.7, 0.3
0.803
0.844
0.647
0.8, 0.2
0.746
0.857
0.603
0.9, 0.1
0.640
0.868
0.508
4.2â€ƒ Youden Index (Y) or Statistic (J)

76
4.3â€ƒ Predictive Summary Index (PSI, Î¨)
Linn and Grunau [27] defined the predictive summary index (PSI, Î¨), combining 
positive and negative predictive values (Sect. 2.3.1), as:
	
PSI
PPV
NPV


â€“1 	
Values of PSI may range from âˆ’1 to +1. However, most values of PSI would be 
expected to fall within the range 0 (no diagnostic value) to 1 (perfect predictive 
value, no false discoveries or false reassurances), with negative values occurring 
only if the test were misleading, i.e. the test result was negatively associated with 
the true diagnosis. PSI may be termed â€œmarkednessâ€ in the informatics litera-
ture [34].
PSI may also be expressed in terms of false discovery rate (FDR) and false reas-
surance rate (FRR) (Sect. 2.3.3) as:
	
PSI
PPV
NPV
PPV
FRR
NPV
PPV
NPV
FDR














1
1
	
This measure may be characterised as the net gain of certainty of a test, by sum-
ming gain in certainty that a condition is either present or absent:
	
PSI
PPV
P
NPV
P
PPV
NPV


 










1
1
	
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Y
Fig. 4.2â€‚ Plot of Youden index (y axis) for dementia diagnosis at fixed Q (MACE cut-off â‰¤20/30) 
versus prevalence P (x axis)
4â€ƒ Unitary Measures

77
In literal notation (Fig. 1.1):
	
PSI
=
TP
TP
FP
TN
FN
TN
TP q
TN q
/
/
/
/




 




 
 



1
1
	
In algebraic notation (Fig. 1.2):
	
PSI
a
a
b
d
c
d





 




 
/
/
1	
PSI may also be computed from the raw cell values from the 2Â Ã—Â 2 contingency 
table without first calculating PPV and NPV:
	
PSI
TP
TN
FP
FN
TP
FP
FN
TN

















â€“
/
	
In algebraic notation:
	
PSI
ad
bc
a
b
c
d
 









â€“
/
.
	
and in terms of marginal totals:
	
PSI
ad
bc
q q


 

â€“
/
.
	
Worked Examples: Predictive Summary Index (PSI or Î¨)
In a screening test accuracy study of MACE [16], at the MACE cut-off giving 
maximal Youden index for dementia diagnosis, â‰¤20/30, TP = 104, FN =10, 
FP = 188, and TN = 453.
Hence the values for PPV and NPV at this cut-off are (Sect. 2.3.1):
PPV
TP
TP
FP









/
/
.
104
104
188
0 356
NPV
TN
TN
FN









/
/
.
453
453 10
0 978
Therefore the value for PSI is:
PSI
PPV
NPV





â€“
.
.
â€“
.
1
0 356
0 978 1
0 334
4.3â€ƒ Predictive Summary Index (PSI, Î¨)

78
PSI varies with test cut-off or Q (Fig.Â 4.3) [16], with a different maximal cut-off 
value from Y.
PSI also varies with prevalence, as shown for the MACE study in TableÂ 4.2 and 
Fig.Â 4.4, with optimal PSI at P = 0.6 (cf. Y, optimal at P = 0.5).
It has been argued that PSI may be useful for making population-based policy 
decisions, but that it adds little useful information to practicing clinicians attempt-
ing to apply research findings to individual patients [10].
The reciprocal (multiplicative inverse) of PSI has been termed the number 
needed to predict (NNP) [27] (see Sect. 5.3).
4.4â€ƒ Harmonic Mean ofÂ Y andÂ PSI (HMYPSI)
Just as Youdenâ€™s index (Y) is an attempt to combine information about Sens and 
Spec, as are likelihood ratios (Sect. 2.3.4) and the receiver operating characteristic 
(ROC) curve (Sect. 6.2), and as predictive summary index (PSI) is an attempt to 
0
0.1
0.2
0.3
0.4
0.5
0.6
10
12
14
16
18
20
22
24
26
28
30
PSI
Fig. 4.3â€‚ Plot of PSI (y axis) for dementia diagnosis at fixed P (= 0.151) versus MACE cut-off (x 
axis) (data from [15])
PSI may also be calculated without first knowing PPV and NP:
PSI
TP
TN
FP
FN
TP
FP
FN
TN
























/
104 453
188 10
104 188 10
453
45232 135196
0 334














/
/
.
4â€ƒ Unitary Measures

79
combine information about predictive values, it may also be helpful to have mea-
sures which attempt to combine Sens and Spec and predictive values. Options 
include the clinical utility indexes (Sect. 2.4.2) and the summary utility index 
(Sect. 4.10).
Another option is the mean of Y and PSI, either geometric, which is the Matthewsâ€™ 
correlation coefficient (MCC; Sect. 4.5), or harmonic, since geometric and har-
monic means have advantages over the arithmetic mean in skewed datasets. To my 
knowledge, the latter has attracted no particular name, so I use the term â€œharmonic 
mean of Y and PSIâ€ or HMYPSI, where:
	
HMYPSI
Y
PSI
Y PSI
Y
PSI








2
1
1
2
/
/
/
. .
/
	
Table 4.2â€‚ Values of PPV, NPV (from Table 3.3), and PSI for dementia diagnosis at fixed MACE 
cut-off of â‰¤20/30 at various prevalence levels
P, Pâ€²
PPV
NPV
PSI
0.1, 0.9
0.257
0.986
0.243
0.2, 0.8
0.437
0.970
0.407
0.3, 0.7
0.571
0.949
0.520
0.4, 0.6
0.675
0.924
0.599
0.5, 0.5
0.757
0.890
0.647
0.6, 0.4
0.824
0.843
0.667
0.7, 0.3
0.879
0.775
0.654
0.8, 0.2
0.926
0.668
0.594
0.9, 0.1
0.966
0.472
0.438
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
PSI
Fig. 4.4â€‚ Plot of PSI (y axis) for dementia diagnosis at fixed Q (MACE cut-off â‰¤20/30) on versus 
prevalence P (x axis)
4.4â€ƒ Harmonic Mean ofÂ Y andÂ PSI (HMYPSI)

80
Like Y and PSI, the value of HMYPSI may range from âˆ’1 to +1, with higher 
values better.
HMYPSI values vary with test cut-off or Q (Fig.Â 4.5), with maximal cut-off 
closer to that of PSI than to that of Y.
HMYPSI values also vary with prevalence (TableÂ 4.3, Fig.Â 4.6).
In one particular case, when b = c in the 2Â Ã—Â 2 contingency table (Fig. 1.2; i.e. 
false positives = false negatives), and hence the marginal totals align (i.e. the matrix 
is symmetric), such that (a + b) = (a + c) and (b + d) = (c + d), then the values of 
HMYPSI and MCC coincide (in terms of marginal totals, when p = q and pâ€² = qâ€²). 
In this situation, HMYPSI would also coincide with the value of the kappa statistic 
(Sect. 7.2.2).
0
0.1
0.2
0.3
0.4
0.5
0.6
10
12
14
16
18
20
22
24
26
28
30
HMYPSI 
Fig. 4.5â€‚ Plot of HMYPSI (y axis) for dementia diagnosis at fixed P (= 0.151) versus MACE cut-Â­
off (x axis)
Worked Example: Harmonic Mean of Y and PSI (HMYPSI)
In the screening test accuracy study of MACE [16], at the MACE cut-off of 
â‰¤20/30 the value of Y = 0.619 (Sect. 4.2) and of PSI = 0.334 (Sect. 4.3).
HMYPSI
Y PSI
Y
PSI











2
2 0 619 0 334
0 619
0 334
0 413 0
. .
/
.
.
/
.
.
.
/ .
.
953
0 433

4â€ƒ Unitary Measures

81
4.5â€ƒ Matthewsâ€™ Correlation Coefficient (MCC)
Matthews [28] defined a correlation coefficient (MCC).
In literal notation:
	MCC
TP
TN
FP
FN
TP
FP
TP
FN
TN
FP
TN
FN








 














â€“
/
	
In algebraic notation:
	
MCC
a
d
b c
a
b
a
c
b
d
c
d
ad
bc








 














 
 
â€“
/
.
.
.
â€“
/
q p p q
. . . 


	
Table 4.3â€‚ Values of Y (from TableÂ 4.1), PSI (from TableÂ 4.2), HMYPSI and MCC for dementia 
diagnosis at fixed MACE cut-off of â‰¤20/30 at various prevalence levels
P, Pâ€²
Y
PSI
HMYPSI
MCC
0.1, 0.9
0.595
0.243
0.345
0.380
0.2, 0.8
0.636
0.407
0.496
0.509
0.3, 0.7
0.659
0.520
0.581
0.585
0.4, 0.6
0.674
0.599
0.634
0.635
0.5, 0.5
0.677
0.647
0.662
0.662
0.6, 0.4
0.670
0.667
0.668
0.668
0.7, 0.3
0.647
0.654
0.650
0.650
0.8, 0.2
0.603
0.594
0.598
0.598
0.9, 0.1
0.508
0.438
0.470
0.472
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
HMYPSI
Fig. 4.6â€‚ Plot of HMYPSI (y axis) for dementia diagnosis at fixed Q (MACE cut-off â‰¤20/30) 
versus prevalence P (x axis)
4.5â€ƒ Matthewsâ€™ Correlation Coefficient (MCC)

82
MCC is equivalent to the Pearson phi (Ï†) coefficient, an effect size from the fam-
ily of measures of association (Sect. 6.4)
MCC is also the geometric mean of the Youden index (Y) or informedness (Sect. 
4.2) and the predictive summary index (PSI) or markedness (Sect. 4.3):
	
MCC
Y
PSI
 


 	
For those geometrically minded, calculation of MCC may be related to a theorem 
in elementary geometry: for a right triangle, ABC, the perpendicular AD divides BC 
into two portions, BD and DC.Â The length of the perpendicular AD = âˆš(BD x DC), 
the geometric mean of BD and DC.Â If we substitute Y and PSI for BD and DC, then 
AD = MCC.
The geometric mean is preferred to the arithmetic mean in skewed datasets, as is 
the harmonic mean (Sect. 4.4).
MCC has a range of âˆ’1 to +1, where +1 represents perfect prediction, 0 is no 
better than random, and âˆ’1 indicates total disagreement between prediction and 
observation.
For ease of comparison with other accuracy metrics, a normalised MMC 
(nMMC), with range 0 to 1, may be calculated [4], as:
	
nMCC
MMC




1
2
/
	
Worked Examples: Matthewsâ€™ Correlation Coefficient (MCC)
In a screening test accuracy study of the MACE in a cohort of 755 consecutive 
patients [16], at the cut-off for dementia diagnosis of â‰¤20/30, TP = 104, FN 
=10, FP = 188, and TN = 453.
Hence the value for MCC is:
MCC
TP
TN
FP
FN
TP
FP
TP
FN
TN
FP
TN
FN



 




 

















/




 




 










104
453
188 10
104
188 104
10
188
453 10
45
/
3
45232 99394 73
0 455










/
.
.
It was previously shown for MACE at this cut-off that Y = 0.619 (Sect. 4.2) 
and PSI = 0.334 (Sect. 4.3).
Hence the value for MCC may also be calculated as:
MCC
Y
PSI
 



 




0 619 0 334
0 455
.
.
.
4â€ƒ Unitary Measures

83
MCC values vary with test cut-off [20] in a pattern almost identical to that shown 
for HMYPSI (Fig.Â 4.5), with the same maximal cut-off (Table 6.2). Likewise, the 
variation of MCC with prevalence is almost identical to that for HMYPSI (TableÂ 4.3), 
diverging only at the extremes.
MCC values have been calculated for several cognitive screening instruments 
and appear to be the least optimistic compared to Acc, area under the receiver oper-
ating characteristic curve (AUC ROC), and the F measure [19].
MCC is widely regarded as being a very informative score for establishing the 
quality of a binary classifier, since it takes into account the size of all four classes in 
the table, and allows for imbalanced data [1, 3, 4]. Hence it may be preferred to F 
measure (Sect. 4.9) [4].
4.6â€ƒ Identification Index (II)
Mitchell [29] proposed an identification index (II) based on Accuracy and Inaccuracy 
(Sect. 3.2.4):
	
II
Acc
Inacc
Acc
Acc
Acc





â€“
â€“
â€“
.
â€“
1
2
1
	
As Acc ranges from 0 to 1, and is the complement or negation of Inacc, II has a 
range of âˆ’1 to +1, with most scores anticipated in the range 0 to +1.
In literal notation:
	
II
TP
TN
TP
FP
FN
TN
TP
TN
N










 





 
2
1
2
1
/
/
	
In algebraic notation:
	
II
a
d
a
b
c
d
a
d
N








 





 
2
1
2
1
/
/
	
The value for nMCC is:
nMCC
MCC









1
2
0 455 1
2
0 727
/
.
/
.
4.6â€ƒ Identification Index (II)

84
In terms of marginal totals:
	
II
r N


 
2
1
/
	
Acc and, hence, II both vary with the chosen test cut-off [16].
The reciprocal (multiplicative inverse) of II has been termed the number needed 
to screen (NNS) [29] (Sect. 5.6).
4.7â€ƒ Net Reclassification Improvement (NRI)
Net reclassification improvement or net reclassification index (NRI) may be used to 
quantify test performance. NRI expresses the change in the proportion of correct 
classification based on an investigation that has been added to the existing diagnos-
tic information [32]. Most simply, this may be calculated as the difference between 
prior (pre-test) probability of diagnosis, or prevalence, P (Sect. 1.3.2), and posterior 
probability or test accuracy, Acc (Sect. 3.2.4) [36]:
	
NRI
posterior probability
pre-test probability
Accuracy
Prev




alence
Acc
P


	
NRI is claimed to be intuitive and easy to use [36]. Evidently, a highly accurate 
test may be associated with small NRI if P is high, and a low accuracy test may be 
associated with large NRI if P is low.
Worked Example: Identification Index (II)
In a screening test accuracy study of MACE [16], at the MACE cut-off giving 
maximal Youden index for dementia diagnosis, â‰¤20/30, TP = 104, FN =10, 
FP = 188, and TN = 453.
Hence the value for Acc (Sect. 3.2.4) at this cut-off is:
Acc
TP
TN
TP
FN
FP
TN



















/
/
.
104
453
104
10
188
453
0 738
Therefore the value for II is:
II
Acc





 

2
1
2 0 738
1
0 475
.
.
.
4â€ƒ Unitary Measures

85
In literal notation (Fig. 1.1):
	
NRI
TP
TN
TP
FP
FN
TN
TP
FN
N
TP
TN
N










 










 
/
/
/
TP
FN
N
TN
FN
N









/
/
	
In algebraic notation (Fig. 1.2):
	
NRI
a
d
a
b
c
d
a
c
N
a
d
N
a
c
N
d





 



 








 







/
/
/
/
c
N

 /
	
In terms of marginal totals:
	
NRI
r N
p N
R
P




/
/
	
Other usages of â€œnet reclassification improvementâ€ based on reclassification 
tables may be used ([13], p.199â€“201).
Worked Example: Net Reclassification Improvement (NRI)
In a screening test accuracy study of MACE [16], in a cohort of 755 consecu-
tive patients the prevalence of dementia was 114/755 = 0.151 (Sect. 1.3.2). At 
the MACE cut-off giving maximal Youden index for dementia diagnosis, 
â‰¤20/30, TP = 104, FN =10, FP = 188, and TN = 453, Acc was 0.738 
(Sect. 3.2.4).
Hence the value for NRI at this cut-off is:
NRI
Acc
P
=
=
=
â€“
.
â€“ .
.
0 738
0 151
0 587
or
NRI
TN
FN
N
 

 


â€“
/
â€“
/
.
453 10
755
0 587
4.7â€ƒ Net Reclassification Improvement (NRI)

86
4.8â€ƒ Critical Success Index (CSI) or Threat Score (TS)
The critical success index (CSI) [37], or threat score (TS) [31], or ratio of verifica-
tion [9], is sometimes used in the context of weather forecasting, and has been 
defined as the ratio of hits to the sum of hits, false alarms, and misses. This might 
also be characterised (Sect. 1.2) as the ratio of true positives to the sum of true posi-
tives, false positives, and false negatives.
In literal notation:
	
CSI
TP
TP
FN
FP





/
	
In algebraic notation:
	
CSI
a
a
b
c





/
	
CSI may also be expressed in terms of Sens and PPV:
	
CSI
PPV
Sens


 
 


1
1
1
1
/
/
/
	
CSI ranges from 0 to 1 (perfect forecast).
Worked Examples: Critical Success Index (CSI)
In a screening test accuracy study of MACE [16], the MACE cut-off giving 
maximal Youden index for dementia diagnosis was â‰¤20/30, where TP = 104, 
FN =10, and FP = 188.
Hence the value for CSI is:
CSI
TP
TP
FN
FP











/
/
.
104
104
10
188
0 344
In the screening test accuracy study of MACE, the values for Sens and 
PPV at cut-off â‰¤20/30 were 0.912 (Sect. 2.2.1) and 0.356 (Sect. 2.3.1) 
respectively.
Hence the value for CSI calculated using these measures is:
CSI
PPV
Sens


 
 




 
 



1
1
1
1
1
1 0 356
1 0 912
1
1
/
/
/
/
/ .
/ .
/ .
.
2 905
0 344

Ignoring TN (= 453), the calculated CSI suggests MACE is a poor fore-
caster of the diagnosis of dementia at this cut-off.
4â€ƒ Unitary Measures

87
Obviously CSI ignores true negatives (TN, or d), or correct â€œnon-eventsâ€. Part of 
the rationale for the initial development of the critical success index was to avoid 
over-inflation of test metrics as a consequence of very large numbers of true nega-
tives [9] (i.e. class skew or imbalance), for example metrics such as specificity (= d/
(b+d)) and correct classification accuracy (= (a+d)/N).
CSI is not unbiased, since CSI = TP/(NÂ â€“ TN) = a/(NÂ â€“ d), and hence gives lower 
scores for rarer events. To offset this, a related score may be used to account for hits 
expected by chance. This is the equitable threat score (ETS) [8], also known as the 
Gilbert skill score [37]:
	
ETS
a
a
a
b
c
a
r
r





â€“
/
â€“
	
where
	
a
total forecasts of event
total observations of event
samp
r
 
 

.
/
le size 	
In literal notation:
	
a
TP
FP
TP
FN
N
r






 /
	
In algebraic notation:
	
a
a
b
a
c
N
r







.
/
	
In terms of marginal totals:
	
a
q p N
r
=
. /
	
Substituting, in literal notation:
	
ETS
TP
TP
FP
TP
FN
N
TP
FN
FP
TP
FP
TP
FN
N





















.
/
/
.
/
 	
In algebraic notation:
	
ETS
a
a
b
a
c
N
a
b
c
a
b
a
c
N



















â€“
.
/
/
â€“
.
/
	
In terms of marginal totals:
	
ETS
a
q p N
a
b
c
q p N
 





â€“ . /
/
â€“ . /
	
This correction for chance is analogous to that used in the kappa statistic (Sect. 
7.2.2). ETS values range from âˆ’1/3 to 1, and are lower than CSI values.
4.8â€ƒ Critical Success Index (CSI) or Threat Score (TS)

88
To my knowledge, CSI and ETS values have only recently been used in the char-
acterisation of cognitive screening test accuracy studies [26], but as the examples 
show they are easy to calculate. Both values vary with test cut-off or Q (Fig.Â 4.7), 
with maximum identical to HMYPSI and MCC in this dataset (Table 6.2).
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
10
12
14
16
18
20
22
24
26
28
30
CSI and ETS
Fig. 4.7â€‚ Plot of CSI (diamonds) and ETS (triangles) on y-axis versus MACE cut-off (x axis) [25]
Worked Example: Equitable Threat Score (ETS)
In a screening test accuracy study of MACE [16], the MACE cut-off giving 
maximal Youden index for dementia diagnosis was â‰¤20/30, where TP = 104, 
FN =10, and FP = 188.
Hence the value for ar is:
a
TP
FP
TP
FN
N
r















.
/
.
/
.
104
188
104
10
755
44 09
Substituting, the value for ETS is:
ETS
TP
a
TP
FN
FP
a
r
r













â€“
/
â€“
â€“
.
/
â€“
.
.
104
44 09
104
10
188
44 09
0 232
The calculated ETS suggests MACE is a poor forecaster of diagnosis of 
dementia at this cut-off, as for CSI.
4â€ƒ Unitary Measures

89
4.9â€ƒ F Measure (F) or F1 Score (Dice Coefficient)
The F measure (F) or F1 score [34, 35] is defined as the harmonic mean of precision 
or positive predictive value (PPV; Sect. 2.3.1) and sensitivity or recall (Sect. 2.2.1). 
This corresponds to the coefficient described by Dice in 1948 [7], and indepen-
dently by SÃ¸rensen [40], itself a reinvention of a metric described by Jaccard in 
1901 (in French; translated into English in 1912 [14]).
	
F
PPV Sens
PPV
Sens
Sens
PPV








2
2
1
1
.
.
/
/
/
/
	
In literal notation:
	
F
TP
TP
FP
FN





2
2
.
/
.
	
In algebraic notation:
	
F
a
a
b
c





2
2
/
	
F has range of 0 to 1, where 1 is perfect precision and recall [34].
Worked Example: F Measure (F)
In a screening test accuracy study of the MACE (N = 755) [16], at the cut-off 
giving maximal Youden index for dementia diagnosis, â‰¤20/30, TP = 104, FN 
=10, and FP = 188.
Hence the value for F is:
F
TP
TP
FP
FN

















2
2
2 104
2 104
188
10
208 406
0 512
.
/
.
/
/
.
This may also be calculated using values of Sens = 0.912 (Sect. 2.2.1) and 
PPV = 0.356 (Sect. 2.3.1):
F
PPV Sens
PPV
Sens











2
2 0 356 0 912
0 356
0 912
0 649
.
.
/
.
.
/
.
.
.
/1 268
0 512
.
.

4.9â€ƒ F Measure (F) or F1 Score (Dice Coefficient)

90
F measure ignores true negatives (TN or d), or correct â€œnon-eventsâ€, as does CSI 
(Sect. 4.8). There is a monotonic relation between the two measures, such that:
	
F
CSI
CSI




2
1
/
	
Hence, when comparing different tests, the ranking is the same for F and CSI 
[15, 26] and the plot of F measure values against test cut-off [20] has the same maxi-
mum as for CSI and ETS (Fig.Â 4.7).
F measure has been calculated for several cognitive screening instruments [19] 
and varies with test cut-off or Q [20]. It also varies with prevalence: for the MACE 
study (TableÂ 4.4; Fig.Â 4.8) the optimum value of F is at P = 0.7 (cf. Y and PSI). CSI 
would be anticipated to vary with P in the same manner.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
F
Fig. 4.8â€‚ Plot of F (y axis) for dementia diagnosis at fixed Q (MACE cut-off â‰¤20/30) versus preva-
lence P (x axis)
Table 4.4â€‚ Values of PPV (from Table 3.3), Sens (from Table 3.1), and F for dementia diagnosis at 
fixed MACE cut-off of â‰¤20/30 at various prevalence levels
P, Pâ€²
PPV
Sens
F
0.1, 0.9
0.257
0.914
0.401
0.2, 0.8
0.437
0.908
0.590
0.3, 0.7
0.571
0.896
0.697
0.4, 0.6
0.675
0.884
0.765
0.5, 0.5
0.757
0.865
0.807
0.6, 0.4
0.824
0.840
0.832
0.7, 0.3
0.879
0.803
0.839
0.8, 0.2
0.926
0.746
0.826
0.9, 0.1
0.966
0.640
0.770
4â€ƒ Unitary Measures

91
F measure is a scalar value based on information from both columns of the 2Â Ã—Â 2 
table (cf. Sens and Spec), hence varies with prevalence, P (Sect. 2.3.2), as well as 
with the level of the test, Q, and hence with test cut-off [20], and is also sensitive to 
class imbalance. Nevertheless, it has been advocated as a measure of agreement, 
using the nomenclature â€œproportion of specific positive agreementâ€ (PA) [6], in 
preference to Cohenâ€™s kappa statistic (Sect. 7.2.2). Although the kappa statistic is 
often characterised as a measure of agreement, it is a relative measure and hence 
may be characterised as a measure of reliability. In this context, de Vet etÂ al. [6] also 
characterised a â€œproportion of specific negative agreementâ€ (NA):
	
NA
TN
TN
FP
FN
d
d
b
c










2
2
2
2
.
/
/
	
Evidently this is equivalent to the harmonic mean of Spec and NPV:
	
NA
NPV Spec
NPV
Spec
Spec
NPV








2
2
1
1
.
.
/
/
/
/
	
Thus, NA ignores true positives (TP or a), or â€œhitsâ€. It has a range of 0 to 1, where 
1 is perfect NPV and specificity.
It is argued that these measures of specific agreement, PA and NA, facilitate 
clinical decision making in a way that relative measures such as Cohenâ€™s kappa do 
not [6].
Worked Example: Proportion of Specific Negative Agreement (NA)
In a screening test accuracy study of the MACE (N = 755) [16], at the cut-off 
giving maximal Youden index for dementia diagnosis, â‰¤20/30, FN =10, FP = 
188, and TN = 453.
Hence the value for NA is:
NA
TN
TN
FP
FN

















2
2
2 453
2 453
188 10
906 1104
0
.
/
.
/
/
.821
This may also be calculated using values of Spec = 0.707 (Sect. 2.2.1) and 
NPV = 0.978 (Sect. 2.3.1):
NA
NPV Spec
NPV
Spec











2
2 0 978 0 707
0 978
0 707
1 383
.
.
/
.
.
/
.
.
.
/ .
.
1 685
0 821

4.9â€ƒ F Measure (F) or F1 Score (Dice Coefficient)

92
4.10â€ƒ Summary Utility Index (SUI) andÂ Summary Disutility 
Index (SDI)
A â€œsummary utility indexâ€ (SUI) has been proposed [17, 21], based on the clinical 
utility indexes [30] (Sect. 2.4.2), defined as:
	
SUI
CUI
CUI
Sens
PPV
Spec
NPV

 






 


 	
SUI may thus range from 0 to 2, as for the â€œgain in certaintyâ€ [5] or overall cor-
rect classification rate [33] measure derived from Sens and Spec (see Sect. 3.2.5). 
SUI is therefore desirably as close to 2 as possible. It may be qualitatively classified, 
based on CUI values (Sect. 2.4.2), as: excellent â‰¥1.62, good â‰¥1.28, adequate â‰¥0.98, 
poor â‰¥0.72, or very poor <0.72 [17, 21].
In literal notation:
	
SUI
TP
TP
FN
TP
TP
FP
TN
FP
TN
TN
FN
TN
TP








 









/
/
/
/
2
2
2
2
/
/
/
.
TP
FN
TP
FP
TN
FP
TN
FN
TN
TP
p q
TN







 










 
/
. 


p q
In algebraic notation:
	
SUI
a
a
c
a
a
b
d
b
d
d
c
d
=
a
a
c
a
b








 














/
/
/
/
/
.
2

 








d
b
d
c
d
2 /
.
	
and in terms of marginal totals:
	
SUI
a
p q
d
p q


 


 
2
2
/
.
/
.
	
Worked Example: Summary Utility Index (SUI)
In a screening test accuracy study of MACE [16], at the MACE cut-off of 
â‰¤20/30 for dementia diagnosis TP = 104, FN =10, FP = 188, and TN = 453.
The values for Sens and Spec (Sect. 2.2.1) are:
Sens
Spec
=
=
0 912
0 707
.
.
The values for PPV and NPV (Sect. 2.3.1) are:
PPV
NPV
=
=
0 356
0 978
.
.
4â€ƒ Unitary Measures

93
SUI values have been calculated for many neurological signs and cognitive 
screening questions and instruments [16, 17, 22â€“25]. SUI values vary with test cut-Â­
off or Q [16], with the same maximum as for other unitary metrics such as HMYPSI, 
MCC, CSI and F measure [20] (Table 6.2). SUI also varies with prevalence ([21], 
p.163â€“5).
SUI may be rescaled according to the level of the test, Q (see Sect. 2.2.2), such 
that [18]:
	
SUI
CUI
CUI
Q
Q
Q

 
 	
The reciprocal (multiplicative inverse) of SUI has been termed the number 
needed for screening utility (NNSU; Sect. 5.7) [17, 21].
A â€œsummary disutility indexâ€ (SDI) may also be proposed based on the clinical 
disutility indexes (Sect. 2.4.2), defined as:
	
SDI
CDI
CDI
FNR
FDR
FPR
FRR

 






 


 	
SDI may thus range from 0 to 2, as for SUI, and is desirably as close to 0 as pos-
sible. It may be qualitatively classified, based on CDI values (Sect, 2.4.2), as: very 
poor â‰¥1.62, poor â‰¥1.28, adequate â‰¥0.98, good â‰¥0.72, or excellent <0.72.
Hence the values for CUI+ and CUI- (Sect. 2.4.2) are:
CUI
Sens
PPV






0 912 0 356
0 325
.
.
.
CUI
Spec
NPV
 




0 707 0 978
0 691
.
.
.
Hence the value for SUI is:
SUI
CUI
CUI

 




0 325
0 691
1 016
.
.
.
This value of SUI is qualitatively classified as adequate.
4.10â€ƒ Summary Utility Index (SUI) andÂ Summary Disutility Index (SDI)

94
References
	 1.	Boughorbel S, Jarray F, El-Anbari M.Â Optimal classifier for imbalanced data using Matthews 
Correlation Coefficient metric. PLoS One. 2017;12(6):e0177678.
	 2.	Brenner H, Gefeller O.Â Variation of sensitivity, specificity, likelihood ratios and predictive 
values with disease prevalence. Stat Med. 1997;16:981â€“91.
	 3.	Chicco D.Â  Ten quick tips for machine learning in computational biology. BioData Min. 
2017;10:35.
	 4.	Chicco D, Jurman G.Â The advantages of the Matthews correlation coefficient (MCC) over F1 
score and accuracy in binary classification evaluation. BMC Genomics. 2020;21:6.
Worked Example: Summary Disutility Index (SDI)
In a screening test accuracy study of MACE [16], at the MACE cut-off of 
â‰¤20/30 for dementia diagnosis TP = 104, FN =10, FP = 188, and TN = 453.
The values for FNR and FPR (Sect. 2.2.3) are:
FNR
FPR
=
=
0 088
0 293
.
.
The values for FDR and FRR (Sect. 2.3.3) are:
FDR
FRR
=
=
0 644
0 022
.
.
Hence the values for CDI+ and CDIâˆ’ (Sect. 2.4.2) are:
CDI
FNR
FDR






0 088 0 644
0 057
.
.
.
CDI
FPR
FRR






0 293 0 022
0 006
.
.
.
Hence the value for SDI is:
SDI
CDI
CDI

 




0 057
0 006
0 063
.
.
.
This value of SDI is qualitatively classified as excellent.
4â€ƒ Unitary Measures

95
	 5.	Connell FA, Koepsell TD.Â Measures of gain in certainty from a diagnostic test. Am J Epidemiol. 
1985;121:744â€“53.
	 6.	De Vet HCW, Mokkink LB, Terwee CB, Hoekstra OS, Knol DL.Â Clinicians are right not to like 
Cohenâ€™s Îº. BMJ. 2013;346:f2515.
	 7.	Dice LR.Â  Measures of the amount of ecological association between species. Ecology. 
1945;26:297â€“302.
	 8.	Doswell CA III, Davies-Jones R, Keller DL.Â On summary measures of skill in rare event fore-
casting based on contingency tables. Weather Forecast. 1990;5:576â€“85.
	 9.	Gilbert GK.Â Finleyâ€™s tornado predictions. Am Meteorol J. 1884;1:166â€“72.
	10.	Heston TF.Â Standardized predictive values. J Magn Reson Imaging. 2014;39:1338.
	11.	Hilden J, Glasziou P.Â Regret graphs, diagnostic uncertainty and Youdenâ€™s index. Stat Med. 
1996;15:969â€“86.
	12.	Hsieh S, McGrory S, Leslie F, Dawson K, Ahmed S, Butler CR, etÂ al. The Mini-Addenbrookeâ€™s 
Cognitive Examination: a new assessment tool for dementia. Dement Geriatr Cogn Disord. 
2015;39:1â€“11.
	13.	Hunink MGM, Weinstein MC, Wittenberg E, Drummond MF, Pliskin JS, Wong JB, etÂ al. 
Decision making in health and medicine. Integrating evidence and values. 2nd ed. Cambridge: 
Cambridge University Press; 2014.
	14.	Jaccard P.Â The distribution of the flora in the alpine zone. New Phytologist. 1912;11:37â€“50.
	15.	Jolliffe IT.Â The Dice co-efficient: a neglected verification performance measure for determin-
istic forecasts of binary events. Meteorol Appl. 2016;23:89â€“90.
	16.	Larner AJ.Â MACE for diagnosis of dementia and MCI: examining cut-offs and predictive val-
ues. Diagnostics (Basel). 2019;9:E51.
	17.	Larner AJ.Â New unitary metrics for dementia test accuracy studies. Prog Neurol Psychiatry. 
2019;23(3):21â€“5.
	18.	Larner AJ.Â Applying Kraemerâ€™s Q (positive sign rate): some implications for diagnostic test 
accuracy study results. Dement Geriatr Cogn Dis Extra. 2019;9:389â€“96.
	19.	Larner AJ.Â What is test accuracy? Comparing unitary accuracy metrics for cognitive screening 
instruments. Neurodegener Dis Manag. 2019;9:277â€“81.
	20.	Larner AJ.Â Defining â€œoptimalâ€ test cut-off using global test metrics: evidence from a cognitive 
screening instrument. Neurodegener Dis Manag. 2020;10:223â€“30.
	21.	Larner AJ.Â  Manual of screeners for dementia: pragmatic test accuracy studies. London: 
Springer; 2020.
	22.	Larner AJ.Â Mini-Addenbrookeâ€™s Cognitive Examination (MACE): a useful cognitive screening 
instrument in older people? Can Geriatr J. 2020;23:199â€“204.
	23.	Larner AJ.Â Mini-Cog versus Codex (cognitive disorders examination): is there a difference? 
Dement Neuropsychol. 2020;14:128â€“33.
	24.	Larner AJ.Â Screening for dementia: Q* index as a global measure of test accuracy revisited. 
medRxiv. 2020; https://doi.org/10.1101/2020.04.01.20050567.
	25.	Larner AJ.Â The â€œattended aloneâ€ and â€œattended withâ€ signs in the assessment of cognitive 
impairment: a revalidation. Postgrad Med. 2020;132:595â€“600.
	26.	Larner AJ.Â Assessing cognitive screening instruments with the critical success index. Prog 
Neurol Psychiatry. 2021;25(3):33â€“7.
	27.	Linn S, Grunau PD.Â New patient-oriented summary measure of net total gain in certainty for 
dichotomous diagnostic tests. Epidemiol Perspect Innov. 2006;3:11.
	28.	Matthews BW.Â Comparison of the predicted and observed secondary structure of T4 phage 
lysozyme. Biochem Biophys Acta. 1975;405:442â€“51.
	29.	Mitchell AJ.Â Index test. In: Kattan MW, editor. Encyclopedia of medical decision making. Los 
Angeles: Sage; 2009. p.Â 613â€“7.
	30.	Mitchell AJ.Â Sensitivity x PPV is a recognized test called the clinical utility index (CUI+). Eur 
J Epidemiol. 2011;26:251â€“2.
	31.	Palmer WC, Allen RA.Â  Note on the accuracy of forecasts concerning the rain problem. 
U.S.Â Weather Bureau manuscript: Washington, DC; 1949.
References

96
	32.	Pencina MJ, Dâ€™Agostino RB Sr, Dâ€™Agostino RB Jr, Vasan RS.Â Evaluating the added predictive 
ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat 
Med. 2008;27:157â€“72.
	33.	Perkins NJ, Schisterman EF.Â The inconsistency of â€œoptimalâ€ cutpoints obtained using two 
criteria based on the receiver operating characteristic curve. Am J Epidemiol. 2006;163:670â€“5.
	34.	Powers DMW.Â  Evaluation: from precision, recall and F-measure to ROC, informedness, 
markedness and correlation. J Mach Learn Technol. 2011;2:37â€“63.
	35.	Powers DMW.Â What the F measure doesnâ€™t measure â€¦ Features, flaws, fallacies and fixes. 
arXiv. 2015; 1503.06410.2015.
	36.	Richard E, Schmand BA, Eikelenboom P, Van Gool WA.Â  The Alzheimerâ€™s Disease 
Neuroimaging Initiative. MRI and cerebrospinal fluid biomarkers for predicting progression to 
Alzheimerâ€™s disease in patients with mild cognitive impairment: a diagnostic accuracy study. 
BMJ Open. 2013;3:e002541.
	37.	Schaefer JT.Â The critical success index as an indicator of warning skill. Weather Forecast. 
1990;5:570â€“5.
	38.	Schisterman EF, Perkins NJ, Liu A, Bondell H.Â Optimal cut-point and its corresponding Youden 
Index to discriminate individuals using pooled blood samples. Epidemiology. 2005;16:73â€“81.
	39.	Smits N.Â A note on Youdenâ€™s J and its cost ratio. BMC Med Res Methodol. 2010;10:89.
	40.	SÃ¸rensen T.Â A method of establishing groups of equal amplitude in plant sociology based on 
similarity of species and its application to analyses of the vegetation on Danish commons. K 
Dan Vidensk Sels. 1948;5:1â€“34.
	41.	Youden WJ.Â Index for rating diagnostic tests. Cancer. 1950;3:32â€“5.
4â€ƒ Unitary Measures

97
Â© Springer Nature Switzerland AG 2021
A. J. Larner, The 2x2 Matrix, https://doi.org/10.1007/978-3-030-74920-0_5
Chapter 5
Reciprocal Measures
Contents
5.1â€ƒ Introduction
â€ƒ 97
5.2â€ƒ Number Needed toÂ Diagnose (NND)
â€ƒ 98
5.3â€ƒ Number Needed toÂ Predict (NNP)
â€ƒ 100
5.4â€ƒ Number Needed toÂ Misdiagnose (NNM)
â€ƒ 101
5.5â€ƒ Likelihood toÂ BeÂ Diagnosed or Misdiagnosed (LDM)
â€ƒ 102
5.6â€ƒ Number Needed toÂ Screen (NNS)
â€ƒ 106
5.7â€ƒ Number Needed forÂ Screening Utility (NNSU) andÂ Number  
Needed forÂ Screening Disutility (NNSD)
â€ƒ 108
References
â€ƒ 110
5.1â€ƒ Introduction
This chapter considers reciprocal or â€œnumber needed toâ€ measures of test outcome 
which can be derived from the basic 2Â Ã—Â 2 contingency table, where reciprocal 
means multiplicative inverse [7, 12].
â€œNumber needed toâ€ measures were initially developed to summarise test impact 
in a manner deemed more intuitive to clinicians and patients than the traditional 
measures of discrimination such as sensitivity and specificity [17]. The â€œnumber 
needed to treatâ€ (NNT) is a measure of therapeutic utility [3], equal to the reciprocal 
of absolute risk reduction, and the â€œnumber needed to harmâ€ (NNH) is a measure of 
the adverse effects of therapeutic interventions [23]. Other adaptations of this 
method have also been made, such as the â€œnumber needed to seeâ€ for a specific 
event or occurrence to be encountered in clinical practice [6]. When â€œnumber 
neededâ€ metrics refer to patients, it is obvious that only positive integer values are 
clinically meaningful, with absolute (â€œrawâ€) values being rounded to the next high-
est integer value for purposes of clinical communication [8]. Although quite widely 
used as an outcome measure in therapeutic trials, NNT is recognised to have 

98
limitations, including the unspecified time frame of treatment, and the assumption 
that benefits are dichotomised rather than partial [21].
5.2â€ƒ Number Needed toÂ Diagnose (NND)
The reciprocal (multiplicative inverse) of the Youden index, Y (Sect. 4.2), has been 
defined by Linn and Grunau as the number needed to diagnose (NND) [18]. It may 
be expressed in terms of sensitivity (Sens) and specificity (Spec), and false positive 
(FPR) and false negative (FNR) rates (Sects. 2.2.1 and 2.2.3):
	
NND
Y
Sens
Spec
Sens
Spec
Sens














1
1
1
1
1
1
1
/
/
/
/



 FPR
/
/
/
/
TPR
FPR
FNR
TNR
FNR



















1
1
1
1
1
Spec
Sens
Spec
/ 1 FPR
FNR





	
As Y may also be expressed in terms of likelihood ratios (LRs) (Sect. 2.3.4) and 
correct classification and misclassification rates (Sect. 3.2.5), NND may also be 
expressed in these terms:
	
NND
LR
LR
LR
LR
LR
LR
LR
LR

 






 






 



 



1
1
1
1
1
/
/
/





	
	
NND
Correct classification rate
Misclassification r






1
1
1
1
/
/
aate


	
NND may be interpreted as the number of patients who need to be examined (for 
clinical signs) or tested (with a screening or diagnostic test) in order to detect cor-
rectly one person with the disease of interest in a study population of persons with 
and without the known disease.
In literal notation (see Fig. 1.1):
	
NND
TP
TP
FN
TN
FP
TN
TP p
TN p



 


 








1
1
1
1
/
/
/
/
/
/
	
In algebraic notation (see Fig. 1.2):
5â€ƒ Reciprocal Measures

99
	
NND
a
a
c
d
b
d
a
c
b
d
ad
bc



 


 










1
1
/
/
/
.
/
	
In error notation (see Fig. 1.5):
	
NND







1
1
/


	
The range of Y is âˆ’1 to +1, so 1/Y could theoretically vary from âˆ’1 to +1. 
However, as the effective range of Y is 0 (no diagnostic value) to 1 (no false posi-
tives or false negatives), the anticipated range of 1/Y is âˆ (no diagnostic value) to 
1 (no false positives or false negatives).
For diagnostic tests, low values of NND will therefore be desirable.
As the value of Y approaches 0, then NND values become inflated, as for any 
reciprocal (indeed if Y = 0, the division may be characterised as forbidden since it 
does not yield a unique result and is hence meaningless). This observation has 
prompted the opinion that NND is not a clinically meaningful number [19]. NND is 
also (notionally) insensitive to variation in disease prevalence, since it depends 
entirely on Sens and Spec [18]. This shortcoming may be addressed by using the 
number needed to predict (Sect. 5.3).
NND values vary with test cut-off [8].
Worked Example: Number Needed to Diagnose (NND)
The Mini-Addenbrookeâ€™s Cognitive Examination (MACE) [5] was subjected 
to a screening test accuracy study [8]. At the MACE cut-off of â‰¤20/30, the 
values for Sens and Spec (Sect. 2.2.1) were 0.912 and 0.707 respectively.
Hence the value for Y (Sect. 4.2) at this cut-off is:
	
Y
Sens
Spec







1
0 912
0 707 1
0 619
.
.
.
	
The value for NND is:
	
NND
Y
=
=
=
1
1 0 619
1 62
/
/ .
.
	
Referring to patients, NND is rounded up to the next whole integer and is 
therefore 2.
5.2â€ƒ Number Needed toÂ Diagnose (NND)

100
A rescaled NND may also be calculated [9]:
	
NND
Y
Q
Q
=
1/
	
5.3â€ƒ Number Needed toÂ Predict (NNP)
The reciprocal (multiplicative inverse) of the predictive summary index, PSI or Î¨ 
(Sect. 4.3), has been defined by Linn and Grunau as the number needed to predict 
(NNP) [18]. It may be expressed in terms of positive and negative predictive values 
(PPV, NPV), and false discovery (FDR) and false reassurance (FRR) rates (Sects. 
2.3.1 and 2.3.3):
	
NNP
PSI
PPV
NPV
PPV
NPV
PPV
FRR
NP


















1
1
1
1
1
1
1
/
/
/
/
/
V
PPV
NPV
FDR










1
1/
	
NNP may be interpreted as the number of patients who need to be examined or 
tested in the patient population in order to predict correctly the diagnosis of 
one person.
In literal notation:
	
NNP
TP
TP
FP
TN
FN
TN
TP q
TN q



 


 








1
1
1
1
/
/
/
/
/
/
	
In algebraic notation:
	
NNP
a
a
b
d
c
d
a
b
c
d
ad
bc



 


 












1
1
/
/
/
.
/
	
As the effective range of PSI is 0 (no diagnostic value) to 1 (no false positives or 
false negatives), the anticipated range of 1/PSI is âˆ (no diagnostic value) to 1 (no 
false positives or false negatives). For diagnostic tests, low values of NNP will 
therefore be desirable. NNP is dependent on disease prevalence and is therefore 
deemed a better descriptor of diagnostic tests than NND in patient populations with 
different prevalence of disease [18].
NNP values vary with test cut-off [8].
5â€ƒ Reciprocal Measures

101
5.4â€ƒ Number Needed toÂ Misdiagnose (NNM)
The reciprocal (multiplicative inverse) of inaccuracy (Sect. 3.2.4) has been defined 
as the â€œnumber needed to misdiagnoseâ€ (NNM) [4]:
	
NNM
Inaccuracy
Accuracy





1
1
1
/
/
	
In literal notation:
	
NNM
FP
FN
TP
FP
FN
TN
FP
FN
N
N
FP
FN





















1
1
/
/
/
/
/
	
In algebraic notation:
	
NNM
b
c
a
b
c
d
b
c
N
N
b
c





 














1
1
/
/
/
/
/
	
Worked Example: Number Needed to Predict (NNP)
In a screening test accuracy study of MACE [8], at the MACE cut-off of 
â‰¤20/30, the values for PPV and NPV (Sect. 2.3.1) were 0.356 and 0.978 
respectively.
Hence the value for PSI (Sect. 4.3) at this cut-off is:
PSI
PPV
NPV







1
0 356
0 978 1
0 334
.
.
.
The value for NNP is:
NNP
PSI
=
=
=
1
1 0 334
2 99
/
/ .
.
Referring to patients, NND is rounded up to the next whole integer and is 
therefore 3.
5.4â€ƒ Number Needed toÂ Misdiagnose (NNM)

102
NNM is characterised as a measure of effectiveness, the number of patients who 
need to be examined or tested in order for one to be misdiagnosed [4]. For diagnos-
tic tests, high values of NNM will therefore be desirable.
NNM values vary with test cut-off [8].
5.5â€ƒ Likelihood toÂ BeÂ Diagnosed or Misdiagnosed (LDM)
Consideration of the numbers needed to diagnose (NND; Sect. 5.2), predict (NNP; 
Sect. 5.3), and misdiagnose (NNM; Sect. 5.4) prompts the inclusion here of the 
likelihood to diagnose or misdiagnose (LDM) parameter, even though it is not a 
reciprocal measure, since it is intimately related to these reciprocal measures 
[10, 12].
The â€œnumber neededâ€ metrics used to describe therapeutic studies, NNT and 
NNH (Sect. 5.1), were combined by Citrome and Ketter [2] to produce a â€œlikelihood 
to be helped or harmedâ€ (LHH) metric to summarise the effects of a therapeutic 
intervention:
Worked Example: Number Needed to Misdiagnose (NNM)
In a screening test accuracy study of MACE [8], at the MACE cut-off of 
â‰¤20/30, the values for Acc and Inacc (Sect. 3.2.4) were 0.738 and 0.262 
respectively.
Hence the value for NNM at this cut-off is:
	
NNM
Inaccuracy
Accuracy







1
1
1
1 0 262
3 82
/
/
/ .
.
	
Alternatively, at this cut-off in the MACE study (N = 755), FN =10 and FP 
= 188 (Fig. 2.2).
	
NNM
N
FP
FN









/
/
.
755
188 10
3 81
	
[The different results relate to rounding errors.]
Referring to patients, NNM is rounded up to the next whole integer and is 
therefore 4.
5â€ƒ Reciprocal Measures

103
	
LHH
NNH NNT
=
/
	
LHH values are ideally as large as possible, since NNH is desirably large and 
NNT is desirably small. LHH values are reported to help clinicians and patients to 
evaluate potential risk-benefit trade-offs of treatment [1].
The â€œlikelihood to be diagnosed or misdiagnosedâ€ (LDM) [7, 8, 10, 11] was 
developed as analogous to LHH but for use in test accuracy studies. Two formula-
tions of LDM were formulated:
	
LDM
NNM NND
=
/
	
and:
	
LDM
NNM NNP
=
/
	
The latter might also be termed the â€œlikelihood to be predicted or misdiagnosedâ€ 
(LPM) to distinguish it from the other formulation.
For LDM = NNM/NND:
	
LDM
Acc
Y
Y Inacc





 


1
1
1
/
/
/
/
	
In literal notation:
	
LDM
FP
FN
TP
FP
FN
TN
TP
TP
FN
TN
FP
TN















 


 
1
1
/
/
/
/
/
/
1
1
1



















 

/
/
/
/
/
/
FP
FN
TP
FP
FN
TN
TP
TP
FN
FP
FP
TN
TP
TP
FN
FP
FP
TN
FP
FN
TP
FP
FN









 












/
/
/
/



TN
	
In algebraic notation:
	
LDM
b
c
a
b
c
d
a
a
c
d
b
d
b





 








 


 






1
1
1
1
/
/
/
/
/
/
/
c
a
b
c
d
a
a
c
b
b
d
a
a
c
b
b
d



 








 










 

/
/
/
/
/
/
/
1








 




/
/
b
c
a
b
c
d
	
A rescaled form may also be calculated for this variant of LDM [9]:
	
LDM
NNM NND
Q
Q
=
/
	
For the likelihood to be predicted or misdiagnosed:
	
LPM
NNM NNP
Acc
PSI
PSI Inacc






 


/
/
/
/
/
1
1
1
	
5.5â€ƒ Likelihood toÂ BeÂ Diagnosed or Misdiagnosed (LDM)

104
In literal notation:
LDM
FP
FN
TP
FP
FN
TN
TP
TP
FP
TN
FN
TN













 


 

1
1
1
/
/
/
/
/
/

















 



1
1
/
/
/
/
/
/
FP
FN
TP
FP
FN
TN
TP
TP
FP
FN
FN
TN







 















TP
TP
FP
FN
FN
TN
FP
FN
TP
FP
FN
TN
/
/
/
/

In algebraic notation:
	
LPM
b
c
a
b
c
d
a
a
b
d
c
d
b





 








 


 






1
1
1
1
/
/
/
/
/
/
/
c
a
b
c
d
a
a
b
c
c
d
a
a
b
c
c
d



 








 










 

/
/
/
/
/
/
/
1








 




/
/
b
c
a
b
c
d
	
Hence LDM and LPM may be conceptualised as ratios of benefits (correct diag-
nosis, correct prediction) and harms (misdiagnosis). These may be compared with 
the net harm to net benefit (H/B) ratio (see Sect. 2.3.5). LDM and LPM values vary 
with test cut-off [8], and plotting these shows maxima similar to many of the other 
unitary tests considered in Chap. 4 (Fig.Â 5.1; Table 6.2).
Both LDM and LPM have a range of âˆ’1 (Y or PSI = âˆ’1, Inacc = 1) to âˆ (Y or 
PSI = +1, Inacc = 0). Since for diagnostic tests low values of NND and NNP and 
Worked Examples: Likelihood to Be Diagnosed or Misdiagnosed (LDM)
In a screening test accuracy study of MACE [8], at the MACE cut-off of 
â‰¤20/30, the absolute (â€œrawâ€) values for NND (Sect. 5.2) and NNM (Sect. 5.4) 
were 1.62 and 3.82 respectively.
Hence the value for LDM at this cut-off is:
	
LDM
NNM NND
=
=
=
/
.
/ .
.
3 82 1 62
2 36
	
LDM may also be calculated from the values of Y (Sect. 4.2) and Inacc 
(Sect. 3.2.4), as:
LDM
Y Inacc
=
=
=
/
.
/ .
.
0 619 0 262
2 36
5â€ƒ Reciprocal Measures

105
high values of NNM are desirable, higher values of LDM and LPM (>1) would sug-
gest a test more likely to favour correct diagnosis or prediction over misdiagnosis, 
whereas lower values of LDM and LPM (<1) suggest misdiagnosis is more likely 
than correct diagnosis or prediction. LDM values as high as â“7 have been recorded 
for tests which are both highly sensitive and specific ( [12], p.75).
LDM and LPM should help clinicians and patients to evaluate potential risk-Â­
benefit trade-offs with particular diagnostic tests, and hence inform clinical decision 
making. For example, testing positive on a test with high LDM may permit a confi-
dent diagnosis, unlike the situation with a low LDM test, indeed the latter might be 
avoided for this very reason, especially if the test is expensive and/or poses risks to 
the patient.
The LDM formulations have found application in the evaluation of individual 
neurological signs and cognitive screening instruments [7, 8, 10â€“16, 24, 25] and 
also using data from meta-analyses of cognitive screening instruments [22, 
24].Â Other methods to calculate a â€œlikelihood to be diagnosed or misdiagnosedâ€ are 
currently in development (Larner, submitted).
Worked Examples: Likelihood to Be Predicted or Misdiagnosed (LPM)
In a screening test accuracy study of MACE [8], at the MACE cut-off of 
â‰¤20/30, the absolute (â€œrawâ€) values for NNP (Sect. 5.3) and NNM (Sect. 5.4) 
are 2.99, and 3.82 respectively.
Hence the value for LPM at this cut-off is:
	
LPM
NNM NNP
=
=
=
/
.
/ .
.
3 82 2 99
1 28
	
LPM may also be calculated from the values of PSI (Sect. 4.3) and Inacc 
(Sect. 3.2.4), as:
	
LPM
PSI Inacc
=
=
=
/
.
/ .
.
0 334 0 262
1 27
	
[The different results relate to rounding errors.]
5.5â€ƒ Likelihood toÂ BeÂ Diagnosed or Misdiagnosed (LDM)

106
5.6â€ƒ Number Needed toÂ Screen (NNS)
A â€œnumber needed to screenâ€ (NNS) metric was first defined for use in public health 
epidemiology, defined as the number of people that need to be screened for a given 
duration to prevent one death or adverse event [20].
In terms of screening or diagnostic test accuracy studies, a â€œnumber needed to 
screenâ€ (NNS) metric has been defined as the number of patients who need to be 
screened in order for one additional correct identification beyond those misidenti-
fied [19]. NNS is derived from the identification index (II) (Sect. 4.6):
	
NNS
II
Acc
Inacc
Acc
Acc
Acc

















1
1
1
1
1
2
1
/
/
/
/
.
	
II ranges from âˆ’1 to +1 (Sect. 4.6), as for Y and PSI. However, whereas negative 
values are not anticipated with Y and PSI, any value of Acc <0.5 (i.e. Inacc >0.5) 
will result in a negative value of II, and hence a negative value of NNS. As only 
positive integer values are clinically meaningful for â€œnumber neededâ€ metrics when 
these refer to patients, negative NNS values are clinically meaningless.
In literal notation:
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
10
12
14
16
18
20
22
24
26
28
30
LDM and LPM
Fig. 5.1â€‚ Plot of likelihood to be diagnosed or misdiagnosed (LDM; diamonds) and likelihood to 
be predicted or misdiagnosed (LPM; triangles) on the y axis versus MACE cut-off (x axis). 
(Adapted from [13])
5â€ƒ Reciprocal Measures

107
	
NNS
TP
TN
TP
FP
FN
TN
TP
TN
N








 









1
2
1
1
2
1
/
.
/
/
.
/
	
In algebraic notation:
	
NNS
a
d
a
b
c
d
a
d
N





 

 









1
2
1
1
2
1
/
.
/
/
.
/
	
NNS varies with test cut-off [8].
Worked Example: Number Needed to Screen (NNS)
In a screening test accuracy study of MACE [8], at the MACE cut-off of 
â‰¤20/30, TP = 104, FN =10, FP = 188, and TN = 453 (Fig. 2.2).
The value for Acc (Sect. 3.2.4) is:
	
Acc
TP
TN
TP
FN
FP
TN



















/
/
.
104
453
104 10 188
453
0 738
	
The value for II (Sect. 4.6) is:
	
II
Acc





 

2
1
2 0 738
1
0 475
.
.
.
	
Hence, the value for NNS is:
	
NNS
Acc






1
2
1
1 0 475
2 11
/
.
/ .
.
	
Referring to patients, NNS is rounded up to the next whole integer and is 
therefore 3.
5.6â€ƒ Number Needed toÂ Screen (NNS)

108
5.7â€ƒ Number Needed forÂ Screening Utility (NNSU) 
andÂ Number Needed forÂ Screening Disutility (NNSD)
The number needed for screening utility (NNSU) is the reciprocal or multiplicative 
inverse of SUI (Sect. 4.10) [10, 12]:
	
NNSU
SUI
CUI
CUI
Sens
PPV
Spec
NPV


 






 



1
1
1
/
/
/
	
SUI ranges from 0 to 2 (Sect. 4.10). Hence NNSU ranges from âˆ (SUI = 0, no 
screening value) to 0.5 (SUI = 2, perfect screening utility), with low values of 
NNSU desirable. All NNSU values are positive (cf. NNS, Sect. 5.6). Following the 
qualitative classification of SUI (Sect. 4.10), it is also possible to classify NNSU 
values qualitatively. Generally, NNSU values may be dichotomised, as <1 being 
acceptable or desirable, >1 not so (â€œinadequateâ€) [10, 12].
In literal notation:
	
NNSU
TP
TP
FN
TP
FP
TN
TN
FP
TN
FN
TP








 









1
1
2
2
2
/
/
/
/
/ .
/
.
p q
TN
p q

  

 
2
	
In algebraic notation:
	
NNSU
a
a
c
a
a
b
d
b
d
d
c
d
a
a
c
a
b






 














1
1
2
/
/
/
/
/
/
/
.
 










d
b
d
c
d
2 /
.
	
A rescaled form may also be calculated [9]:
	
NNSU
SUI
Q
Q
=
1/
	
NNSU values vary with test cut-off [8].
5â€ƒ Reciprocal Measures

109
NNSU values have been calculated for many neurological signs and cognitive 
screening questions and instruments [8, 10, 12, 14â€“16].
The number needed for screening disutility (NNSD) is the reciprocal or multipli-
cative inverse of SDI (Sect. 4.10):
	
NNSD
SDI
CDI
CDI
FNR
FDR
FPR
FRR


 






 





1
1
1
/
/
/
	
SDI ranges from 0 to 2 (Sect. 4.10). Hence NNSD ranges from âˆ (SDI = 0, no 
screening disutility) to 0.5 (SDI = 2, maximum screening disutility), with high val-
ues of NNSD desirable. Generally, as for NNSU, NNSD values may be dichot-
omised, as >1 being acceptable or desirable, <1 not so.
Worked Example: Number Needed for Screening Utility (NNSU)
In a screening test accuracy study of MACE [8], at the MACE cut-off of 
â‰¤20/30, CUI+ = 0.325 and CUIâˆ’ = 0.691 (Sect. 2.4.2).
Hence the value for SUI (Sect. 4.10) is:
	
SUI
CUI
CUI

 




0 325
0 691
1 016
.
.
.
	
The value for NNSU is:
	
NNSU
SUI
=
=
=
1
1 1 016
0 984
/
/ .
.
	
This value of NNSU is qualitatively classified as adequate. As it refers to 
patients, NNSU is rounded up to the next whole integer and is therefore 1.
5.7â€ƒ Number Needed forÂ Screening Utility (NNSU) andÂ Number Needed forÂ Screeningâ€¦

110
References
	 1.	Andrade C.Â Likelihood of being helped or harmed as a measure of clinical outcomes in psy-
chopharmacology. J Clin Psychiatry. 2017;78:e73â€“5.
	 2.	Citrome L, Ketter TA.Â When does a difference make a difference? Interpretation of number 
needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin 
Pract. 2013;67:407â€“11.
	 3.	Cook RJ, Sackett DL.Â The number needed to treat: a clinically useful measure of treatment 
effect. BMJ. 1995;310:452â€“4.
	 4.	Habibzadeh F, Yadollahie M.Â Number needed to misdiagnose: a measure of diagnostic test 
effectiveness. Epidemiology. 2013;24:170.
	 5.	Hsieh S, McGrory S, Leslie F, Dawson K, Ahmed S, Butler CR, etÂ al. The Mini-Addenbrookeâ€™s 
Cognitive Examination: a new assessment tool for dementia. Dement Geriatr Cogn Disord. 
2015;39:1â€“11.
	 6.	Larner AJ.Â Teleneurology by internet and telephone. A study of medical self-help. London: 
Springer; 2011.
	 7.	Larner AJ.Â  Number needed to diagnose, predict, or misdiagnose: useful metrics for non-Â­
canonical signs of cognitive status? Dement Geriatr Cogn Dis Extra. 2018;8:321â€“7.
	 8.	Larner AJ.Â MACE for diagnosis of dementia and MCI: examining cut-offs and predictive val-
ues. Diagnostics (Basel). 2019;9:E51.
	 9.	Larner AJ.Â Applying Kraemerâ€™s Q (positive sign rate): some implications for diagnostic test 
accuracy study results. Dement Geriatr Cogn Dis Extra. 2019;9:389â€“96.
	10.	Larner AJ.Â New unitary metrics for dementia test accuracy studies. Prog Neurol Psychiatry. 
2019;23(3):21â€“5.
Worked Example: Number Needed for Screening Disutility (NNSD)
In a screening test accuracy study of MACE [8], at the MACE cut-off of 
â‰¤20/30, CDI+ = 0.057 and CDIâˆ’ = 0.006 (Sect. 2.4.2).
Hence the value for SDI (Sect. 4.10) is:
	
SDI
CDI
CDI

 




0 057
0 006
0 063
.
.
.
	
The value for NNSD is:
	
NNSD
SDI
=
=
=
1
1 0 063
15 87
/
/ .
.
	
This value of NNSD is qualitatively classified as adequate. As it refers to 
patients, NNSD is rounded up to the next whole integer and is therefore 16.
5â€ƒ Reciprocal Measures

111
	11.	Larner AJ.Â Evaluating cognitive screening instruments with the â€œlikelihood to be diagnosed or 
misdiagnosedâ€ measure. Int J Clin Pract. 2019;73:e13265.
	12.	Larner AJ.Â  Manual of screeners for dementia: pragmatic test accuracy studies. London: 
Springer; 2020.
	13.	Larner AJ.Â Defining â€œoptimalâ€ test cut-off using global test metrics: evidence from a cognitive 
screening instrument. Neurodegener Dis Manag. 2020;10:223â€“30.
	14.	Larner AJ.Â Mini-Addenbrookeâ€™s Cognitive Examination (MACE): a useful cognitive screening 
instrument in older people? Can Geriatr J. 2020;23:199â€“204.
	15.	Larner AJ.Â Mini-Cog versus Codex (cognitive disorders examination): is there a difference? 
Dement Neuropsychol. 2020;14:128â€“33.
	16.	Larner AJ.Â The â€œattended aloneâ€ and â€œattended withâ€ signs in the assessment of cognitive 
impairment: a revalidation. Postgrad Med. 2020;132:595â€“600.
	17.	Laupacis A, Sackett DL, Roberts RS.Â An assessment of clinically useful measures of the con-
sequences of treatment. N Engl J Med. 1988;318:1728â€“33.
	18.	Linn S, Grunau PD.Â New patient-oriented summary measure of net total gain in certainty for 
dichotomous diagnostic tests. Epidemiol Perspect Innov. 2006;3:11.
	19.	Mitchell AJ.Â Index test. In: Kattan MW, editor. Encyclopedia of medical decision making. Los 
Angeles: Sage; 2009. p.Â 613â€“7.
	20.	Rembold CM.Â Number needed to screen: development of a statistic for disease screening. 
BMJ. 1998;317:307â€“12.
	21.	Wald NJ, Morris JK.Â  Two under-recognized limitations of number needed to treat. Int J 
Epidemiol. 2020;49:359â€“60.
	22.	Williamson JC, Larner AJ. â€œLikelihood to be diagnosed or misdiagnosedâ€: application to meta-Â­
analytic data for cognitive screening instruments. Neurodegener Dis Manag. 2019;9:91â€“5.
	23.	Zermansky A.Â  Number needed to harm should be measured for treatments. 
BMJ. 1998;317:1014.
	24.	Ziso B, Larner AJ.Â  AD8: Likelihood to diagnose or misdiagnose. J Neurol Neurosurg 
Psychiatry. 2019;90:A20. (https://jnnp.bmj.com/content/90/12/A20.1)
	25.	Ziso B, Larner AJ.Â Codex (cognitive disorders examination) decision tree modified for the 
detection of dementia and MCI.Â Diagnostics (Basel). 2019;9:E58.
References

113
Â© Springer Nature Switzerland AG 2021
A. J. Larner, The 2x2 Matrix, https://doi.org/10.1007/978-3-030-74920-0_6
Chapter 6
Measures Not Directly Related toÂ theÂ 2Â Ã—Â 2 
Contingency Table
Contents
6.1â€ƒ Introduction
â€ƒ 113
6.2â€ƒ Receiver Operating Characteristic (ROC) Plot or Curve
â€ƒ 114
6.2.1â€ƒ Defining Optimal Cut-Off: Youden Index (Y)
â€ƒ 119
6.2.2â€ƒ Defining Optimal Cut-Off: Euclidean Index (d)
â€ƒ 120
6.2.3â€ƒ Defining Optimal Cut-Off: Q* Index
â€ƒ 121
6.2.4â€ƒ Defining Optimal Cut-Off: Other ROC-Based Methods
â€ƒ 122
6.2.5â€ƒ Defining Optimal Cut-Off: Diagnostic Odds Ratio (DOR)
â€ƒ 123
6.2.6â€ƒ Defining Optimal Cut-Off: Non-ROC-Based Methods
â€ƒ 123
6.3â€ƒ Other Graphing Methods
â€ƒ 123
6.3.1â€ƒ ROC Plot inÂ Likelihood Ratio Coordinates
â€ƒ 123
6.3.2â€ƒ Precision-Recall (PR) Plot or Curve
â€ƒ 125
6.3.3â€ƒ Prevalence Value Accuracy Plots
â€ƒ 125
6.3.4â€ƒ Agreement Charts
â€ƒ 125
6.4â€ƒ Effect Sizes
â€ƒ 125
6.4.1â€ƒ Correlation Coefficient
â€ƒ 126
6.4.2â€ƒ Cohenâ€™s d
â€ƒ 126
6.4.3â€ƒ Binomial Effect Size Display (BESD)
â€ƒ 128
References
â€ƒ 129
6.1â€ƒ Introduction
The methods of analysis of 2Â Ã—Â 2 contingency tables considered in the previous 
chapters of this book have all been arithmetical or algebraic. Graphical depiction of 
test performance is also possible, and the core content of this chapter. One of these 
performance graphing methods, the receiver operating characteristic (ROC) curve 
or plot, is also relevant to the definition of â€œoptimalâ€ test cut-offs which may in turn 
be used to calibrate test results when constructing 2Â  Ã—Â  2 contingency tables 
(Sect. 1.5).

114
6.2â€ƒ Receiver Operating Characteristic (ROC) Plot or Curve
The receiver operating characteristic (ROC) curve or plot is a frequently used 
method to display the cumulated results of a quantitative test accuracy study [11, 24, 
57, 59], which takes its origins in signal detection theory [38, 39]. In unit 
2-Â­dimensional ROC space, the Sensitivity (Sens), or â€œhit rateâ€ or true positive rate 
(TPR), of the test is plotted on the ordinate against false positive rate (FPR), the 
complement of Specificity (Spec), or (1Â â€“ Specificity), on the abscissa across the 
range of possible test scores with linear interpolation between points (an example is 
shown in Fig.Â 6.1 [28]). Empirically, this is a step function, tending to a curve as the 
number of instances, and hence points, approaches infinity.
(Sometimes authors reverse the direction of the x-axis on the ROC plot, such that 
the origin coordinates become (1,0), and the abscissa thus plots specificity.)
The ROC plot is a graph of the relative trade-off of benefits, TPR (Sect. 2.2.1), 
against costs, FPR (Sect. 2.2.3), extending from conservative cut-offs (bottom left, 
coordinates (0,0), SensÂ =Â 0, SpecÂ =Â 1) to liberal cut-offs (top right, coordinates (1,1), 
SensÂ =Â 1, SpecÂ =Â 0). ROC plots ideally approximate the top left hand (â€œnorth westâ€) 
corner of the ROC space (coordinates (0,1), SensÂ =Â 1, SpecÂ =Â 1), corresponding to 
isosensitivity. In the situation where false positive rates are very low, it has been 
questioned whether ROC plotting is profitable ([55], p.Â 153).
ROC curves may be described as â€œthreshold agnosticâ€ or â€œthreshold freeâ€, since 
test performance is shown without a specific threshold. ROC curves may also be used 
to define an optimal threshold (methods discussed below, Sects. 6.2.1, 6.2.2, 6.2.3, 
and 6.2.4). Moreover, as TPR and FPR are strict columnar ratios, algebraically inde-
pendent of base rate, the ROC plot is insensitive to changes in class distribution.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Sens or TPR
1 - Spec or FPR
ROC curve
Fig. 6.1â€‚ Empirical ROC plot for diagnosis of dementia using the Mini-Addenbrookeâ€™s Cognitive 
Examination (MACE), with chance diagonal (yÂ =Â x). (Modified from [28]). TPR true positive rate, 
FPR false positive rate
6â€ƒ Measures Not Directly Related toÂ theÂ 2Â Ã—Â 2 Contingency Table

115
ROC plots typically include the diagonal 45Â° line through ROC space (yÂ =Â x, or 
SensÂ =Â 1Â â€“ Spec, or TPRÂ =Â FPR) which represents the performance of a random 
classifier or the chance level (Fig.Â 6.1). This line also corresponds to a diagnostic 
odds ratio (DOR)Â =Â 1, indicative of a useless test, and reflective of the relationship 
between DOR and Sens and Spec (Sect. 2.4.1). ROC curves which are symmetrical 
with respect to the anti-diagonal line through ROC space (yÂ =Â 1Â âˆ’Â x) have a constant 
DOR (isocontours, which might be termed â€œisoDORsâ€), with DOR value varying 
from âˆ in the optimal (â€œnorth westâ€) plot, running through coordinates (0,1) with 
yÂ =Â 1 at the intersection with the ROC anti-diagonal, to âˆ’âˆ at the bottom right hand 
(â€œsouth eastâ€) corner, running through coordinates (1,0) with yÂ =Â 0 at the intersec-
tion with the ROC anti-diagonal.
The slope of a tangent to the ROC curve at any point is equal to the likelihood 
ratio (= TPR/FPR; Sect. 2.3.4) at that point [3], but the step function nature of most 
ROC plots makes it difficult to identify the point of maximum slope [13]. The slope 
is also related to the net harm to net benefit (H/B) ratio (Sects. 2.3.5 and 3.2.5), since:
	
NetHarm H
NetBenefit B
Pre-test odds
LR
P P
LR
P P
 
 











/
/
/


TPR FPR
/
	
and:
	
NetHarm H
NetBenefit B
C
C
C
C
FP
TN
FN
TP
 
  


/
/
	
Combining:
	
C
C
C
C
Pre-test odds
LR
Pre-test odds
LR
P P
LR
FP
TN
FN
TP











/
/






P P
TPR FPR
/
/
	
and rearranging:
	
LR
TPR FPR
C
C
C
C
P
P
H B
P
P
FP
TN
FN
TP













/
/
/
/
/
	
The area under the ROC curve (AUC) is the probability that a random person 
with disease has a value of the measurement above the cut-off compared to a ran-
dom person without disease, or the percentage correct in a two-alternative forced 
choice task. This scalar value, also referred to as the concordance statistic or 
c-statistc, represents expected test performance and hence may be used as a measure 
of diagnostic accuracy (cf. other meanings of â€œaccuracyâ€, Sect. 3.2.4 [29]). The 
performance of a random classifier gives AUC ROCÂ =Â 0.5; confidence intervals of 
AUC overlapping this value suggest the null hypothesis cannot be rejected. AUC 
<0.5 is an outcome worse than random guessing. Various qualitative classification 
6.2â€ƒ Receiver Operating Characteristic (ROC) Plot or Curve

116
schemata for AUC values have been reported (TableÂ 6.1) [21, 42, 53]. AUC values 
tend to be optimistic compared to other accuracy measures [29].
Methods for calculation of AUC are mainly based on a non-parametric statistical 
test, the Wilcoxon rank-sum test, namely the proportion of all possible pairs of non-Â­
diseased and diseased test subjects for which the diseased result is higher than the 
Table 6.1â€‚ Classifications of 
ROC plot AUC values
Metz [42] (1978):
 â€ƒ â€¢ between 0.9â€“1.0: excellent
 â€ƒ â€¢ 0.8â€“0.9: good
 â€ƒ â€¢ 0.7â€“0.8: fair
 â€ƒ â€¢ 0.6â€“0.7: poor
 â€ƒ â€¢ 0.5â€“0.6: failed
Swets [53] (1988):
 â€ƒ â€¢ â‰¥0.91: high accuracy
 â€ƒ â€¢ 0.71â€“0.90: moderate accuracy
 â€ƒ â€¢ 0.50â€“0.70: low accuracy
Jones and Athanasiou [21] (2005):
 â€ƒ â€¢ â‰¥0.97: excellent
 â€ƒ â€¢ 0.93â€“0.96: very good
 â€ƒ â€¢ 0.75â€“0.92: good
Worked Example: AUC ROC Plot
The Mini-Addenbrookeâ€™s Cognitive Examination (MACE) [18], a brief cog-
nitive screening instrument, was subjected to a screening test accuracy study 
in a large patient cohort, NÂ  =Â  755 [28]. From a ROC plot of the results 
(Fig.Â 6.1), AUC was calculated by rank-sum methods as AUCÂ =Â 0.886, a value 
which may be qualitatively categorised as good [21, 42] or moderate [53].
The MACE ROC plot is asymmetric (Fig.Â 6.1), so DOR varies with test 
cut-off, with a maximal value of 52.8 at MACE cut-off of â‰¤23/30 [31]. AUC 
was calculated, at this maximal DOR [30], as [54]:
AUC
DOR
DOR
DOR
DOR
e






 







/
.
log
.
.
.
1
1
0 0197
47 833
0 941
2
This is greater than the AUC value by rank-sum methods (0.886), presum-
ably because the equation assumes a symmetric ROC curve with DORÂ =Â 52.8. 
The DOR-based AUC value may be qualitatively categorised as excellent 
[42], very good [21], or high accuracy [53]. Hence the categorisation of AUC 
has changed according to method of its calculation.
6â€ƒ Measures Not Directly Related toÂ theÂ 2Â Ã—Â 2 Contingency Table

117
non-diseased plus half the proportion of ties [9, 15, 16, 59, 60]. AUC may also be 
calculated from the DOR using the formula [54]:
	
AUC
DOR
DOR
DOR
DOR
e






 




/
.
log
1
1
2
	
The latter may tend to overestimate AUC compared to the rank-sum method 
[30, 41].
ROC plots have some shortcomings. The combination of test accuracy over a 
range of thresholds includes those which may be both clinically relevant and clini-
cally nonsensical [40]. Hence only parts of ROC plots may be of clinical interest. 
Methods for partial ROC curve analysis are available [58]. A ROC plot may also be 
divided graphically to illustrate zones of test efficacy, the so-called zombie (â€œzones 
of mostly bad imaging efficacyâ€) plot [48], although the technique is applicable to 
diagnostic tests other than imaging.
For a categorical classifier with n thresholds, there will be (n âˆ’ 1) points in ROC 
space. Hence classifiers with a binary outcome produce a ROC dot rather than plot, 
and an area under a triangle rather than an area under a curve (Fig.Â 6.2). For the 
particular case of a binary classifier, it has been shown that the value of AUC also 
simplifies [44], to:
	
AUC
Sens
Spec




Â½.
	
This corresponds to â€œbalanced accuracyâ€ defined as (SensÂ +Â Spec)/2.
This may also be expressed in terms of the Youden index, Y (Sect. 4.2):
	
Y
Sens
Spec
Y
Sens
Spec





â€“1
1
	
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Sens
1 - Spec
ROC plot
Fig. 6.2â€‚ ROC plot for a binary classifier: attended alone/attended with sign for the diagnosis of 
any cognitive impairment (dementia + MCI) versus no cognitive impairment, with chance diagonal 
(yÂ =Â x). (Data from [32], plot adapted from [41])
6.2â€ƒ Receiver Operating Characteristic (ROC) Plot or Curve

118
Substituting:
	
AUC
Y




Â½.
1 	
or:
	
Y
AUC


2
1
.
	
Whether ROC plots can be meaningfully applied in the assessment of binary 
categorical tests remains moot [41, 44].
One of the key functions of ROC plots is to permit the definition of â€œoptimalâ€ test 
cut-offs (Sect. 1.6). Other methods for defining optimal cut-offs independent of the 
ROC plot are also available. These various approaches are now considered.
Worked Example: AUC ROC Plot for Single Fixed Threshold
If MACE is treated as a binary classifier with a single fixed threshold of 
â‰¤20/30 (based on maximal Youden index; Sect. 4.2), as shown in Fig.Â 6.3, 
AUC by rank-sum methodsÂ  =Â  0.809. This may also be calculated from 
SensÂ =Â 0.912 and SpecÂ =Â 0.707 at this MACE cut-off (Sect. 2.2.1):
AUC
Sens
Spec









Â½.
Â½.
.
.
.
0 912
0 707
0 809
AUC may also be calculated from the maximal Youden index at this thresh-
old, which is 0.619 (Sect. 4.2):
AUC
Y









Â½.
Â½.
.
.
1
0 619 1
0 809
Hence, treating MACE as a binary classifier with a single fixed threshold 
underestimates AUC compared to the full ROC plot (= 0.886) [41].
AUC may also be calculated from DORÂ =Â 25.06 at this MACE cut-off:
AUC
DOR
DOR
DOR
DOR
e






 







/
.
log
.
.
.
1
1
0 0433 20 839
0 902
2
This is greater than the AUC value calculated from Sens and Spec (0.809), 
presumably because the equation assumes the ROC curve to be symmetric 
with DOR = 25.06.
6â€ƒ Measures Not Directly Related toÂ theÂ 2Â Ã—Â 2 Contingency Table

119
6.2.1â€ƒ Defining Optimal Cut-Off: Youden Index (Y)
As previously discussed (Sect. 4.2), Youden index (Y) is a global or unitary measure 
of test performance given by YÂ =Â SensÂ +Â SpecÂ âˆ’Â 1.
The maximal value of Y corresponds to the point on the ROC curve which is the 
maximal vertical distance from the diagonal line (yÂ =Â x) which represents the per-
formance of a random classifier. Also known as c*, this point minimizes misclassi-
fication (the sum of FPR and FNR) [52]:
	
Y
Sens c
Spec c
Sens c
FPR c
FPR c



 


 





 






max
max
min
1
 







FNR c
	
In error notation:
	
Y



 


 








max
min
1
1
1




	
The cut-point maximising Sens and Spec is the point on the ROC curve which 
also represents the minimization of expected costs if and only if the cost of FN 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Sens
1 - Spec
ROC plot
Fig. 6.3â€‚ ROC plot for MACE for the diagnosis of dementia versus no dementia, comparing 
MACE as a continuous scale (upper curve, = same as Fig.Â 6.1) or as a single fixed threshold binary 
classifier (lower triangle), with chance diagonal (yÂ =Â x) [41]
6.2â€ƒ Receiver Operating Characteristic (ROC) Plot or Curve

120
(misclassifying the diseased as undiseased) is equal to the cost of FP (misclassify-
ing the undiseased as diseased) [22]. As previously discussed, this equivalence 
rarely if ever holds in clinical practice (Sect. 3.2.5).
In a study examining the Mini-Addenbrookeâ€™s Cognitive Examination (MACE) 
[18],Â optimal cut-off defined using the maximal Youden index was â‰¤20/30. This 
cut-off gave a relatively good balance of test sensitivity and specificity (TableÂ 6.2) 
[28, 31].
6.2.2â€ƒ Defining Optimal Cut-Off: Euclidean Index (d)
The Euclidean index (d) is the point minimally distant from the top left hand (â€œnorth 
westâ€) corner of the ROC plot, with coordinates (0,1), with the ROC intersect of a 
line joining these points designated c [6, 60], such that:
	
d
Sens c
Spec c
FNR c
FPR c



 

 

 








 

 
 
min
min
1
1
2
2
2






2
	
Table 6.2â€‚ MACE sensitivity, specificity, and predictive values at optimal cut-off values as defined 
by various global parameters (Data from [28, 30, 31, 33, 35])
Optimal cut-off
Metric used to define optimal cut-off
Sens
Spec
Y
PPV
NPV
PSI
â‰¤13/30
LDM (= NNM/NNP)
0.48
0.93
0.41
0.57
0.91
0.48
â‰¤14/30
Acc
LDM (= NNM/NNP)
0.59
0.92
0.51
0.56
0.93
0.49
â‰¤15/30
CSI
F measure
HMYPSI
MCC
LDM (= NNM/NND)
SUI
0.66
0.90
0.56
0.53
0.94
0.47
â‰¤18/30
Q* index (graphically)
0.80
0.80
0.60
0.42
0.96
0.38
â‰¤19/30
Euclidean index (d)
0.86
0.76
0.62
0.38
0.97
0.35
â‰¤20/30
Youden index (Y)
0.91
0.71
0.62
0.36
0.98
0.34
â‰¤23/30
DOR
Q* index (calculated)
0.98
0.49
0.47
0.25
0.99
0.24
Abbreviations: Acc correct classification accuracy, CSI critical success index, DOR diagnostic 
odds ratio, HMYPSI harmonic mean of Y and PSI, LDM likelihood to be diagnosed or misdiag-
nosed, MCC Matthewsâ€™ correlation coefficient, NND number needed to diagnose, NNM number 
needed to misdiagnose, NNP number needed to predict, NPV negative predictive index, PPV posi-
tive predictive index, PSI predictive summary index, Sens sensitivity, Spec specificity, SUI sum-
mary utility index, Y Youden index
6â€ƒ Measures Not Directly Related toÂ theÂ 2Â Ã—Â 2 Contingency Table

121
Hence this will be seen to minimize the misclassification rate (Sect. 3.2.5). When 
c and c* (Sect. 7.2.1) do not agree, c* is deemed preferable since it maximizes the 
overall rate of correct classification ([58], p.Â 51â€“2).
In a study examining the MACE, optimal cut-off defined using the minimal 
Euclidean index was â‰¤19/30, giving a relatively good balance of sensitivity and 
specificity (TableÂ 6.2) [31].
6.2.3â€ƒ Defining Optimal Cut-Off: Q* Index
Using a summary ROC (SROC) curve based on data from meta-analyses, another 
index was proposed to determine optimal test cut-off: the Q* index. This is the point 
where the downward, negative, or anti-diagonal line through unit ROC space 
(yÂ =Â 1Â âˆ’Â x, or SensÂ =Â Spec, or SensÂ â€“ SpecÂ =Â 0, or TPRÂ =Â 1Â âˆ’Â FPR) intersects the 
ROC curve [43] (Fig.Â 6.4). Q* index may also be defined as the â€œpoint of indiffer-
ence on the ROC curveâ€, where the sensitivity and specificity are equal, or, in other 
words, where the probabilities of incorrect test results are equal for disease cases 
and non-cases (i.e. indifference between false positive and false negative diagnostic 
errors, with both assumed to be of equal value). For the particular case of a sym-
metrical ROC curve, Q* will be equal to the Euclidean index [54].
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Sens
1 - Spec
ROC curve
Fig. 6.4â€‚ ROC curve for diagnosis of dementia using MACE (= same as Fig.Â 6.1), intersecting with 
the anti-diagonal (yÂ =Â 1Â âˆ’Â x) line for assessment of Q* index. (Modified from [28])
6.2â€ƒ Receiver Operating Characteristic (ROC) Plot or Curve

122
Q* index has also been suggested as useful global measure of test accuracy [26], 
although its use for the comparison of diagnostic tests is controversial and has been 
generally discouraged [36].
As well as being assessed graphically, as the point of intersection of the ROC 
curve and the anti-diagonal through ROC space (Fig.Â 6.4), Q* index may also be 
calculated based on its relationship to the diagnostic odds ratio (DOR; Sect. 2.4.1). 
Q* may be calculated [54] as:
Q
DOR
DOR



 


/ 1
6.2.4â€ƒ Defining Optimal Cut-Off: Other ROC-Based Methods
Other ROC-based methods to define optimal cut-off are described. In the â€œempirical 
methodâ€ [37], also known as the â€œproduct indexâ€ [14], a concordance probability 
maximizing the product of Sens and Spec is used. Another method uses the maxi-
mal â€œnumber needed to misdiagnoseâ€ [12] (Sect. 5.4) weighted according to an 
estimate of the relative costs of FN and FP test results [13].
Worked Example: Q* Index
A ROC plot of the results of the MACE study [28] intersected with the anti-Â­
diagonal line (yÂ  =Â  1Â  âˆ’Â  x) through unit ROC space, the Q* index, at 0.8 
(Fig.Â 6.4), corresponding to an optimal MACE cut-off value of â‰¤18/30, where 
SensÂ =Â SpecÂ =Â 0.8.
Q* index was also calculated from DOR. The MACE ROC plot is not sym-
metric, so DOR varies with test cut-off, with a maximal value of 52.8 at 
MACE cut-off of â‰¤23/30 [31].
Hence the value for Q* index [54] using this DOR was:
Q
DOR
DOR



 




 



/
. /
.
.
1
52 8
1
52 8
0 879
At this cut-off, SensÂ =Â 0.98 and SpecÂ =Â 0.49, a poorer balance than seen 
with the graphical estimation of Q* index (TableÂ 6.2) [30].
6â€ƒ Measures Not Directly Related toÂ theÂ 2Â Ã—Â 2 Contingency Table

123
6.2.5â€ƒ Defining Optimal Cut-Off: Diagnostic Odds Ratio (DOR)
Maximal diagnostic odds ratio (DOR; Sect. 2.4.1) or its logarithm has frequently 
been used to define test cut-points. However, some authors have recommended 
against use of DOR because it produces a concave curve, and hence extremely high 
and low cut-points [2, 14]. Examining the MACE study data [31], maximal DOR 
cut-off (â‰¤23/30) was an outlier compared to other ROC and non-ROC methods (as 
for Q* index calculated from DOR; Sect. 6.2.3 [30]), resulting in a high sensitivity 
but poor specificity test performance (TableÂ 6.2).
6.2.6â€ƒ Defining Optimal Cut-Off: Non-ROC-Based Methods
Various other global or unitary measures may be used to define test cut-off [31], for 
example maximal accuracy (Sect. 3.2.4) or kappa (Sect. 7.2.2), critical success 
index (Sect. 4.8) [35], F measure (Sect. 4.9), Matthewsâ€™ correlation coefficient 
(Sect. 4.5), summary utility index (Sect. 4.10) [33] and the two formulations of the 
likelihood to be diagnosed of misdiagnosed (LDM and LPM; Sect. 5.5) [33].
In the study examining MACE, optimal cut-offs defined by these measures clus-
tered around â‰¤13/30 to â‰¤15/30, resulting in greater specificity than sensitivity 
(TableÂ 6.2) [31, 35].
6.3â€ƒ Other Graphing Methods
A number of other graphing methods which display some of the measures derived 
from a 2Â Ã—Â 2 contingency table have been reported. None has achieved the breadth 
of usage of the ROC plot.
6.3.1â€ƒ ROC Plot inÂ Likelihood Ratio Coordinates
Johnson advocated transformation of ROC curves into positive and negative likeli-
hood ratio (LR+, LRâˆ’; Sect. 2.3.4) coordinates, in part because half the potential 
region for ROC curves was deemed to have no meaning [20] (test performance fall-
ing in the area below the diagonal is an outcome worse than random guessing; this 
has been termed the â€œperverse zoneâ€ [48]).
Using logarithmic scales, optimal LR ROC curves bend further from the lower 
left corner, where log10LR+Â =Â log10LRâˆ’Â =Â 0, and towards the upper right (â€œnorth 
eastâ€) area where log10LR+ and log10LRâˆ’ approach infinity. The slope of the LR 
ROC curve equals the log diagnostic odds ratio at that point (whereas the slope of 
6.3â€ƒ Other Graphing Methods

124
the ROC curve in its usual coordinates of Sens and 1Â â€“ Spec equals LR; Sect. 6.2). 
Using the transformed axes, AUCÂ =Â 0 is a useless test, rather than 0.5Â in the usual 
ROC plot. Comparison of tests is also possible using this method, as for regret 
graphs [17].
An attempt to convert data from the MACE study [28] to likelihood ratio coordi-
nates is shown in Fig.Â 6.5 (compare with the conventional ROC plot of Fig.Â 6.1).
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
-1.6
-1.5
-1.4
-1.3
-1.2
-1.1
-1
-0.9
-0.8
-0.7
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
0
log10LR+
log10LR-
ROC curve with LR coordinates
Fig. 6.5â€‚ ROC curve with LR coordinates for diagnosis of dementia using MACE. (Data from [28])
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Precision (= PPV)
Recall (= Sens)
PR curve
Fig. 6.6â€‚ Precision-recall (PR) plot or curve for diagnosis of dementia using MACE. (Modified 
from [28])
6â€ƒ Measures Not Directly Related toÂ theÂ 2Â Ã—Â 2 Contingency Table

125
6.3.2â€ƒ Precision-Recall (PR) Plot or Curve
The precision recall (PR) plot or curve is, like the ROC plot, a performance graph-
ing method. It plots precision or positive predictive value (Sect. 2.3.1) on the ordi-
nate against recall or sensitivity (Sect. 2.2.1) on the abscissa with linear interpolation 
between points [8] (Fig.Â 6.6). Like ROC curves, PR curves may be described as 
â€œthreshold freeâ€.
PR curves avoid some of the â€œoptimismâ€ of ROC curves [7, 45] and are more 
informative than ROC curves when analysing skewed datasets [50]. Area under the 
PR curve may be calculated, although this is not straightforward [23], and visual 
interpretation may be adequate to denote better classification performance (as for 
ROC curves). Little use has been made of PR curves in assessing clinical diagnostic 
and screening tests [28].
6.3.3â€ƒ Prevalence Value Accuracy Plots
Prevalence value accuracy contour plots attempt to include the cost of misclassifica-
tions (FP and FN; z-axis) as well as prevalence (x-axis) and unit cost ratio (y-axis) 
in graphing test performance. A derived misclassification index may give a different 
interpretation of the relative merit of tests compared to AUC ROC [47].
6.3.4â€ƒ Agreement Charts
The agreement chart is a two-dimensional graph permitting visual assessment of the 
agreement or concordance between two observers. Unlike the kappa statistic (Sect. 
7.2.2), the agreement chart helps to uncover patterns of disagreement between 
observers, but it can only be used for ordinal scale variables [1].
6.4â€ƒ Effect Sizes
There are many effect size measures, which may be broadly categorised into: mea-
sures of association (the r family), of which the phi (Ï†) coefficient (as Matthewsâ€™ 
correlation coefficient) has already been described (Sect. 4.5); and differences 
between groups (the d family) [10]. The latter group, specifically Cohenâ€™s d, is the 
focus of this section.
6.4â€ƒ Effect Sizes

126
6.4.1â€ƒ Correlation Coefficient
Correlation coefficients, of which the best known is Pearsonâ€™s product moment cor-
relation coefficient (r), quantify the strength of relationship between two variables 
which may be either dichotomous or continuous. Correlations vary between +1 
(perfect positive linear relationship) through 0 (no relationship between variables) 
to âˆ’1 (perfect negative linear relationship).
6.4.2â€ƒ Cohenâ€™s d
Cohenâ€™s d effect size [4] is calculated as the difference of the means of the two 
groups being compared divided by the weighted pooled standard deviations of the 
groups (Fig.Â 6.7) if they are roughly the same (if not, then other options such as 
Glassâ€™s Î” or Hedgesâ€™ g may be more appropriate [10]). Rules of thumb for the 
qualitative classification of Cohenâ€™s d effect size were given by Cohen [4, 5] and 
updated by Sawilowsky [51] (TableÂ 6.3).
Hence Cohenâ€™s d is not calculated on the basis of the 2Â Ã—Â 2 contingency table; it 
is independent of cut point, and of base rate. Nevertheless, like AUC ROC (Sect. 
6.2), Cohenâ€™s d quantifies the amount of separation between the distribution of 
scores for groups with and without the criterion diagnosis ([57], p.Â 208). Cohenâ€™s d 
may be used to compare between tests, such as cognitive screening instruments [25, 
27], and values may change with disease prevalence [56].
As both Cohenâ€™s d and r are standardised, they can be interconverted [10], e.g.
	
r
d
d



/
2
4 	
Cohenâ€™s d formula:
Where d = Cohenâ€™s d effect size
X1 and X2 = means of two groups
s1 and s2 = standard deviations of two groups
d
X
=
+
1
s1
2
s2
2
2
X 2
Fig. 6.7â€‚ Cohenâ€™s d 
formula
Table 6.3â€‚ Classification of Cohenâ€™s d (After [4, 5, 50])
Huge
Very large
Large
Medium
Small
Very poor
Cohenâ€™s d
â‰¥ 2.00
â‰¥ 1.20
â‰¥ 0.80
â‰¥ 0.50
â‰¥ 0.20
â‰¥ 0.01
6â€ƒ Measures Not Directly Related toÂ theÂ 2Â Ã—Â 2 Contingency Table

127
Worked Examples: Cohenâ€™s d
In a large (NÂ =Â 755) screening test accuracy study of MACE [28], a reference 
(criterion) diagnosis of dementia, based on the application of widely accepted 
diagnostic criteria for dementia, was made in 114 patients; the remaining 
patients without dementia (nÂ =Â 641) had either mild cognitive impairment 
(MCI; nÂ =Â 222) or subjective memory complaints (SMC; nÂ =Â 419).
In the dementia group, mean MACE test score +/âˆ’ standard deviation was 
13.56 +/âˆ’ 5.19. In the non-demented group, the mean score was 22.39 +/âˆ’ 
4.98. Hence;
d








22 39 13 56
5 19
4 98
2
8 83 5 09
1 74
2
2
.
.
/
.
.
/
.
/ .
.
According to the suggested classification of Cohenâ€™s d values (TableÂ 6.3), 
this was a very large effect size.
Comparing MACE scores in the MCI group (mean = 19.09 +/âˆ’ 4.78) with 
the SMC group (24.14 +/âˆ’ 4.12):
d








24 14
19 09
4 78
4 12
2
5 05 4 46
1 13
2
2
.
.
/
.
.
/
.
/ .
.
According to the classification (TableÂ 6.3), this was a large effect size [28].
To examine the change in various metrics with disease prevalence, values 
were calculated for those aged â‰¥65 (nÂ =Â 287) and â‰¥75Â years (nÂ =Â 119) com-
paring the dementia group with the non-dementia group [34]. In the â‰¥65Â years 
group the mean MACE score in the dementia group was =Â 13.65 +/âˆ’ 4.93 and 
in the non-dementia group it was 21.81 +/âˆ’ 4.77. Hence calculating for 
Cohenâ€™s d:
d








21 81 13 65
4 93
4 77
2
8 16 4 85
1 68
2
2
.
.
/
.
.
/
.
/ .
.
According to the classification (TableÂ 6.3), this was a very large effect size.
For the â‰¥75 years group, mean MACE score in the dementia group was 
=Â 13.07 +/âˆ’ 4.62 and in the non-dementia group was 19.58 +/âˆ’ 4.37:
d








19 58 13 07
4 62
4 37
2
6 51 4 50
1 45
2
2
.
.
/
.
.
/
.
/ .
.
According to the classification (TableÂ 6.3), this was a very large effect size 
(Larner, unpublished observations).
6.4â€ƒ Effect Sizes

128
6.4.3â€ƒ Binomial Effect Size Display (BESD)
The binomial effect size display (BESD) is a 2Â Ã—Â 2 contingency table designed to 
present correlational effects in a manner indicating the â€œreal-worldâ€ importance of 
the findings [49].
Correlation is expressed as a success rate difference, in rows expressing indepen-
dent variables (e.g. treatment and control groups) and columns expressing any 
dependent variable which can be dichotomised (e.g. success, failure). For a given 
correlation, r, success rate is calculated for treatment and control groups as 0.5 +/âˆ’ 
r/2, each column and row summing to 100. However it has been argued that success 
rate differences may be biased by various factors and overestimate these values 
[19, 46].
Worked Example: Binomial Effect Size Display (BESD)
In the screening test accuracy study of MACE [28], it was found that for the 
diagnosis of dementia Cohenâ€™s d effect size = 1.74. To display this finding in 
a â€œreal-worldâ€ manner, a binomial effect size display (BESD) was con-
structed. Firstly, r was calculated from Cohenâ€™s d:
r
d
d







/
.
/
.
.
2
2
4
1 74
1 74
4
0 656
For this correlation, success rate was calculated for patients diagnosed 
with and without dementia as 0.5 +/âˆ’ r/2Â =Â 0.172 and 0.828. Hence, the BESD:
Criterion diagnosis: 
dementia
Criterion diagnosis: no 
dementia
MACE diagnosis: dementia
82.8
17.2
MACE diagnosis: no 
dementia
17.2
82.8
Diagnosis was therefore about five times more successful than unsuccess-
ful. This gives a more optimistic result than the likelihood to be diagnosed or 
misdiagnosed (LDM) metric (Sect. 5.5): even at the optimal MACE cut-off 
defined by maximal LDMÂ =Â NNM/NND, â‰¤15/30 (TableÂ 6.2), the unrounded 
LDM was only 3.94.
6â€ƒ Measures Not Directly Related toÂ theÂ 2Â Ã—Â 2 Contingency Table

129
References
	 1.	Bangdiwala SI, Shankar V.Â The agreement chart. BMC Med Res Methodol. 2013;13:97.
	 2.	Bohning D, Holling H, Patilea V.Â A limitation of the diagnostic-odds ratio in determining an 
optimal cut-off value for a continuous diagnostic test. Stat Methods Med Res. 2011;20:541â€“50.
	 3.	Choi BC.Â Slopes of a receiver operating characteristic curve and likelihood ratios for a diag-
nostic test. Am J Epidemiol. 1998;148:1127â€“32.
	 4.	Cohen J.Â Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence 
Erlbaum; 1988.
	 5.	Cohen J.Â A power primer. Psychol Bull. 1992;112:155â€“9.
	 6.	Coffin M, Sukhatme S.Â  Receiver operating characteristic studies and measurement errors. 
Biometrics. 1997;53:823â€“37.
	 7.	Cook J, Ramadas V.Â When to consult precision-recall curves. Stata J. 2020;20:131â€“48.
	 8.	Davis J, Goadrich M.Â The relationship between Precision-Recall and ROC curves. In: ICML 
â€™06: Proceedings of the 23rd International Conference on Machine Learning. NewÂ  York: 
ACM; 2006, p.Â 233â€“40.
	 9.	DeLong ER, DeLong DM, Clarke-Pearson DL.Â  Comparing the areas under two or more 
correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 
1988;44:837â€“45.
	10.	Ellis PD.Â The essential guide to effect sizes: statistical power, meta-analysis, and the interpre-
tation of research results. Cambridge: Cambridge University Press; 2010.
	11.	Fawcett T.Â An introduction to ROC analysis. Pattern Recogn Lett. 2006;27:861â€“74.
	12.	Habibzadeh F, Yadollahie M.Â Number needed to misdiagnose: a measure of diagnostic test 
effectiveness. Epidemiology. 2013;24:170.
	13.	Habibzadeh F, Habibzadeh P, Yadollahie M.Â On determining the most appropriate test cut-off 
value: the case of tests with continuous results. Biochem Med (Zagreb). 2016;26:297â€“307.
	14.	Hajian-Tilaki K.Â The choice of methods in determining the optimal cut-off value for quantita-
tive diagnostic test evaluation. Stat Methods Med Res. 2018;27:2374â€“83.
	15.	Hanley JA, McNeil BJ.Â The meaning and use of the area under a receiver operating character-
istic (ROC) curve. Radiology. 1982;143:29â€“36.
	16.	Hanley JA, McNeil BJ.Â A method of comparing the areas under receiver operating character-
istic curves derived from the same cases. Radiology. 1983;148:839â€“43.
	17.	Hilden J, Glasziou P.Â Regret graphs, diagnostic uncertainty and Youdenâ€™s index. Stat Med. 
1996;15:969â€“86.
	18.	Hsieh S, McGrory S, Leslie F, Dawson K, Ahmed S, Butler CR, etÂ al. The Mini-Addenbrookeâ€™s 
Cognitive Examination: a new assessment tool for dementia. Dement Geriatr Cogn Disord. 
2015;39:1â€“11.
	19.	Hsu LM.Â Biases of success rate differences shown in binomial effect size displays. Psychol 
Methods. 2004;9:183â€“97.
	20.	Johnson NP.Â Advantages to transforming the receiver operating characteristic (ROC) curve 
into likelihood ratio co-ordinates. Stat Med. 2004;23:2257â€“66.
	21.	Jones CM, Athanasiou T.Â Summary receiver operating characteristic curve analysis techniques 
in the evaluation of diagnostic tests. Ann Thorac Surg. 2005;79:16â€“20.
	22.	Kaivanto K.Â Maximization of the sum of sensitivity and specificity as a diagnostic cutpoint 
criterion. J Clin Epidemiol. 2008;61:516â€“7.
	23.	Keilwagen J, Grosse I, Grau J.Â Area under precision-recall curves for weighted and unweighted 
data. PLoS One. 2014;9(3):e92209.
	24.	Krzanowski WJ, Hand DJ.Â ROC curves for continuous data. NewÂ York: CRC Press; 2009.
	25.	Larner AJ.Â Effect size (Cohenâ€™s d) of cognitive screening instruments examined in pragmatic 
diagnostic accuracy studies. Dement Geriatr Cogn Disord Extra. 2014;4:236â€“41.
	26.	Larner AJ.Â  The Q* index: a useful global measure of dementia screening test accuracy? 
Dement Geriatr Cogn Dis Extra. 2015;5:265â€“70.
References

130
	27.	Larner AJ.Â Cognitive screening instruments for the diagnosis of mild cognitive impairment. 
Prog Neurol Psychiatry. 2016;20(2):21â€“6.
	28.	Larner AJ.Â MACE for diagnosis of dementia and MCI: examining cut-offs and predictive val-
ues. Diagnostics (Basel). 2019;9:E51.
	29.	Larner AJ.Â What is test accuracy? Comparing unitary accuracy metrics for cognitive screening 
instruments. Neurodegener Dis Manag. 2019;9:277â€“81.
	30.	Larner AJ.Â Screening for dementia: Q* index as a global measure of test accuracy revisited. 
medRxiv. 2020. https://doi.org/10.1101/2020.04.01.20050567.
	31.	Larner AJ.Â Defining â€œoptimalâ€ test cut-off using global test metrics: evidence from a cognitive 
screening instrument. Neurodegener Dis Manag. 2020;10:223â€“30.
	32.	Larner AJ.Â The â€œattended aloneâ€ and â€œattended withâ€ signs in the assessment of cognitive 
impairment: a revalidation. Postgrad Med. 2020;132:595â€“600.
	33.	Larner AJ.Â  Manual of screeners for dementia: pragmatic test accuracy studies. London: 
Springer; 2020.
	34.	Larner AJ.Â Mini-Addenbrookeâ€™s Cognitive Examination (MACE): a useful cognitive screening 
instrument in older people? Can Geriatr J. 2020;23:199â€“204.
	35.	Larner AJ.Â Assessing cognitive screening instruments with the critical success index. Prog 
Neurol Psychiatry. 2021;25(3):33â€“7.
	36.	Lee J, Kim KW, Choi SH, Huh J, Park SH.Â Systematic review and meta-analysis of stud-
ies evaluating diagnostic test accuracy: a practical review for clinical researchersÂ  â€“ part 
II.Â Statistical methods of meta-analysis. Korean J Radiol. 2015;16:1188â€“96.
	37.	Liu X.Â Classification accuracy and cut point selection. Stat Med. 2012;31:2676â€“86.
	38.	Lusted L.Â Introduction to medical decision making. Springfield: Charles Thomas; 1968.
	39.	Lusted LB.Â Signal detectability and medical decision-making. Science. 1971;171:1217â€“9.
	40.	Mallett S, Halligan S, Thompson M, Collins GS, Altman DG.Â Interpreting diagnostic accuracy 
studies for patient care. BMJ. 2012;345:e3999.
	41.	Mbizvo GK, Larner AJ. Receiver operating characteristic plot and area under the curve with 
binary classifiers: pragmatic analysis of cognitive screening instruments. Neurodegener Dis 
Manag. 2021;11:353â€“60.
	42.	Metz CE.Â Basic principles of ROC analysis. Semin Nucl Med. 1978;8:283â€“98.
	43.	Moses LE, Shapiro D, Littenberg B.Â Combining independent studies of a diagnostic test into a 
summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 
1993;12:1293â€“316.
	44.	Muschelli J.Â ROC and AUC with a binary predictor: a potentially misleading metric. J Classif. 
2020;37:696â€“708.
	45.	Ozenne B, Subtil F, Maucort-Boulch D.Â The precision-recall curve overcame the optimism of 
the receiver operating characteristic curve in rare diseases. J Clin Epidemiol. 2015;68:855â€“9.
	46.	Randolph JJ, Edmondson RS.Â Using the binomial effect size display to present the magnitude 
of effect sizes to the evaluation audience. Pract Assess Res Eval. 2005;10:14.
	47.	Remaley AT, Sampson ML, DeLeo JM, Remaley NA, Farsi BD, Zweig MH.Â Prevalence-value-Â­
accuracy plots: a new method for comparing diagnostic tests based on misclassification costs. 
Clin Chem. 1999;45:934â€“41.
	48.	Richardson ML.Â The zombie plot: a simple graphic method for visualizing the efficacy of a 
diagnostic test. AJR Am J Roentgenol. 2016;207:W43â€“52.
	49.	Rosenthal R, Rubin DR.Â A simple, general purpose display of magnitude of experimental 
effect. J Educ Psychol. 1982;74:166â€“9.
	50.	Saito T, Rehmsmeier M.Â The precision-recall plot is more informative than the ROC plot when 
evaluating binary classifiers on imbalanced datasets. PLoS One. 2015;10(3):e0118432.
	51.	Sawilowsky SS.Â New effect sizes rules of thumb. J Mod Appl Stat Methods. 2009;8:597â€“9.
	52.	Schisterman EF, Perkins NJ, Liu A, Bondell H.Â Optimal cut-point and its corresponding Youden 
Index to discriminate individuals using pooled blood samples. Epidemiology. 2005;16:73â€“81.
	53.	Swets JA.Â Measuring the accuracy of diagnostic systems. Science. 1988;240:1285â€“93.
6â€ƒ Measures Not Directly Related toÂ theÂ 2Â Ã—Â 2 Contingency Table

131
	54.	Walter SD.Â Properties of the summary receiver operating characteristic (SROC) curve for diag-
nostic test data. Stat Med. 2002;21:1237â€“56.
	55.	Weiskrantz L.Â Blindsight. A case study and implications, Oxford Psychology Series No. 12. 
Oxford: Clarendon Press; 1986.
	56.	Wojtowicz A, Larner AJ.Â Diagnostic test accuracy of cognitive screeners in older people. Prog 
Neurol Psychiatry. 2017;21(1):17â€“21.
	57.	Youngstrom EA.Â  A primer on receiver operating characteristic analysis and diagnos-
tic efficiency statistics for pediatric psychology: we are ready to ROC.Â J Pediatr Psychol. 
2014;39:204â€“21.
	58.	Zhou XH, Obuchowski NA, McClish DK.Â Statistical methods in diagnostic medicine. 2nd ed. 
Hoboken: Wiley; 2011.
	59.	Zou KH, Oâ€™Malley J, Mauri L.Â Receiver-operating characteristic analysis for evaluating diag-
nostic tests and predictive models. Circulation. 2007;115:654â€“7.
	60.	Zweig MH, Campbell G.Â Receiver-operating characteristic (ROC) plots: a fundamental evalu-
ation tool in clinical medicine. Clin Chem. 1993;39:561â€“77.
References

133
Â© Springer Nature Switzerland AG 2021
A. J. Larner, The 2x2 Matrix, https://doi.org/10.1007/978-3-030-74920-0_7
Chapter 7
Other Measures, Other Tables
Contents
7.1â€ƒ Introduction
â€ƒ 133
7.2â€ƒ Other measures
â€ƒ 133
7.2.1â€ƒ Measure ofÂ Association: McNemarâ€™s Test
â€ƒ 133
7.2.2â€ƒ Measure ofÂ Agreement: Cohenâ€™s Kappa (Îº) Statistic
â€ƒ 136
7.2.3â€ƒ Limits ofÂ Agreement: Bland-Altman Method
â€ƒ 142
7.3â€ƒ Other Tables
â€ƒ 142
7.3.1â€ƒ Higher Order Tables
â€ƒ 142
7.3.2â€ƒ Interval Likelihood Ratios (ILRs)
â€ƒ 142
7.3.3â€ƒ Three-Way Classification (Trichotomisation)
â€ƒ 144
7.3.4â€ƒ Combining Test Results
â€ƒ 145
7.3.5â€ƒ Decision Trees; Machine Learning
â€ƒ 154
7.3.6â€ƒ Fourfold Pattern ofÂ Risk Attitudes
â€ƒ 157
7.3.7â€ƒ Epistemological Matrix
â€ƒ 157
7.4â€ƒ Conclusion: Which Measure(s) Should BeÂ Used?
â€ƒ 158
References
â€ƒ 159
7.1â€ƒ Introduction
2Â Ã—Â 2 contingency tables may be used for purposes other than generating the various 
measures which have been discussed in Chaps. 2, 3, 4, 5, and 6. There are methods, 
based on the 2Â Ã—Â 2 contingency table, to assess association and agreement between 
measures. Other measures of association, such as correlation coefficient, have 
already been described (Sect. 6.3.1).
7.2â€ƒ Other measures
7.2.1â€ƒ Measure ofÂ Association: McNemarâ€™s Test
The test first described by McNemar [45] examines paired nominal data in a 2Â Ã—Â 2 
contingency table to determine whether row and column marginal frequencies are 
equal. It tests the null hypothesis of marginal homogeneity.

134
In algebraic notation (see Fig. 1.2):
	
2
2
 




b
c
b
c
â€“
/
	
This may sometimes be expressed by representing the larger number of pairs as 
n1 and the smaller as n2:
	
2
1
2
2
1
2
 




n
n
n
n
â€“
/
	
When numbers are small (bÂ +Â cÂ <Â 25), a continuity correction is applied [19]:
	
2
2
1








b
c
b
c
â€“
â€“
/
	
or:
	
2
1
2
2
1
2
1








n
n
n
n
â€“
â€“
/
	
Worked Examples: McNemar Test of Association
In a study examining memory complaints in patients attending a dedicated 
epilepsy clinic (NÂ =Â 100) [2], easily dichotomised screeners for both mood [4] 
and sleep disturbance [27, 29] were administered. There was a statistically 
significant difference in sleep disturbance and mood disturbance between the 
patients who reported subjective memory complaints and those who did not.
McNemarâ€™s test of association was used to examine whether there was a 
statistically significant association between disturbed sleep and disturbed 
mood in this patient cohort. Twenty patients had disturbed mood but not dis-
turbed sleep (b), whereas 6 patients had disturbed sleep but not disturbed 
mood (c). Hence:



2
2
2
20
6
20
6
196 26
7 538














b
c
b
c
/
/
/
.
p =
0 009
.
Hence a statistically significant association between disturbed sleep and 
disturbed mood was found in this cohort of epilepsy patients, permitting 
rejection of the null hypothesis [2].
McNemarâ€™s test of association was used similarly in a study of patients 
diagnosed with functional cognitive disorders (NÂ =Â 44) [6] to examine whether 
7â€ƒ Other Measures, Other Tables

135
there was a statistically significant association between disturbed sleep and 
disturbed mood, using the same screeners for these constructs [4, 27, 29]. Five 
patients had disturbed mood but not disturbed sleep (b), whereas 6 patients 
had disturbed sleep but not disturbed mood (c). Hence, since bÂ +Â cÂ <Â 25, a 
continuity correction [19] was applied:
2
2
1








b
c
b
c
â€“
â€“
/
or, since cÂ >Â b:
2
1
2
2
1
2
1








n
n
n
n
â€“
â€“
/
Let n1Â =Â 6, n2Â =Â 5:
 2
2
6
5
1
6
5
0 11
0












/
/
p
=
1
Hence no statistically significant association between disturbed sleep and 
disturbed mood was found in this patient cohort [39].
Using data from the same study [6], the association between mood [4] and 
subjective memory complaint assessed with a dichotomised Likert scale [49] 
was also examined (NÂ =Â 44). Four patients had disturbed mood but not subjec-
tive memory complaint (b), whereas 8 patients had subjective memory com-
plaint but not disturbed mood (c). Again, a continuity correction was applied, 
since bÂ +Â cÂ <Â 25. As cÂ >Â b, let n1Â =Â 8, n2Â =Â 4:
 2
1
2
2
1
2
2
1
8
4
1
8
4
9 12
0 75


















n
n
n
n




/
/
/
.
p
=
0 39
.
Hence no statistically significant association between subjective memory 
complaint and disturbed mood was found in this patient cohort [39].
7.2â€ƒ Other measures

136
As will be noted, McNemarâ€™s test is a test of the null hypothesis, with resultant 
conditional probability p values. The shortcomings of p values are well-recognised 
(Sect. 1.5), as they confound effect size with sample size, and a value â€œdichot-
omisedâ€ as significant at p < 0.05 is not a guarantee that a result is real (it could still 
be a false positive result or type I error), nor that a value deemed non-significant at 
p > 0.05 is inconclusive (it could still be a false negative result or type II error). The 
practice of using p values is increasingly controversial, with some advocating their 
â€œretirementâ€ [3].
7.2.2â€ƒ Measure ofÂ Agreement: Cohenâ€™s Kappa (Îº) Statistic
The kappa statistic, Îº, is usually designated as a measure of agreement or concor-
dance beyond chance, for example between different observers, assessors or raters, 
or between different screening or diagnostic tests [15]. This is calculated by com-
paring the proportion of observed agreement, Pa, with the proportion of agreement 
expected by chance alone, Pc, for a total of N observations, where:
	

 
 

P
P
P
a
c
c
â€“
/
â€“
1
	
Worked Example: McNemar Test of Association
Two brief cognitive screening instruments, the Mini-Cog [8] and the cognitive 
disorders examination (Codex) [5], were examined in a screening test accu-
racy study (NÂ =Â 162) [40]. Using test cut-offs for dementia from the index 
studies, 16 patients categorised as â€œnot dementiaâ€ by Codex were categorized 
as â€œdementiaâ€ by Mini-Cog, whereas in only 3 patients was the reverse dis-
cordance observed. Hence, since bÂ +Â cÂ <Â 25, a continuity correction [19] was 
applied:





2
2
2
1
16
3
1
16
3
144 19
7 579


















b
c
b
c
/
/
/
.
p
=
0 0059
.
Hence the null hypothesis of marginal homogeneity was rejected. The mar-
ginal proportions were significantly different from each other. This is proba-
bly related to the better specificity of Codex than Mini-Cog for dementia 
diagnosis (Larner, unpublished observations).
7â€ƒ Other Measures, Other Tables

137
In algebraic notation (see Fig. 1.2):
	
P
a
d
N
a



 /
	
Note that this corresponds to the definition previously given for Accuracy (Acc; 
Sect. 3.2.4). Hence this may also be expressed as:
	

 
 

Acc
P
P
c
c
â€“
/
â€“
1
	
The proportion of agreement expected by chance alone, Pc, is given by:
	
P
a
b
a
c
N
c
d
b
d
N
c














/
/
2
2
	
Hence:
	
 



























a
d
N
a
b
a
c
N
c
d
b
d
N
a
b
a
c
N
/
/
/
/
/
2
2
2
1
c
d
b
d
N





 /
2
	
or:
	
  






 








2 ad
bc
a
c
c
d
a
b
b
d
â€“
/
	
Îº ranges from +1 to âˆ’1, with most values expected to fall within the range 0 
(agreement due to chance alone) to 1 (perfect agreement), with negative values 
occurring only when agreement occurs less often than predicted by chance alone, a 
rare situation in clinical practice. Interpretation of Îº values is often based on the 
convention of Landis and Koch [30]: very good agreement (>0.8â€“1.0), good agree-
ment (>0.6â€“0.8), moderate agreement (>0.4â€“0.6), fair agreement (>0.2â€“0.4), slight 
agreement (0â€“0.2), and poor agreement worse than chance (<0).
Worked Example: Accuracy with Kappa Statistic
The Mini-Addenbrookeâ€™s Cognitive Examination (MACE) [25] was exam-
ined in a large (NÂ =Â 755) prospective screening test accuracy study [35]. At the 
MACE cut-off of â‰¤20/30 the test outcomes were as follows: a (=TP)Â =Â 104, b 
(=FP)Â =Â 188, c (=FN)Â =Â 10, and d (=TN)Â =Â 453 (Fig. 2.2). Hence:
P
a
d
N
Acc see Sect
a









/
/
.
. . .
557 755
0 738
3 2 4
7.2â€ƒ Other measures

138
De Vet etÂ al. [18] argued that Cohenâ€™s kappa is a relative measure, adjusting 
observed agreement for expected agreement, and hence is in fact a measure of reli-
ability rather than a measure of agreement, hence accounting for the observation of 
instances of high agreement with low kappa and vice versa, for example in cases of 
class imbalance. Bangdiwalaâ€™s B statistic is another summary measure of 
concordance.
Despite these caveats, Cohenâ€™s kappa may also be used for the comparison of 
assessors and the comparison of tests, as demonstrated in the following examples.
P
a
b
a
c
N
c
d
b
d
N
c 


















/
/
/
/
2
2
2
2
292 114 755
463 641 755
33288 570025
296783 570025
0 0584
0 521
0 579
/
/
.
.
.











 



 



P
P
P
a
c
c
/
.
.
/
.
.
/ .
.
1
0 738
0 579
1 0 579
0 159 0 421
0 378
Note that this result agrees with the calculation of â€œunbiased Accâ€ (= 
0.378) shown in Sect. 3.2.4.
This may also be calculated using:










 












 
2
2 45232
114 463
292
ad
a
c
c
d
a
b
b
d
bc /
/










641
2 45232 52782 187172
90464 239954
0 377
/
/
.
[The different results relate to rounding errors.]
7â€ƒ Other Measures, Other Tables

139
Worked Example: Cohenâ€™s Kappa (Îº) StatisticÂ â€“ Comparison of 
Assessors
The Ascertain Dementia 8 (AD8) cognitive screening questionnaire was used 
in a study examining the frequency of cognitive impairment in patients with 
epilepsy [1]. AD8 may be administered to both patients [24] and informants 
[23]. The AD8 cut-off from the index studies was used, where a score â‰¥2/8 
indicates cognitive impairment is likely to be present.
In the study population (NÂ =Â 100), there were 44 patient:informant dyads 
for whom both self-rated and informant AD8 scores were available. 21/44 
patients self-rated AD8 â‰¥2/8, and 24/44 informants rated patientsâ€™ AD8 score 
â‰¥2/8, with agreement in 21 dyads. 23/44 patients self-rated AD8 <2/8 and 
20/44 informants rated patientsâ€™ AD8 score <2/8, with agreement in 20 dyads. 
Constructing a 2Â Ã—Â 2 table the values for a, b, c, and d were therefore 21, 3, 0, 
and 20 respectively,
Hence observed agreement was:
P
a
d
N
a 








/
/
.
21
20
44
0 932
Agreement expected by chance was:
P
a
b
a
c
N
c
d
b
d
N
c 

























/
/
/
2
2
2
21 3
21
0
44
0
20
3
20





/
.
.
.
44
0 260
0 238
0 498
2
Therefore:







 



 


P
P
P
a
c
c
/
.
.
/
.
.
1
0 932
0 498
1 0 498
0 864
Based on the convention of Landis and Koch [30], this value of Îº would be 
interpreted as very good agreement (>0.8â€“1.0).
7.2â€ƒ Other measures

140
Kappa can be extended to encompass more than two categories and more than 
two raters, in which case some form of weighting may be required [16, 21].
In certain circumstances, kappa and Matthewsâ€™ correlation coefficient (MCC; 
Sect. 4.5) coincide (symmetric matrix) [17], although these circumstances are 
unlikely to occur in clinical practice. Delgado and Tibau characterized kappa as the 
harmonic mean of the Youden index (Y; Sect. 4.2) and predictive summary index 
(PSI; Sect. 4.3) in this particular situation [17] (Sect. 4.4).
Worked Example: Cohenâ€™s Kappa (Îº) StatisticÂ â€“ Comparison of 
Screening Tests
Two cognitive screening instruments, the Mini-Addenbrookeâ€™s Cognitive 
Examination (MACE) [25] and the Montreal Cognitive Assessment (MoCA) 
[46], were examined in counterbalanced fashion in a screening test accuracy 
study [33] using cut-offs from the index studies of the tests (MACE â‰¤25/30; 
MoCA <26/30).
In the study population (NÂ =Â 260), 182 had MACE scores â‰¤25/30 and 192 
had MoCA scores <26/30. Constructing a 2Â Ã—Â 2 table, the values for a, b, c, 
and d were 164, 28, 18, and 50 respectively.
Hence observed agreement was:
P
a
d
N
a 








/
/
.
164
50
260
0 823
Agreement expected by chance was:
P
a
b
a
c
N
c
d
b
d
N
c 






















/
/
/
2
2
2
164
28 164 18
260
18
50








28
50
260
0 517
0 078
0 595
2
/
.
.
.
Therefore:







 



 


P
P
P
a
c
c
/
.
.
/
.
.
1
0 823
0 595
1 0 595
0 563
Based on the convention of Landis and Koch [30], this value of Îº would be 
interpreted as moderate agreement (>0.4â€“0.6) (Larner, unpublished 
observations).
7â€ƒ Other Measures, Other Tables

141
Kappa statistic has shortcomings. It is affected by prevalence, and hence com-
parisons of its value determined in different populations may not be appropriate. As 
mentioned, it is also affected by class imbalance, when kappa scores may be low 
even when observed agreement is high. Moreover, kappa does not distinguish 
between types and sources of disagreement. It has been argued that the proportion 
of specific agreement, expressing the agreement separately for positive and negative 
ratings, is more clinically informative [18]. The first of these measures is identical 
Worked Example: Kappa Statistic as Harmonic Mean of Y and PSI
In the screening test accuracy study of MACE [35], at the MACE cut-off of 
â‰¤20/30 the value of Y was 0.619 (Sect. 4.2) and of PSI was 0.334 (Sect. 4.3). 
If the kappa statistic is calculated as the harmonic mean of Y and PSI (Sect. 
4.4), then:
 












2
1
1
2
2 0 619 0 334
0 619
0 334
/
/
/
. .
/
.
.
/
.
.
Y
PSI
Y PSI
Y
PSI



0 413 0 953
0 433
.
/ .
.
Note that this result does not agree with the calculation of â€œAccuracy with 
kappa statisticâ€ (= 0.378) above, nor with the â€œunbiased Accâ€ (= 0.378) shown 
in Sect. 3.2.4. However, if the equation for kappa is re-written as:









 








2 ad
bc
a
c
b
d
a
b
c
d
â€“
/
then using the data from the MACE study where a (=TP)Â  =Â  104, b 
(=FP)Â =Â 188, c (=FN)Â =Â 10, and d (=TN)Â =Â 453, we obtain:










 












 
2
2 45232
114 641
292
ad
a
c
b
d
a
b
c
d
bc /
/










463
2 45232 73074 135196
90464 208270
0 434
/
/
.
[The different results relate to rounding errors.]
Hence the different result of â€œkappa statistic as harmonic mean of Y and 
PSIâ€ compared to â€œAccuracy with kappa statisticâ€ and â€œunbiased Accâ€ is a 
consequence of the different marginal totals. In the situation where bÂ =Â c (i.e. 
a symmetric matrix) then the results would align, and would also be equal to 
the Matthewsâ€™ correlation coefficient (Sect. 4.5).
7.2â€ƒ Other measures

142
to the F measure or Dice coefficient (Sect. 4.9). Some advocate that kappa should 
be avoided altogether [17]. Perhaps HMYPSI (Sect. 4.4) might be preferred, as it is 
an absolute measure rather than a relative measure.
7.2.3â€ƒ Limits ofÂ Agreement: Bland-Altman Method
Limits of agreement are not related to the 2Â Ã—Â 2 contingency table and are included 
here for completeness, in order to contrast with the previously described Cohenâ€™s 
kappa â€œmeasure of agreementâ€. This is a method to provide a measure of agreement 
between tests by estimating how far apart the two values are on average and putting 
an interval around this [7]. The findings may be illustrated in a Bland-Altman plot 
of difference between test scores against their mean. The limits of agreement thus 
defined indicate how closely two methods agree, but what is accepted as â€œcloseâ€ 
remains a clinical rather than a statistical judgement. The Bland-Altman methodol-
ogy is a simple way to evaluate bias between mean differences which avoids the 
potentially erroneous conclusions based on correlation analyses.
7.3â€ƒ Other Tables
7.3.1â€ƒ Higher Order Tables
As previously discussed (Sect. 1.5), setting a decision threshold or dichotomisation 
point is critical to the construction of a 2Â Ã—Â 2 contingency table (potential methods 
for doing this are discussed in Sects. 6.2.1, 6.2.2, 6.2.3, 6.2.4, 6.2.5, and 6.2.6). This 
is not always a straightforward process. In clinical practice, dichotomisation may be 
inappropriate, for example when the object of tests is something other than simply 
identifying the presence or absence of disease. Furthermore, in screening or diag-
nostic test accuracy studies patients may not be tested with either the diagnostic test 
or the reference standard, or values may be lost or indeterminate. To accommodate 
the vagaries of real world practice, it may be more appropriate to use larger contin-
gency tables, such as 2Â Ã—Â 3 [52], 2Â Ã—Â 4 [14], or 3Â Ã—Â 3 ([51], p.Â 31), although this 
complicates the calculation of any of the measures previously discussed.
7.3.2â€ƒ Interval Likelihood Ratios (ILRs)
An example of a higher order table may be provided by the use of interval likelihood 
ratios [12], as opposed to the more usual dichotomisation into positive and negative 
likelihood ratios (Sect. 2.3.4). Selecting the intervals is somewhat arbitrary, and the 
smaller the numbers in each interval the wider the confidence intervals (Sect. 1.7) 
are likely to be.
7â€ƒ Other Measures, Other Tables

143
0
10
20
30
40
50
60
70
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
Dementia
No dementia
Fig. 7.1â€‚ MACE scores (x axis) by patient diagnosis (NÂ =Â 755). (Adapted from [35])
Worked Example: Higher Order TablesÂ â€“ Interval Likelihood Ratios
In the screening test accuracy study of MACE [35], category-specific positive 
and negative likelihood ratios were calculated at the MACE cut-off â‰¤20/30, 
such that LR+Â =Â 3.11 and LRâˆ’Â =Â 0.124 at this cut-off (Sect. 2.3.4). However, 
looking at the spread of MACE scores in the whole patient study cohort 
(NÂ =Â 755), as shown in Fig.Â 7.1, the overlap between dementia and no demen-
tia patients extended over a range of MACE scores.
Although category-specific LRs may be calculated for each cut-off [35], 
another approach would be to calculate interval LRs (ILRs). Hence, a 2Â Ã—Â 5 
table was constructed, from which ILRs were calculated, as TPR/FPR, or as 
p(T+ Ç€ D+)/p(T+ Ç€ Dâˆ’), as shown:
MACE 
score/30
Diagnosis: 
Dementia
Diagnosis: No 
dementia
Interval Likelihood Ratio 
(ILR)
26â€“30
1
202
(1/114)/(202/641)Â =Â 0.028
21â€“25
9
251
(9/114)/(251/641)Â =Â 0.202
16â€“20
29
121
(29/114)/(121/641)Â =Â 1.348
11â€“15
40
52
(40/114)/(52/641)Â =Â 4.325
â‰¤10
35
15
(35/114)/(15/641)Â =Â 13.12
TOTAL
114
641
The ILR for MACE scores in the interval 26â€“30/30 was very small, 0.028, 
suggesting a very large change in probability (see Table 2.1 for a qualitative 
classification of LR values) and hence diagnostic gain for a diagnosis of no 
dementia. Likewise for the interval â‰¤10/30 the LR value, 13.12, was very 
7.3â€ƒ Other Tables

144
7.3.3â€ƒ Three-Way Classification (Trichotomisation)
As previously mentioned (Sect. 1.6), three-way classification, or trichotomisation, 
is a method which may permit better classification accuracy by excluding or dese-
lecting uncertain test scores, usually those falling near a dichotomous cut-off (Sect. 
7.3.2), which are most error-prone. Unclassified individuals or instances may then 
require further assessment for correct classification. A downside of this approach is 
that calculation of sensitivity and specificity becomes cumbersome, being meant for 
dichotomous classification [31].
large for a diagnosis of dementia. For the intervals 21â€“25/30 and 11â€“15/30 the 
LR values were qualitatively only moderate, although it should be noted that 
they represent an approximate change in probability of +/âˆ’25% (Table 2.1). 
The LR for the interval 16â€“20/30 was close to unity, suggesting only slight 
change in probability, and hence no diagnostic gain. This contrasts with the 
finding when the test was simply dichotomised at the cut-off â‰¤20/30. Results 
falling near a dichotomous cut-off may be distorted. The information from 
ILRs may assist clinical decision making to a greater extent than the simple 
dichotomised values for LR+ and LRâˆ’ (Larner, unpublished observations).
Worked Example: Three-Way Classification (Trichotomisation)
In the screening test accuracy study of MACE [35], result-specific likelihood 
ratios were calculated at all MACE cut-offs and plotted (Fig.Â 7.2).
If LR values >0.5 and <2 are considered to produce only a â€œslightâ€ 
(decrease or increase respectively) in the probability of disease, whereas val-
ues â‰¤0.5 or â‰¥2 produce moderate change (Table 2.1), the former range might 
be deemed a zone of uncertainty. From the calculations and the plot it is pos-
sible to read off the range of MACE test scores corresponding to this range of 
LRs, namely â‰¤16/30 to â‰¤21/30 (the LR value at 18/30 is outside the 0.5<LR<2 
range, but it is included here for convenience). This range contains 25.9% of 
all scores (196/755) and has an interval LR of (33/114)/(163/641)Â =Â 1.14. At 
the optimal MACE cut-off of â‰¤20/30, this range contains 63.1% of all the 
errors (4/10 false negatives, 121/188 false positives) (Larner, unpublished 
observations).
7â€ƒ Other Measures, Other Tables

145
7.3.4â€ƒ Combining Test Results
If some results are uncertain, requiring further tests for correct classification, then 
methods to combine test scores may be required. As previously mentioned in pass-
ing (Sect. 2.3.4), calculation of likelihood ratios provides a method for combining 
the results of multiple tests (1,2,â€¦n), assuming the conditional independence of the 
tests in the presence and absence of the target diagnosis, by using Bayesâ€™ formula 
such that:
	
Post-test odds
Pre-test odds LR
LR
LRn




1
2
	
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
6
11
16
21
26
LR
MACE cut-off
LR vs MACE cut-off 
Fig. 7.2â€‚ Plot of result-specific likelihood ratios (LRs) on y axis versus MACE scores (x axis) for 
dementia diagnosis. (Data from [35]). Below MACE cut-off 6/30, LR values tend to âˆ
7.3â€ƒ Other Tables

146
Worked Example: Combining Tests: MACE and SMC Likert Scale (1)
In the screening test accuracy study of MACE [35], some patients (NÂ =Â 129) 
were also administered a single-item cognitive screening question, the 
Subjective Memory Complaint (SMC) Likert Scale [49], in order to assess 
whether combining a patient-performance cognitive screener (MACE) with 
subjective memory evaluation (SMC Likert Scale) gave additional diagnostic 
information [34].
In the SMC Likert Scale, participants are asked: â€œIn general, how would 
you rate your memory?â€ and given a choice of five possible responses: 
1Â =Â poor; 2Â =Â fair; 3Â =Â good; 4Â =Â very good; 5Â =Â excellent. SMC Likert Scale 
scores may be easily dichotomised: a score of 1 or 2 is categorised as SMC+, 
scores >2 as SMCâˆ’ (i.e. higher scores better) [49].
60 of the 129 patients administered both tests, MACE and SMC Likert 
Scale, received a clinical diagnosis of cognitive impairment, hence pre-test 
probability (prevalence) of cognitive impairment in this cohort was 0.465, and 
pre-test odds were 0.869. Pre-test probability against disease was 
69/129Â =Â 0.535, and pre-test odds against disease were (1 âˆ’ 0.465)/0.465Â =Â 1.15 
(see Sect. 1.3.3).
Using the MACE cut-off of â‰¤25/30 for cognitive impairment, established 
in the index study [25], LR+ for a diagnosis of cognitive impairment was p(Ri 
Ç€ D+)/p(Ri Ç€ Dâˆ’)Â =Â (54/60)/(44/69)Â =Â 1.41, a value producing only a slight 
increase in the probability of disease (Table 2.1). LRâˆ’ for a diagnosis of no 
cognitive impairment was (6/60)/(25/69)Â =Â 0.276, a value producing a moder-
ate increase in the probability of no disease (Table 2.1).
Using the SMC Likert Scale cut-off of â‰¤2, LR+ for a diagnosis of cogni-
tive impairment was p(Ri Ç€ D+)/p(Ri Ç€ Dâˆ’)Â =Â (42/60)/(60/69)Â =Â 0.805, suggest-
ing that subjective evaluation of memory actually slightly decreased the 
probability of a diagnosis of cognitive impairment (it increases the probability 
of a diagnosis of functional cognitive disorder [6, 39]). LRâˆ’ for a diagnosis 
of no cognitive impairment was (18/60)/(9/69)Â =Â 2.3, a value producing a 
moderate decrease in the probability of no disease (Table 2.1).
The results of the two tests were combined using Bayesâ€™ formula:
Post-test odds
Pre-test odds
LR
LR
MACE
SMC








0 869 1 41 0 805
.
.
.

0 986
.
This can be converted back to a post-test-probability using the equation:
Post-test probability
Post-test odds
post-test odds





/
.
1
0 986 /
.
.
1
0 986
0 496




7â€ƒ Other Measures, Other Tables

147
This Bayesian approach to combining test results may be compared with combi-
nation using simple logical rules ([36], p.Â 81â€“2, 133â€“6), or Boolean operators.
Using simple logical rules, one may construct tables akin to the truth tables 
developed for use in logic by Wittgenstein for the â€œandâ€ and â€œorâ€ connectives used 
to determine the truth or falsity of simple propositions (Fig.Â 7.3)
The Bayesian approach may also be compared with Boolean operators, after 
George Boole (1815â€“64), specifically combination using the â€œANDâ€ rule, where 
both tests are required to be positive for the target diagnosis to be made (i.e. any 
combination other than both tests positive is considered to rule out the diagnosis, an 
approach which privileges identification of true and false positives; Fig.Â 7.3a). This 
is sometimes known as series, serial or conjunctive combination, â€œbelieve the nega-
tiveâ€, or sequency (the first of these terms is avoided here as ambiguous, sometimes 
being used to refer to the situation where performance of a second test is dependent 
on the outcome of the first test, rather than all tests being performed on all subjects 
regardless of the result of the first).
Another Boolean operator, or method of combination, is the â€œORâ€ rule, also 
known as parallel or compensatory combination, â€œbelieve the positiveâ€, or simulta-
neity (i.e. any combination other than both tests negative is considered to rule in the 
diagnosis, an approach which privileges identification of true and false negatives; 
Fig.Â 7.3b). (The Boolean operator â€œNOTâ€ applies to the paired logical complemen-
tary measures or negations considered in Chapter 3.)
Evidently the â€œANDâ€ criterion is more severe, and preferable if FP outcomes are 
particularly to be avoided, whilst the â€œORâ€ criterion is more liberal and preferable 
if FN outcomes are particularly undesirable.
Thus, this combination of tests shows only a marginal improvement over 
the pre-test probability (0.465).
It is also possible to calculate the combined odds against disease using 
Bayesâ€™ formula:
Post-test odds against
Pre-test odds against
LR
LR
MACE
SMC






1.15 0 276 2 3
0 73



.
.
.
This can be converted back to a post-test-probability against disease using 
the equation:
Post-test probability against
post-test odds against





1
1
1
1
/
/




0 73
0 578
.
.
Thus, this combination of tests shows a marginal increase over the pre-test 
probability against disease (0.535) (Larner, unpublished observations).
7.3â€ƒ Other Tables

148
a) â€œandâ€
Classifier diagnosis
Test 1
Test 2
Test 3
Test 1 â€œandâ€ Test 2 
D+
D+
â€“
D+
D+
Dâ€“
â€“
Dâ€“
Dâ€“
D+
â€“
Dâ€“
Dâ€“
Dâ€“
â€“
Dâ€“
â€œandâ€ Test 3
D+
D+
D+
D+
D+
D+
Dâ€“
Dâ€“
D+
Dâ€“
D+
Dâ€“
Dâ€“
D+
D+
Dâ€“
D+
Dâ€“
Dâ€“
Dâ€“
Dâ€“
D+
Dâ€“
Dâ€“
Dâ€“
Dâ€“
D+
Dâ€“
Dâ€“
Dâ€“
Dâ€“
Dâ€“
b) â€œorâ€
Classifier diagnosis
Test 1
Test 2
Test 3
Test 1 â€œorâ€ Test 2
D+
D+
â€“
D+
D+
Dâ€“
â€“
D+
Dâ€“
D+
â€“
D+
Dâ€“
Dâ€“
â€“
Dâ€“
â€œorâ€ Test 3
D+
D+
D+
D+
D+
D+
Dâ€“
D+
D+
Dâ€“
D+
D+
Dâ€“
D+
D+
D+
D+
Dâ€“
Dâ€“
D+
Dâ€“
D+
Dâ€“
D+
Dâ€“
Dâ€“
D+
D+
Dâ€“
Dâ€“
Dâ€“
Dâ€“
Fig. 7.3â€‚ Truth tables for simple logical rules of combination for 2 or 3 tests: (a) â€œandâ€; (b) â€œorâ€
Worked Example: Combining Tests: MACE and SMC Likert Scale (2)
MACE and SMC Likert results were combined in series: both tests were 
required to be positive (MACE â‰¤25/30 and SMC â‰¤2) for the target diagnosis 
of cognitive impairment to be made. This permitted the construction of a 2Â Ã—Â 2 
contingency table accommodating both tests (Fig.Â 7.4a).
From the combined contingency table, the positive predictive value may be 
calculated as TP/(TPÂ +Â FP)Â =Â 40/(40Â +Â 40)Â =Â 0.5, similar to the post-test-Â­
probability value obtained using the Bayesian method based on multiplication 
of pre-test odds and individual test LRs (0.496).
The negative predictive value may be calculated as TN/(FNÂ +Â TN)Â =Â 29/
(20Â +Â 29)Â =Â 0.59, similar to the post-test-probability against (0.578) (Larner, 
unpublished observations).
7â€ƒ Other Measures, Other Tables

149
It is also possible to calculate Sens and Spec for two tests (Test 1, Test 2) applied 
in series (â€œANDâ€) or in parallel (â€œORâ€) based on individual test Sens and Spec 
using the equations:
	
Sens
Sens
Sens
AND
1
2
1
2
â€œ
â€


	
	
Spec
Spec
Spec
Spec
Spec
Spec
Spec
Sp
AND"
1
2
1
1
2
1
2
1
1
"

 








ec2

 	
	
Sens
Sens
Sens
Sens
Sens
Sens
Sens
Sen
1 OR"
"
2
1
1
2
1
2
1
1

 








s2

 	
	
Spec
Spec
Spec
OR
1
2
1
2
â€œ
â€


	
a)
b)
Diagnosis
MACE 
â€œANDâ€
SMC
outcome
Cognitive
impairment
present
Cognitive
impairment
absent
â‰¤25/30
and â‰¤2
â‰¤25/30
and >2, 
or >25/30
True positive
[TP] = 40
False positive
[FP] = 40
True negative 
[TN] = 29
False negative
[FN] = 20
Diagnosis
MACE 
â€œORâ€
SMC
outcome
Cognitive
impairment
present
Cognitive
impairment
absent
â‰¤25/30
or â‰¤2
>25/30
and >2
True positive
[TP] = 56
False positive
[FP] = 64
True negative 
[TN] = 5
False negative
[FN] = 4
Fig. 7.4â€‚ 2Â Ã—Â 2 contingency 
tables for combination of 
Mini-Addenbrookeâ€™s 
Cognitive Examination 
(MACE) and SMC Likert 
Scale outcomes (NÂ =Â 129) 
for the diagnosis of 
cognitive impairment: (a) 
â€œANDâ€ rule, series 
combination; (b) â€œORâ€ 
rule, parallel combination. 
(Data from [34])
7.3â€ƒ Other Tables

150
These two approaches, Bayesian and Boolean, to combining test results have 
also been examined for another pair of screening tests [44].
Worked Example: Combining Tests: MACE and SMC Likert Scale (3)
Sens and Spec for the combination of MACE and SMC Likert results were 
calculated for the â€œANDâ€ and â€œORâ€ combinations.
For the â€œANDâ€ combination:
Sens
Sens
Sens
MACE"AND"SMC
MACE
SMC





0 70 0 90
0 63
.
.
.
Spec
Spec
Spec
Spec
MACE"AND"SMC
MACE
MACE
SMC

 





1
0 13
0

.
.87 0 36
0 44




.
.
Looking at the 2Â Ã—Â 2 contingency table for series combination of MACE 
and SMC Likert (FigureÂ 7.3a), SensMACEâ€œANDâ€SMCÂ =Â TP/(TPÂ +Â FN)Â =Â 40/60Â =Â 0.67, 
and SpecMACEâ€œANDâ€SMCÂ =Â TN/(FPÂ +Â TN)Â =Â 29/69Â =Â 0.42, both results similar to 
the above calculations.
For the â€œORâ€ combination:
Sens
Sens
Sens
Sens
MACE"OR"SMC
MACE
MACE
SMC

 





1
0 70
0 3

.
. 0 0 90
0 97




.
.
Spec
Spec
Spec
MACE"OR"SMC
MACE
SMC





0 13 0 36
0 05
.
.
.
Looking at the 2Â Ã—Â 2 contingency table for parallel combination of MACE 
and SMC Likert (Fig.Â 7.4b), SensMACEâ€œORâ€œSMCÂ =Â TP/(TPÂ +Â FN)Â =Â 54/60Â =Â 0.93, 
and SpecMACEâ€œORâ€SMCÂ =Â TN/(FPÂ +Â TN)Â =Â 5/69Â =Â 0.07, both results similar to the 
above calculations (Larner, unpublished observations).
7â€ƒ Other Measures, Other Tables

151
Worked Example: Combining Tests: AD8 and 6CIT
In the assessment of cognitive complaints, some authorities recommend the 
use of both a patient performance measurement and an informant interview 
before making a diagnosis of dementia. A previous study [32] in a dedicated 
cognitive disorders clinic examined both the informant AD8 scale [23] and 
the Six-item Cognitive Impairment Test (6CIT) patient performance cognitive 
screening instrument [11]. Both of these tests are negatively scored (i.e. higher 
scoresÂ =Â impairment worse).
51 of the 177 patients administered both tests were diagnosed with demen-
tia based on clinical diagnostic criteria, hence pre-test probability (preva-
lence) of dementia in this cohort was 0.288, and pre-test odds (Sect. 1.3.3) 
was 0.405.
Using the AD8 cut-off of â‰¥2/8, LR+ for a diagnosis of dementia was p(Ri 
Ç€ D+)/p(Ri Ç€ Dâˆ’)Â =Â (49/51)/(112/126)Â =Â 1.08, a value producing only a slight 
increase in the probability of dementia (Table 2.1), notwithstanding its very 
high sensitivity.
Using the 6CIT cut-off of â‰¥8/28, LR+ for a diagnosis of dementia was p(Ri 
Ç€ D+)/p(Ri Ç€ Dâˆ’)Â =Â (44/51)/(48/126)Â =Â 2.26, a value producing a moderate 
increase in the probability of dementia (Table 2.1).
The results of the two tests were combined using Bayesâ€™ formula:
Post-test odds
Pre-test odds
LR
LR
AD
CIT







8
6
0 405 1 08 2 26
0
.
.
.
.988
This can be converted back to a post-test-probability using the equation:
Post-test probability
Post-test odds
post-test odds





/
.
1
0 988 /
.
.
1
0 988
0 497




This combination of tests therefore shows improvement compared to the 
pre-test probability of 0.288.
The Bayesian approach to combining test results may be compared with 
combination using the simple logical â€œANDâ€ rule (series combination or 
sequency): both tests were required to be positive (AD8 â‰¥2/8 and 6CIT 
â‰¥8/28) for the target diagnosis of dementia to be made. This permitted the 
construction of a 2Â Ã—Â 2 contingency table accommodating both tests (Fig.Â 7.5).
From the contingency table, the positive predictive value may be calcu-
lated as TP/(TPÂ +Â FP)Â =Â 42/(42Â +Â 45)Â =Â 0.483, similar to the post-test-proba-
bility value obtained using the Bayesian method based on multiplication of 
pre-test odds and individual test LRs (Larner, unpublished observations).
7.3â€ƒ Other Tables

152
Generally, sequential combination of tests leads to improvement in specificity, 
false positive rate, positive predictive value, and positive likelihood ratio. Conversely, 
sensitivity, false negative rate, negative predictive value and negative likelihood 
ratio are generally inferior with this method of combination ([36], p.Â 81â€“2, 133â€“6; 
[41], p.Â 119â€“43).
One possible advantage of the sequency method over the Bayesian method is that 
it requires construction of a new 2Â Ã—Â 2 contingency table and hence the opportunity 
to calculate many of the outcome measures discussed in previous chapters of this 
book for the combination of tests, not only post-test probability. For example, it is 
immediately evident (Fig.Â 7.5) that the combination of AD8 and 6CIT is sensitive 
for dementia diagnosis (0.82) with a high negative predictive value (0.90).
When more than two tests are involved, the Bayesian approach of multiplying 
the pre-test odds by the individual LR values may become easier to apply than con-
structing new 2Â Ã—Â 2 tables. However, this may conceal some shortcomings of com-
bining tests.
Diagnosis
AD8 
â€œANDâ€
6CIT
outcome
Dementia
present
Dementia
absent
â‰¥2/8 and 
â‰¥8/28
â‰¥2/8 and 
>8/28, or 
<2/8
True positive
[TP] = 42
False positive
[FP] = 45
True negative 
[TN] = 81
False negative
[FN] = 9
Fig. 7.5â€‚ 2Â Ã—Â 2 contingency 
table for series 
combination of informant 
Ascertain Dementia 8 
(AD8) â€œANDâ€ Six-item 
Cognitive Impairment Test 
(6CIT) outcomes 
(NÂ =Â 177) for the diagnosis 
of dementia. (Data updated 
from [32])
Worked Example: Combining Tests: The Triple Test
The Attended With sign (AW), the Applause Sign (AS), and the Head-Turning 
Sign (HTS), have individually been noted as possible clinical markers of the 
presence of cognitive impairment. Their combination as the â€œTriple Testâ€ to 
detect cognitive impairment has been suggested [26] and this has been exam-
ined [38].
Of 85 patients administered all three tests, 44 were diagnosed with cogni-
tive impairment based on clinical diagnostic criteria, hence pre-test probabil-
ity (prevalence) of cognitive impairment in this cohort was 0.52, and pre-test 
odds (Sect. 1.3.3) was 1.07.
LR+ for each sign was as follows (unpublished observations from data in 
[36]): LRAWÂ =Â 2.07; LRASÂ =Â 2.08; and LRHTSÂ =Â 11.33.
7â€ƒ Other Measures, Other Tables

153
Diagnosis
AW, AS, 
â€œANDâ€
HTS
outcome
Cognitive 
impairment
present
Cognitive 
impairment
absent
All  tests
positive
Any one 
negative
True positive
[TP] = 3
False positive
[FP] = 0
True negative 
[TN] = 41
False negative
[FN] = 41
Fig. 7.6â€‚ 2Â Ã—Â 2 contingency 
table for Triple Test (series 
combination of AW 
â€œANDâ€ AS â€œANDâ€ HTS) 
(NÂ =Â 85) for the diagnosis 
of cognitive impairment. 
(Data from [38]). See also 
Fig.Â 7.3a.
The results of the three tests were combined:
Post-test odds
Pre-test odds
LR
LR
LR
AW
AS
HTS








1 07
2 07
2 08
.
.
.
11 33
52 19
.
.

This can be converted back to a post-test-probability using the equation:
Post-test probability
Post-test odds
post-test odds





/
.
1
52 20 /
.
.
1 52 20
0 998




This combination of tests, the Triple Test, therefore shows a positive pre-
dictive value of 1, a marked improvement compared to the pre-test probabil-
ity (0.52).
However, it may not be immediately evident from this approach, but clear 
from the 2Â Ã—Â 2 contingency table (Fig.Â 7.6), that although both the PPV and 
specificity are perfect, the NPV is poor (0.5) and the sensitivity is negligible 
(0.07), with many false negatives, a pattern to be expected with the sequential 
combination of tests (Larner, unpublished observations). Many clinicians 
would find such test sensitivity unfit for purpose. The truth table for three tests 
combined using the â€œandâ€ connective (Fig.Â 7.3a) also indicates the likelihood 
of many false negatives since so many of the outcomes are classified as 
negative.
7.3â€ƒ Other Tables

154
7.3.5â€ƒ Decision Trees; Machine Learning
As these examples have shown, clinical problems may often be defined as staged 
processes consisting of successive dichotomous actions, concordant with the mode 
of clinical practice. Sequential testing strategies may be conveniently structured in 
the form of a decision tree.
Decision trees represent the chronological order of events with probabilities 
assigned to outcomes denoted by chance nodes (circles), to model uncertain events, 
and decision nodes (squares). Decision trees should incorporate all possible options 
(e.g. actions which may be chosen, or outcomes which may occur with each option) 
and hence extend beyond binary classification. Decision trees may be useful for the 
development of both diagnostic and prognostic predictions in the form of decision 
rules and algorithms. Such algorithms may permit standardization of approach, but 
may risk stifling innovation.
A clinical example is the cognitive disorders examination or Codex, a two-step 
decision tree for diagnostic prediction which incorporates results of two sequential 
tests (three-word recall and spatial orientation followed by a simplified clock draw-
ing test) resulting in four terminal nodes with different probabilities of dementia 
diagnosis [5, 57]. Other screening instruments may be reformulated as decision 
trees [40].
The data of the MACE and SMC Likert Scale study [34] (Sect. 7.3.4 and 
Fig.Â 7.4a) may be reformatted as a simple decision tree (Fig.Â 7.7). Following the 
root node of â€œsuspected cognitive impairmentâ€, the administration of tests is denoted 
by chance nodes (circles), modelling uncertain outcomes, with the continuous input 
variables collapsed into two categories according to test cut-off. Classifier diagnosis 
is denoted by decision nodes (squares), in this instance forming the terminal or leaf 
nodes of the tree. Decision trees may be arranged running from left to right, or from 
top to bottom, with the latter preferred here so that the terminal nodes may be seen 
to correspond to the rows of the 2Â Ã—Â 2 contingency table, both denoting classifier 
diagnosis (compare with Fig.Â 7.4a).
Decision trees may incorporate either absolute numbers or probabilities (see 
Fig.Â 7.7a, b respectively for the MACE â€œANDâ€ SMC Likert Scale). That the order 
of tests gives the same classification is evident (Fig.Â 7.7c, an inversion of Fig.Â 7.7a), 
and the â€œORâ€ combination can also be represented (Fig.Â 7.7d).
Although not part of typical decision trees, more distal â€œbranchesâ€ or â€œleavesâ€ 
have been added to these figures to show criterion diagnoses for comparison with 
the classifier diagnoses, information which permits summation of TP, FP, FN, and 
TN and hence construction of â€œANDâ€ and â€œORâ€ 2Â Ã—Â 2 contingency tables (Fig.Â 7.4).
Each path or route through the decision tree represents a classification decision 
rule, which may be characterised by â€œif-thenâ€ rules or conditional statements: if 
condition 1 and condition 2 occur, then a specified outcome occurs. For example, in 
Fig.Â 7.7, if MACE â‰¤25/30 and SMCÂ =Â 1â€“2, then classifier diagnosis is cognitive 
impairment. If MACE â‰¤25/30 and SMCÂ =Â 3â€“5 then, according to one classification 
rule, classifier diagnosis is no cognitive impairment (Fig.Â 7.7a), whereas following 
7â€ƒ Other Measures, Other Tables

155
a different classification rule, classifier diagnosis is cognitive impairment (Fig.Â 7.7d). 
In this particular instance, these two rules happen to be equivalent to the â€œANDâ€ and 
â€œORâ€ Boolean classifiers.
Binary decision tree methodology may be used to segment test groups into 
meaningful subgroups according to certain variables that may encompass a predic-
tive value, for example using a Classification and Regression Tree (CART) [10]. 
Other algorithms are available to develop decision trees and may be found in data 
mining software [53].
Machine learning (â€œartificial intelligenceâ€) classifiers â€œlearnâ€ to predict outcome 
based on large sets of variables. Support vector machines are typically used for 
binary classification whilst neural networks can map a large number of possible 
a) â€œANDâ€ absolute numbers
b) â€œANDâ€ probabilities
Fig. 7.7â€‚ Decision trees for combination of Mini-Addenbrookeâ€™s Cognitive Examination (MACE) 
and SMC Likert Scale outcomes (NÂ =Â 129) for the diagnosis of cognitive impairment (data from 
[34]): (a) â€œANDâ€ absolute numbers; (b) â€œANDâ€ probabilities; (c) â€œANDâ€ tree inverted; (d) â€œORâ€ 
absolute numbersÂ (an extra, detached, set of leaves denoting criterion diagnoses has been addedÂ in 
each case to permit easy calculation of TP, FP, FN, and TN numbers)
7.3â€ƒ Other Tables

156
outcomes. Variables are projected to high dimensional space (one variable mapped 
to one dimension); the classifier is the hyperplane which separates the data points, a 
line in two dimensions, a surface in three dimensions. This may be straight or flat 
with linear hyperplane solutions, curvy or rippled if non-linear (with risk of overfit-
ting). The suggestion (Sect. 1.7) that 2Â Ã—Â 2 table outcomes might be explored in 
4-dimensional space might be susceptible to such methods.
Machine learning methods are unbiased and very sensitive. Large amounts of 
data are needed to build reliable classification, using a training dataset to train the 
classifier, and validation. Measures such as accuracy, AUC ROC, F measure, and a 
test of significance (producing a p value) are often used to evaluate the quality of 
such classification models.
Whether these methods can be brought to effective use in clinical diagnosis 
remains to be seen [13]. Diagnostic classifiers are not yet in regular clinical use; 
human judgment currently prevails.
c) â€œANDâ€ tree inverted
d) â€œORâ€ absolute numbers
Fig. 7.7â€‚ (continued)
7â€ƒ Other Measures, Other Tables

157
7.3.6â€ƒ Fourfold Pattern ofÂ Risk Attitudes
Tversky and Kahneman noted that â€œthe most distinctive implication of prospect 
theory is the fourfold pattern of risk attitudesâ€ ([56], p.306). Essentially this is a 
2Â Ã—Â 2 contingency table cross-classifying gains and losses as classes against high 
and low probabilities as potential classifiers (Fig.Â 7.8). To preserve benefits, one 
may be risk averse for gains, whereas to avoid harms one may be risk seeking for 
losses. The fourfold pattern has applications in many fields, including economics 
and law, and is relevant to the net harm to net benefit (H/B) ratio (described in 
Sect. 2.3.5).
7.3.7â€ƒ Epistemological Matrix
â€œWhat do I know?â€ asked Montaigne (1533-92). Do we know, or simply think we 
know? Is there an objective knowledge, which we may only perceive subjectively, 
as through a prism, through the medium of the workings of our brain? â€œWe do not 
look at things as they are, but as we areâ€ said Kant (1724â€“1804).
Such reflections might also be summarised in a 2Â Ã—Â 2 table, which I venture to 
call an epistemological matrix (Fig.Â 7.9), and which may have relevance not only to 
that sphere of philosophy (as all knowledge is historically contingent) but also to 
Objectivity
Subjectivity
Known
Unknown
Known
Unknown
Known 
known
Unknown 
known
Unknown 
unknown
Known 
unknown
Fig. 7.9â€‚ The (2Â Ã—Â 2) 
epistemological matrix
Outcome
Probability
Gain
Loss
High
Low
Risk averse
Risk seeking
Risk averse
Risk seeking
Fig. 7.8â€‚ The fourfold 
pattern of risk attitudes
7.3â€ƒ Other Tables

158
psychology. It takes uncertainty as inherent to the human condition, with marked 
class imbalance due to the predominance of the unknown column, and to the 
unknown unknown category in particular. We are blind to our blindness, and have 
an almost unlimited ability to ignore our ignorance ([28], p.Â 24, 201); â€œunobserv-
ables cannot be detected, and are epistemically unavailableâ€ [55]. Consider the 
experiential and intellectual limitations of the residents of Edwin Abbottâ€™s two-Â­
dimensional Flatland (even the pentagonal doctors!). Here one might also include 
the anoetic or nonknowing consciousness proposed by Tulving, encompassing abil-
ities such as implicit memory (we all have a degree of cognitive anosognosia). The 
omniscient lies outside the matrix.
7.4â€ƒ Conclusion: Which Measure(s) Should BeÂ Used?
As in any sorting-out process, Roget was plagued by the big problem inherent in classifica-
tion: the validity of categories vs. the continuum of nature ([20], p.Â 268).
As I have learned more over the years, I have been intrigued by the number of 
measures which may be derived from an ostensibly simple 2Â Ã—Â 2 grid (and have 
added to this number: CDI+, CDIâˆ’, Sect. 2.4.2; HMYPSI, Sect. 4.4; SUI, SDI, 
Sect. 4.10; LDM, LPM, Sect. 5.5; NNSU, NNSD, Sect. 5.7), and by their interrela-
tionships. The analysis offered in this book has been restricted, in the interests of 
simplicity and by the authorâ€™s limited abilities, to binary classification. This is rec-
ognised to have shortcomings (e.g. loss of information, Sects. 1.5, 1.6, and 7.3.1; 
misclassification, Sect. 3.2.5) and potential solutions (e.g. higher order tables, Sect. 
7.3.2; trichotomisation, Sects. 1.6 and 7.3.3) although these may not be straightfor-
ward to apply. Moreover, correct construction of 2Â Ã—Â 2 tables and calculation of 
outputs does not obviate the necessity to assess risk of bias (internal validity) and 
generalisability of findings (external validity). However, in medical practice, dichot-
omisation is pragmatic for clinical decision making [22], and hence likely to 
continue.
How, then, should one steer a course through the many summary measures which 
have been described in this text? What metric(s) should be selected for analysis of a 
study? This may depend in part on the particular question being asked, the context, 
and also familiarity, personal preference (what one finds most intuitive, or easily 
communicable to patients) and fashion. In clinical medicine the F measure and 
Matthewsâ€™ correlation coefficient are seldom used [37, 42] whereas the former is 
almost obligatory in information retrieval and machine learning contexts despite its 
shortcomings [50].
The outputs of meta-analyses are usually given in terms of summary sensitivity 
and specificity and ROC curve but, as has been pointed out [22], these measures do 
not answer cliniciansâ€™ questions, being orientated to the test rather than to the 
patient. Predictive values, being orientated to the patient, might seem more clini-
cally useful but these values are unstable because of their dependence on 
7â€ƒ Other Measures, Other Tables

159
prevalence. Positive and negative likelihood ratios may obviate these problems, but 
dichotomisation risks loss of information and distortion, and calculation of interval 
likelihood ratios is more involved and the choice of intervals may be arbitrary.
As stated in the Introductory chapter (Sect. 1.7), it might be intuited that the very 
multiplicity of the measures which may be derived from 2Â Ã—Â 2 contingency tables 
suggests their inadequacy, if summary statistics reduce the information to a single 
characteristic of the data. Is there a minimum set or a standard â€œdashboardâ€ [54], a 
limited set of metrics which shows what â€œreally mattersâ€ (i.e. guides what we do) 
and hence which might be agreed by expert consensus? None yet exist, to my 
knowledge. Both the STAndards for the Reporting of Diagnostic accuracy studies 
guideline (STARD [9]) and its iteration for studies in dementia (STARDdem [48]) 
recommend sensitivity and specificity as keywords of papers reporting diagnostic 
test accuracy studies. Likelihood ratios may be used as the basis for recommenda-
tions about suitable tests (e.g. for dementia [47]). Some measures may be preferred 
as test-oriented (Sens, Spec, FPR, FNR, LRs), or patient-oriented (PPV, NPV, pre-
dictive ratios), or as indices of validity (LR, DOR, Y), or as more intuitive (Net 
reclassification improvement, â€œNumber needed toâ€ measures). Test shortcomings, 
as evidenced by the use of error notation (Sect. 1.4) wherever appropriate through-
out this book, may also be denoted by what I have ventured to term â€œmetrics of limi-
tationâ€ [43] such as false rates (positive, negative, discovery, reassurance; Sects. 
2.2.3 and 2.3.3), misclassification rate (Sect. 3.2.5), net harm to net benefit (H/B) 
ratio (Sect. 2.3.5), likelihood to be diagnosed or misdiagnosed (Sect. 5.5), and clini-
cal disutility indexes (Sect. 2.4.2). Other metrics may be less familiar, and outside 
clinician literacy, but this could be addressed if the measures were deemed suffi-
ciently useful, for example in communicating information to patients. Ultimately, 
the provision of test datasets should allow researchers to calculate any parameter of 
interest not explicitly stated in the index paper.
â€œArs longa vita brevisâ€ wrote Hippocrates (or one of his followers). The art of 
medicine may be, for the gifted, an intuitive process, but for others the art is long 
and deliberative. Intuitive thinking may be liable to error [28]. The use of the mea-
sures described in this book may assist deliberative medical decision making and 
the avoidance of error, and also find application in other disciplines as well.
References
	 1.	Aji BM, Larner AJ.Â  Cognitive assessment in an epilepsy clinic using AD8 questionnaire. 
Epilepsy Behav. 2018;85:234â€“6.
	 2.	Aji BM, Elhadd K, Larner AJ.Â Cognitive symptoms in people with epilepsy: role of sleep and 
mood disturbance. J Sleep Disord Ther. 2019;8:1.
	 3.	Amrhein V, Greenland S, McShane B.Â Scientists rise up against statistical significance. Nature. 
2019;567:305â€“7.
	 4.	Arroll B, Khin N, Kerse N.Â Screening for depression in primary care with two verbally asked 
questions: cross sectional study. BMJ. 2003;327:1144â€“6.
References

160
	 5.	Belmin J, Pariel-Madjlessi S, Surun P, Bentot C, Feteanu D, Lefebvre des Noettes V, etÂ al. The 
cognitive disorders examination (Codex) is a reliable 3-minute test for detection of dementia 
in the elderly (validation study in 323 subjects). Presse Med. 2007;36:1183â€“90.
	 6.	Bharambe V, Larner AJ.Â Functional cognitive disorders: demographic and clinical features 
contribute to a positive diagnosis. Neurodegener Dis Manag. 2018;8:377â€“83.
	 7.	Bland JM, Altman DG.Â Statistical methods for assessing agreement between two methods of 
clinical measurement. Lancet. 1986;1:307â€“10.
	 8.	Borson S, Scanlan J, Brush M, Vitiliano P, Dokmak A.Â  The Mini-Cog: a cognitive â€œvital 
signsâ€ measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 
2000;15:1021â€“7.
	 9.	Bossuyt PM, Reitsma JB, Bruns DE, etÂ al. The STARD statement for reporting studies of 
diagnostic accuracy: explanation and elaboration. Clin Chem. 2003;49:7â€“18.
	10.	Breiman L, Friedman JH, Olshen RA, Stone CJ.Â Classification and regression trees. Boca 
Raton: Taylor & Francis; 1984.
	11.	Brooke P, Bullock R.Â Validation of a 6 item cognitive impairment test with a view to primary 
care usage. Int J Geriatr Psychiatry. 1999;14:936â€“40.
	12.	Brown MD, Reeves MJ.Â Interval likelihood ratios: another advantage for the evidence-based 
diagnostician. Ann Emerg Med. 2003;42:292â€“7.
	13.	Bruffaerts R.Â Machine learning in neurology: what neurologists can learn from machines and 
vice versa. J Neurol. 2018;265:2745â€“8.
	14.	Burch J, Marson A, Beyer F, etÂ al. Dilemmas in the interpretation of diagnostic accuracy stud-
ies on presurgical workup for epilepsy surgery. Epilepsia. 2012;53:1294â€“302.
	15.	Cohen J.Â A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37â€“46.
	16.	Cohen J.Â Weighted kappa: nominal scale agreement with provision for scaled disagreement or 
partial credit. Psychol Bull. 1968;70:213â€“20.
	17.	Delgado R, Tibau XA.Â Why Cohenâ€™s Kappa should be avoided as performance measure in 
classification. PLoS One. 2019;14(9):e0222916.
	18.	De Vet HCW, Mokkink LB, Terwee CB, Hoekstra OS, Knol DL.Â Clinicians are right not to like 
Cohenâ€™s Îº. BMJ. 2013;346:f2515.
	19.	Edwards A.Â Note on the â€œcorrection for continuityâ€ in testing the significance of the difference 
between correlated proportions. Psychometrika. 1948;13:185â€“7.
	20.	Emblen DJ.Â Peter Mark Roget. The word and the man. London: Longman; 1970.
	21.	Fleiss JL.Â  Measuring nominal scale agreement among many raters. Psychol Bull. 
1971;76:378â€“82.
	22.	Gallagher EJ.Â  The problem with sensitivity and specificityâ€¦. Ann Emerg Med. 
2003;42:298â€“303.
	23.	Galvin JE, Roe CM, Xiong C, Morris JE.Â Validity and reliability of the AD8 informant inter-
view in dementia. Neurology. 2006;67:1942â€“8.
	24.	Galvin JE, Roe CM, Coats MA, Morris JC.Â Patientâ€™s rating of cognitive ability: using the 
AD8, a brief informant interview, as a self-rating tool to detect dementia. Arch Neurol. 
2007;64:725â€“30.
	25.	Hsieh S, McGrory S, Leslie F, Dawson K, Ahmed S, Butler CR, etÂ al. The Mini-Addenbrookeâ€™s 
Cognitive Examination: a new assessment tool for dementia. Dement Geriatr Cogn Disord. 
2015;39:1â€“11.
	26.	Isik AT, Soysal P, Kaya D, Usarel C.Â Triple test, a diagnostic observation, can detect cognitive 
impairment in older adults. Psychogeriatrics. 2018;18:98â€“105.
	27.	Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM.Â A scale for the estimation of sleep problems 
in clinical research. J Clin Epidemiol. 1988;41:313â€“21.
	28.	Kahneman D.Â Thinking, fast and slow. London: Penguin; 2012.
	29.	Lallukka T, Dregan A, Armstrong D.Â Comparison of a sleep item from the General Health 
Questionnaire-12 with the Jenkins Sleep Questionnaire as measures of sleep disturbance. J 
Epidemiol. 2011;21:474â€“80.
7â€ƒ Other Measures, Other Tables

161
	30.	Landis JR, Koch GG.Â The measurement of observer agreement for categorical data. Biometrics. 
1977;33:159â€“74.
	31.	Landsheer JA.Â Impact of prevalence of cognitive impairment on the accuracy of the Montreal 
Cognitive Assessment. The advantage of using two MoCA thresholds to identify error-prone 
test scores. Alzheimer Dis Assoc Disord. 2020;34:248â€“53.
	32.	Larner AJ.Â AD8 informant questionnaire for cognitive impairment: pragmatic diagnostic test 
accuracy study. J Geriatr Psychiatry Neurol. 2015;28:198â€“202.
	33.	Larner AJ.Â MACE versus MoCA: equivalence or superiority? Pragmatic diagnostic test accu-
racy study. Int Psychogeriatr. 2017;29:931â€“7.
	34.	Larner AJ.Â Dementia screening: a different proposal. Future Neurol. 2018;13:177â€“9.
	35.	Larner AJ.Â MACE for diagnosis of dementia and MCI: examining cut-offs and predictive val-
ues. Diagnostics (Basel). 2019;9:E51.
	36.	Larner AJ.Â  Diagnostic test accuracy studies in dementia. A pragmatic approach. 2nd ed. 
London: Springer; 2019.
	37.	Larner AJ.Â What is test accuracy? Comparing unitary accuracy metrics for cognitive screening 
instruments. Neurodegener Dis Manag. 2019;9:277â€“81.
	38.	Larner AJ.Â Response to â€œTriple test, a diagnostic observation, can detect cognitive impairment 
in older adultsâ€. Psychogeriatrics. 2019;19:407â€“8.
	39.	Larner AJ.Â  Functional cognitive disorders: update on diagnostic status. Neurodegener Dis 
Manag. 2020;10:67â€“72.
	40.	Larner AJ.Â Mini-Cog versus Codex (cognitive disorders examination): is there a difference? 
Dement Neuropsychol. 2020;14:128â€“33.
	41.	Larner AJ.Â  Manual of screeners for dementia. Pragmatic test accuracy studies. London: 
Springer; 2020.
	42.	Larner AJ.Â Defining â€œoptimalâ€ test cut-off using global test metrics: evidence from a cognitive 
screening instrument. Neurodegener Dis Manag. 2020;10:223â€“30.
	43.	Larner AJ.Â Cognitive screening instruments for dementia: comparing metrics of test limitation. 
medRxiv. 2020; https://doi.org/10.1101/2020.10.29.20222109v1.
	44.	Larner AJ.Â  Combining results of performance-based and informant test accuracy studies: 
Bayes or Boole? Dement Geriatr Cogn Disord. 2021;50:29-35.
	45.	McNemar Q.Â Note on the sampling error of the difference between correlated proportions or 
percentages. Psychometrika. 1947;12:153â€“7.
	46.	Nasreddine ZS, Phillips NA, BÃ©dirian V, Charbonneau S, Whitehead V, Collin I, etÂ al. The 
Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. 
J Am Geriatr Soc. 2005;53:695â€“9.
	47.	National Institute for Health and Care Excellence. Dementia. Assessment, management and 
support for people living with dementia and their carers. NICE Guideline 97. Methods, evi-
dence and recommendations (https://www.nice.org.uk/guidance/ng97). London: NICE; 2018.
	48.	Noel-Storr AH, McCleery JM, Richard E, etÂ al. Reporting standards for studies of diagnostic 
test accuracy in dementia: the STARDdem Initiative. Neurology. 2014;83:364â€“73.
	49.	Paradise MB, Glozier NS, Naismith SL, Davenport TA, Hickie IB.Â Subjective memory com-
plaints, vascular risk factors and psychological distress in the middle-aged: a cross-sectional 
study. BMC Psychiatry. 2011;11:108.
	50.	Powers DMW.Â What the F measure doesnâ€™t measure â€¦ Features, flaws, fallacies and fixes. 
arXiv. 2015:1503.06410.2015.
	51.	Sackett DL, Haynes RB.Â The architecture of diagnostic research. In: Knottnerus JA, editor. 
The evidence base of clinical diagnosis. London: BMJ Books; 2002.
	52.	Schuetz GM, Schlattmann F, Dewey M.Â Use of 3Â Ã—Â 2 tables with an intention to diagnose 
approach to assess clinical performance of diagnostic tests: meta-analytical evaluation of coro-
nary CT angiography studies. BMJ. 2012;345:e6717.
	53.	Song Y, Lu Y.Â Decision tree methods: applications for classification and prediction. Shanghai 
Arch Psychiatry. 2015;27:130â€“5.
	54.	Stiglitz JE.Â Measuring what matters. Sci Am. 2020;323(2):20â€“7.
References

162
	55.	Thiebaut de Schotten M, Foulon C, Nachev P.Â Brain disconnections link structural connectivity 
with function and behaviour. Nat Commun. 2020;11:5094.
	56.	Tversky A, Kahneman D.Â Advances in prospect theory: cumulative representation of uncer-
tainty. J Risk Uncertain. 1992;5:297â€“323.
	57.	Ziso B, Larner AJ.Â Codex (cognitive disorders examination) decision tree modified for the 
detection of dementia and MCI.Â Diagnostics (Basel). 2019;9:E58.
7â€ƒ Other Measures, Other Tables

163
Â© Springer Nature Switzerland AG 2021 
A. J. Larner, The 2x2 Matrix, https://doi.org/10.1007/978-3-030-74920-0
A
Accuracy (Acc), 6, 17, 49, 71, 99, 114, 136
Agreement charts, 125
â€œANDâ€ rule, 147, 149, 151
Aristotle, 1
B
Bayes, T., 24â€“29, 35, 37, 38, 62, 145, 146, 151
Bayes formula, 24â€“27, 29, 62, 145â€“147, 151
Binomial effect size display (BESD), 128â€“129
Bland-Altman method, 142
Boole, G., 147
Boolean operators, 147
C
Category-specific likelihood ratios, 31â€“33, 143
Class imbalance, 5, 6, 23, 24, 53, 55, 91, 138, 
141, 158
Clinical disutility indexes (CDI+, CDI-), 
43â€“45, 158, 159
Clinical utility indexes (CUI+, CUI-), 43â€“45, 
79, 92, 93
Cohenâ€™s d effect size, 126, 128
Cohenâ€™s kappa (Îº) statistic, 91, 136â€“142
Combining tests, 10, 145â€“154
Conditional probability plot, 26, 35â€“37, 66
Confidence intervals, 13, 19, 115, 142
Confusion matrix, 1, 2
Contingency table, vii, 1â€“5, 7, 8, 10â€“13, 15, 
17, 18, 23, 50, 53, 55, 71, 72, 77, 80, 
97, 113â€“129, 133, 142, 148â€“154, 
157, 159
Correct classification accuracy, see Accuracy
Correct classification rate, 57, 58, 59, 71, 
72, 74, 92
Correlation coefficient, 81, 126, 133
Critical success index (CSI), ix, 86â€“90, 93, 
120, 123
Cross-product ratio, see Diagnostic odds 
ratio (DOR)
D
Decision tree, 154â€“156
Diagnostic likelihood ratios (DLR), see 
Likelihood ratios (LR+, LR-)
Diagnostic odds ratio (DOR), 23, 39â€“43, 53, 
60, 71, 115â€“117, 119, 120, 122, 
123, 159
Dice coefficient, 89â€“92, 142
Dichotomisation, 12, 142, 158, 159
E
Effectiveness rate, see Accuracy
Effect sizes, 82, 125â€“129, 136
Efficiency, see Accuracy
Epistemological matrix, viii, 157â€“158
Equitable threat score (ETS), 87, 88, 90
Error matrix, see Confusion matrix
Error odds ratio (EOR), 39â€“42, 71
Error rate, see Inaccuracy
Euclidean index (d), 120, 121
F
False alarm rate (FAR), see False discovery 
rate (FDR)
Index

164
False discovery rate (FDR), 21, 27â€“29, 39, 45, 
60â€“63, 65, 66, 76, 94, 100
False negative rate (FNR), 21â€“23, 27, 33, 45, 
50â€“52, 55, 57, 59, 63, 64, 72, 94, 98, 
118, 152, 159
False omission rate (FOR), see False 
reassurance rate (FRR)
False positive rate (FPR), 21â€“23, 27, 32, 33, 
35, 45, 51, 52, 55, 57, 59, 63, 64, 72, 
94, 98, 114, 115, 118, 121, 143, 
152, 159
False reassurance rate (FRR), 27â€“29, 35, 36, 
39, 45, 61â€“63, 65, 66, 76, 94, 100
F measure (F1), 53, 83, 89â€“93, 120, 123, 142, 
156, 158
Fraction correct (FC), see Accuracy
G
Gain in certainty, 57, 76, 92
Gilbert skill score, see Equitable threat 
score (ETS)
H
Harmonic mean of Y and PSI (HMYPSI), 
78â€“81, 83, 88, 93, 120, 141, 142, 158
Higher order tables, 142, 143, 158
Hippocrates, 159
I
Identification index (II), 10â€“11, 22, 83â€“84, 
106, 107, 136
â€œIf-thenâ€ rules, 154
Inaccuracy (Inacc), 8, 49, 53â€“57, 63, 65, 71, 
83, 101, 102, 104, 106
Interval likelihood ratios (ILRs), 33, 
142â€“144, 159
J
J statistic, see Youden index (Y)/statistic (J)
K
Kant, I., 157
Kappa statistic, see Cohenâ€™s kappa (Îº) statistic
L
Leibniz, G., 2
Likelihood ratios (LR+, LRâˆ’), 13, 15, 29, 30, 
32, 34, 36, 40, 42, 71, 73, 78, 98, 123, 
142â€“145, 158
Likelihood to be diagnosed or misdiagnosed 
(LDM), 102â€“106, 120, 123, 128, 
158, 159
Likelihood to be predicted or misdiagnosed 
(LPM), 103â€“106, 123, 158
Limits of agreement, 142
M
Matthewsâ€™ correlation coefficient (MCC), 53, 
79â€“83, 88, 93, 120, 123, 125, 140, 
141, 158
McNemarâ€™s test, 133â€“136
Measures of agreement, 91, 136â€“142
Measures of association, 82, 125, 133â€“136
Mini-Addenbrookeâ€™s Cognitive Examination 
(MACE), vii, 6, 8â€“10, 17â€“20, 22, 
24â€“27, 29, 32â€“40, 42, 44, 45, 50â€“52, 
54â€“56, 59, 60â€“68, 73â€“82, 84â€“86, 
88â€“92, 94, 99, 101, 102, 104â€“107, 109, 
110, 114, 116, 118â€“124, 127, 128, 137, 
140, 141, 143â€“146, 148â€“150, 154, 155
Misclassification cost, 35, 57â€“60, 74
Misclassification rate, 49, 54, 57â€“60, 72, 74, 
98, 121, 159
Montaigne, M., 157
N
Negative likelihood ratio (LRâˆ’), 29â€“33, 123, 
142, 143, 152, 158, 159
Negative predictive ratio (NPR), 36â€“39, 41
Negative predictive value (NPV), 23â€“28, 35, 
38, 39, 44, 45, 61â€“67, 77â€“79, 91, 92, 
100, 101, 120, 148, 152, 153, 159
Negative sign rate, see Q (level of test)
Net harm to net benefit ratio (H/B), 34, 35, 58, 
60, 104, 115, 157, 159
Net reclassification improvement/index (NRI), 
84, 85, 159
Null hypothesis, 10, 11, 115, 133, 134, 136
Number needed for screening disutility 
(NNDU), 108â€“110
Number needed for screening utility (NNSU), 
93, 108â€“110, 158
Number needed to diagnose (NND), 75, 
98â€“104, 120, 128
Number needed to misdiagnose (NNM), 55, 
101â€“105, 120, 122, 128
Index

165
Number needed to predict (NNP), 78, 99â€“102, 
104, 105, 120
Number needed to screen (NNS), 84, 106â€“108
O
â€œORâ€ rule, 147, 149
P
Pearson, K., 1, 82, 126
Pearsonâ€™s product moment correlation 
coefficient, see Correlation coefficient
Phi coefficient (Ï†), 82, 125
Positive likelihood ratio (LR+), 29, 32â€“34, 152
Positive predictive ratio (PPR), 36â€“39, 41
Positive predictive value (PPV), 23â€“28, 35, 36, 
38, 39, 44, 45, 60â€“63, 65â€“67, 77â€“79, 
86, 89, 90, 92, 100, 101, 120, 125, 148, 
151â€“153, 159
Positive sign rate, see Q (level of test)
Posterior probability, see Accuracy
Post-test odds, 10, 29, 34, 35
Post-test probability, 23, 34â€“37, 
146â€“148, 151â€“153
Precision, see Positive predictive value (PPV)
Precision-recall (PR) plot or curve, 125
Predictive ratios (PPR, NPR), 15, 36â€“40, 159
Predictive summary index (PSI), 76â€“82, 90, 
100, 101, 104â€“106, 120, 140, 141
Predictive values (PPV/NPV), 13, 15, 23â€“27, 
35, 36, 39, 40, 60, 61, 76, 78, 89, 100, 
120, 125, 148, 151â€“153, 155, 158
Pre-test odds, 7, 9â€“10, 29, 34, 146, 148, 
151, 152
Pre-test probability, 6, 7, 9, 19, 34, 36, 37, 49, 
146, 147, 151â€“153
Prevalence, 6, 7, 9, 10, 19, 23â€“26, 33, 36, 49, 
53â€“56, 60, 62â€“68, 74â€“76, 78â€“81, 
83â€“85, 90, 91, 93, 99, 100, 125â€“127, 
141, 146, 151, 152, 159
Prevalence value accuracy plots, 125
Probability of detection (POD), see Positive 
predictive value (PPV)
Product index, 122
Proportion correct, Proportion incorrect, 
8, 9, 57
Proportion of specific negative agreement 
(NA), 91
Proportion of specific positive agreement 
(PA), 91
p values, 11, 136, 156
Q
Q (level of test), 49
Q* index, 120â€“123
Quality measures (QSN/QSP), 19â€“21, 26, 27, 
51, 56, 75
R
Ratio of verification, 86
Recall, see Sensitivity
Receiver Operating Characteristic (ROC)  
plot or curve, 8, 35, 42, 53, 57, 60,  
73, 75, 78, 83, 113â€“115, 117, 119, 
121, 123
Result-specific likelihood ratios, 144, 145
Risk attitudes, 157
Roget, P., 158
S
Sensitivity, 13, 15â€“20, 22, 27, 29, 32, 33, 35, 
50â€“53, 58, 64, 67, 71, 89, 97, 98, 114, 
120, 121, 123, 125, 144, 151â€“153, 
158, 159
Series combination, 149â€“153
â€œSnNoutâ€ rule, 52, 53
Specificity, 13, 15, 16, 18â€“21, 29, 33, 35, 
51â€“53, 58, 64, 67, 71, 87, 91, 97, 98, 
114, 120, 121, 123, 136, 144, 152, 153, 
158, 159
â€œSpPinâ€ rule, 52, 53
Standardized positive and negative predictive 
values (SPPV/SNPV), 23â€“27, 
35, 76, 100
Summary disutility index (SDI), 92â€“94, 109, 
110, 158
Summary utility index (SUI), 79, 92â€“94, 108, 
109, 120, 123, 158
T
Table of confusion, see Confusion matrix
Threat score (TS), see Critical success 
index (CSI)
Three-way classification, 12, 144â€“145
Trichotomisation, 12, 144â€“145, 158
True negative rate (TNR), see Specificity
True positive rate (TPR), see Sensitivity
Truth tables, 2, 5, 147, 148, 153
Tulving, E., 158
Type I and type II errors, 10, 11, 21,  
22, 136
Index

166
W
Weighted comparison (WC), 60
Wittgenstein, L., 2, 147
Y
Yerushalmy, J., 16
Youden index (Y) or statistic (J), 23, 57, 58, 
60, 62, 63, 65, 71â€“74, 77, 82, 84â€“86, 
88, 89, 91, 98, 118â€“120, 140
Z
Zombie plot, 117
Index

